0001437749-21-025042.txt : 20211103 0001437749-21-025042.hdr.sgml : 20211103 20211103092258 ACCESSION NUMBER: 0001437749-21-025042 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211103 DATE AS OF CHANGE: 20211103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NATURAL HEALTH TRENDS CORP CENTRAL INDEX KEY: 0000912061 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-MISCELLANEOUS NONDURABLE GOODS [5190] IRS NUMBER: 592705336 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36849 FILM NUMBER: 211373926 BUSINESS ADDRESS: STREET 1: UNITS 1205-07, 12F, MIRA PLACE TOWER A STREET 2: 132 NATHAN ROAD, TSIMSHATSUI, KOWLOON CITY: HONG KONG STATE: K3 ZIP: 00000 BUSINESS PHONE: 852-3107-0800 MAIL ADDRESS: STREET 1: UNITS 1205-07, 12F, MIRA PLACE TOWER A STREET 2: 132 NATHAN ROAD, TSIMSHATSUI, KOWLOON CITY: HONG KONG STATE: K3 ZIP: 00000 10-Q 1 nhtc20210930_10q.htm FORM 10-Q nhtc20210930_10q.htm
0000912061 Natural Health Trends Corp. false --12-31 Q3 2021 0.001 0.001 5,000,000 5,000,000 0 0 0 0 0.001 0.001 50,000,000 50,000,000 12,979,414 12,979,414 1,556,875 1,556,875 0.20 0.20 0.20 0.20 0.20 0.20 14 1 0 0 0 0 0 0 0 0 5 8 0 10 3 0.20 0.20 1 90 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors” in this report and in our most recent Annual Report on Form 10-K. FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. 00009120612021-01-012021-09-30 xbrli:shares 00009120612021-10-29 thunderdome:item iso4217:USD 00009120612021-09-30 00009120612020-12-31 iso4217:USDxbrli:shares 00009120612021-07-012021-09-30 00009120612020-07-012020-09-30 00009120612020-01-012020-09-30 0000912061us-gaap:PreferredStockMember2020-12-31 0000912061us-gaap:CommonStockMember2020-12-31 0000912061us-gaap:AdditionalPaidInCapitalMember2020-12-31 0000912061us-gaap:RetainedEarningsMember2020-12-31 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-31 0000912061us-gaap:TreasuryStockMember2020-12-31 0000912061us-gaap:PreferredStockMember2021-01-012021-03-31 0000912061us-gaap:CommonStockMember2021-01-012021-03-31 0000912061us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-31 0000912061us-gaap:RetainedEarningsMember2021-01-012021-03-31 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-31 0000912061us-gaap:TreasuryStockMember2021-01-012021-03-31 00009120612021-01-012021-03-31 0000912061us-gaap:PreferredStockMember2021-03-31 0000912061us-gaap:CommonStockMember2021-03-31 0000912061us-gaap:AdditionalPaidInCapitalMember2021-03-31 0000912061us-gaap:RetainedEarningsMember2021-03-31 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-31 0000912061us-gaap:TreasuryStockMember2021-03-31 00009120612021-03-31 0000912061us-gaap:PreferredStockMember2021-04-012021-06-30 0000912061us-gaap:CommonStockMember2021-04-012021-06-30 0000912061us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-30 0000912061us-gaap:RetainedEarningsMember2021-04-012021-06-30 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-30 0000912061us-gaap:TreasuryStockMember2021-04-012021-06-30 00009120612021-04-012021-06-30 0000912061us-gaap:PreferredStockMember2021-06-30 0000912061us-gaap:CommonStockMember2021-06-30 0000912061us-gaap:AdditionalPaidInCapitalMember2021-06-30 0000912061us-gaap:RetainedEarningsMember2021-06-30 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-30 0000912061us-gaap:TreasuryStockMember2021-06-30 00009120612021-06-30 0000912061us-gaap:PreferredStockMember2021-07-012021-09-30 0000912061us-gaap:CommonStockMember2021-07-012021-09-30 0000912061us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-30 0000912061us-gaap:RetainedEarningsMember2021-07-012021-09-30 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-30 0000912061us-gaap:TreasuryStockMember2021-07-012021-09-30 0000912061us-gaap:PreferredStockMember2021-09-30 0000912061us-gaap:CommonStockMember2021-09-30 0000912061us-gaap:AdditionalPaidInCapitalMember2021-09-30 0000912061us-gaap:RetainedEarningsMember2021-09-30 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-30 0000912061us-gaap:TreasuryStockMember2021-09-30 0000912061us-gaap:PreferredStockMember2019-12-31 0000912061us-gaap:CommonStockMember2019-12-31 0000912061us-gaap:AdditionalPaidInCapitalMember2019-12-31 0000912061us-gaap:RetainedEarningsMember2019-12-31 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-31 0000912061us-gaap:TreasuryStockMember2019-12-31 00009120612019-12-31 0000912061us-gaap:PreferredStockMember2020-01-012020-03-31 0000912061us-gaap:CommonStockMember2020-01-012020-03-31 0000912061us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-31 0000912061us-gaap:RetainedEarningsMember2020-01-012020-03-31 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-31 0000912061us-gaap:TreasuryStockMember2020-01-012020-03-31 00009120612020-01-012020-03-31 0000912061us-gaap:PreferredStockMember2020-03-31 0000912061us-gaap:CommonStockMember2020-03-31 0000912061us-gaap:AdditionalPaidInCapitalMember2020-03-31 0000912061us-gaap:RetainedEarningsMember2020-03-31 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-31 0000912061us-gaap:TreasuryStockMember2020-03-31 00009120612020-03-31 0000912061us-gaap:PreferredStockMember2020-04-012020-06-30 0000912061us-gaap:CommonStockMember2020-04-012020-06-30 0000912061us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-30 0000912061us-gaap:RetainedEarningsMember2020-04-012020-06-30 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-30 0000912061us-gaap:TreasuryStockMember2020-04-012020-06-30 00009120612020-04-012020-06-30 0000912061us-gaap:PreferredStockMember2020-06-30 0000912061us-gaap:CommonStockMember2020-06-30 0000912061us-gaap:AdditionalPaidInCapitalMember2020-06-30 0000912061us-gaap:RetainedEarningsMember2020-06-30 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-30 0000912061us-gaap:TreasuryStockMember2020-06-30 00009120612020-06-30 0000912061us-gaap:PreferredStockMember2020-07-012020-09-30 0000912061us-gaap:CommonStockMember2020-07-012020-09-30 0000912061us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-30 0000912061us-gaap:RetainedEarningsMember2020-07-012020-09-30 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-30 0000912061us-gaap:TreasuryStockMember2020-07-012020-09-30 0000912061us-gaap:PreferredStockMember2020-09-30 0000912061us-gaap:CommonStockMember2020-09-30 0000912061us-gaap:AdditionalPaidInCapitalMember2020-09-30 0000912061us-gaap:RetainedEarningsMember2020-09-30 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-30 0000912061us-gaap:TreasuryStockMember2020-09-30 00009120612020-09-30 utr:D 0000912061srt:MinimumMember2021-01-012021-09-30 utr:Y 0000912061srt:MaximumMember2021-01-012021-09-30 xbrli:pure 0000912061us-gaap:ProductMember2021-07-012021-09-30 0000912061us-gaap:ProductMember2020-07-012020-09-30 0000912061us-gaap:ProductMember2021-01-012021-09-30 0000912061us-gaap:ProductMember2020-01-012020-09-30 0000912061nhtc:AdministrativeFeesFreightAndOtherMember2021-07-012021-09-30 0000912061nhtc:AdministrativeFeesFreightAndOtherMember2020-07-012020-09-30 0000912061nhtc:AdministrativeFeesFreightAndOtherMember2021-01-012021-09-30 0000912061nhtc:AdministrativeFeesFreightAndOtherMember2020-01-012020-09-30 0000912061us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2021-07-012021-09-30 0000912061us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2021-01-012021-09-30 0000912061us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2020-01-012020-09-30 0000912061us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMember2020-07-012020-09-30 0000912061us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-09-30 0000912061us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-30 0000912061us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-09-30 0000912061us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-09-30 0000912061nhtc:UnshippedProductMember2021-09-30 0000912061nhtc:UnshippedProductMember2020-12-31 0000912061nhtc:AutoShipAdvancesMember2021-09-30 0000912061nhtc:AutoShipAdvancesMember2020-12-31 0000912061us-gaap:ProductAndServiceOtherMember2021-09-30 0000912061us-gaap:ProductAndServiceOtherMember2020-12-31 0000912061us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2021-09-30 0000912061us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2020-12-31 0000912061us-gaap:FairValueInputsLevel2Memberus-gaap:BankTimeDepositsMember2021-09-30 0000912061us-gaap:FairValueInputsLevel2Memberus-gaap:BankTimeDepositsMember2020-12-31 0000912061us-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalBondsMember2021-09-30 0000912061us-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalBondsMember2020-12-31 0000912061us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2021-09-30 0000912061us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2020-12-31 utr:sqft 0000912061country:HK2021-09-30 0000912061nhtc:RollingHillsEstatesMember2021-09-30 0000912061nhtc:RichmondBritishColumbiaMember2021-09-30 0000912061nhtc:MetuchenNewJerseyMember2021-09-30 0000912061country:CN2021-09-30 0000912061us-gaap:DomesticCountryMember2021-09-30 0000912061us-gaap:StateAndLocalJurisdictionMember2021-09-30 0000912061us-gaap:ForeignCountryMember2021-09-30 0000912061nhtc:EquityIncentivePlan2016Member2021-09-30 0000912061us-gaap:RestrictedStockMember2020-12-31 0000912061us-gaap:RestrictedStockMember2021-01-012021-09-30 0000912061us-gaap:RestrictedStockMember2021-09-30 0000912061nhtc:ThePhantomPlanMember2021-03-152021-03-15 0000912061nhtc:PhantomSharesMembernhtc:ThePhantomPlanMembernhtc:EmployeesAndNonEmployeeDirectorsMember2021-03-152021-03-15 utr:M 0000912061nhtc:PhantomSharesMembernhtc:ThePhantomPlanMembersrt:MaximumMembernhtc:EmployeesAndNonEmployeeDirectorsMember2021-03-15 0000912061nhtc:PhantomSharesMembernhtc:ThePhantomPlanMembernhtc:NewnonemployeedirectorsMember2021-05-142021-05-14 0000912061nhtc:PhantomSharesMembernhtc:ThePhantomPlanMembernhtc:EmployeesAndNonEmployeeDirectorsMember2021-07-012021-09-30 0000912061nhtc:PhantomSharesMembernhtc:ThePhantomPlanMembernhtc:EmployeesAndNonEmployeeDirectorsMember2021-01-012021-09-30 00009120612015-07-28 00009120612016-01-12 0000912061us-gaap:AccumulatedTranslationAdjustmentMember2020-12-31 0000912061us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-12-31 0000912061us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-09-30 0000912061us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-09-30 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-30 0000912061us-gaap:AccumulatedTranslationAdjustmentMember2021-09-30 0000912061us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-09-30 0000912061srt:DirectorMember2021-06-30 0000912061nhtc:RoyaltyAgreementAndLicenseMembernhtc:BHSMember2021-07-012021-09-30 0000912061nhtc:RoyaltyAgreementAndLicenseMembernhtc:BHSMember2020-07-012020-09-30 0000912061nhtc:RoyaltyAgreementAndLicenseMembernhtc:BHSMember2021-01-012021-09-30 0000912061nhtc:RoyaltyAgreementAndLicenseMembernhtc:BHSMember2020-01-012020-09-30 0000912061nhtc:PrimaryReportingSegmentMember2021-07-012021-09-30 0000912061nhtc:PrimaryReportingSegmentMember2020-07-012020-09-30 0000912061nhtc:PrimaryReportingSegmentMember2021-01-012021-09-30 0000912061nhtc:PrimaryReportingSegmentMember2020-01-012020-09-30 0000912061country:CN2021-07-012021-09-30 0000912061country:CN2020-07-012020-09-30 0000912061country:CN2021-01-012021-09-30 0000912061country:CN2020-01-012020-09-30 0000912061nhtc:RussiaAndKazakhstanMember2021-07-012021-09-30 0000912061nhtc:RussiaAndKazakhstanMember2020-07-012020-09-30 0000912061nhtc:RussiaAndKazakhstanMember2021-01-012021-09-30 0000912061nhtc:RussiaAndKazakhstanMember2020-01-012020-09-30 0000912061us-gaap:OperatingSegmentsMembernhtc:PrimaryReportingSegmentMember2021-07-012021-09-30 0000912061us-gaap:OperatingSegmentsMembernhtc:PrimaryReportingSegmentMember2020-07-012020-09-30 0000912061us-gaap:OperatingSegmentsMembernhtc:PrimaryReportingSegmentMember2021-01-012021-09-30 0000912061us-gaap:OperatingSegmentsMembernhtc:PrimaryReportingSegmentMember2020-01-012020-09-30 0000912061us-gaap:OperatingSegmentsMembercountry:CN2021-07-012021-09-30 0000912061us-gaap:OperatingSegmentsMembercountry:CN2020-07-012020-09-30 0000912061us-gaap:OperatingSegmentsMembercountry:CN2021-01-012021-09-30 0000912061us-gaap:OperatingSegmentsMembercountry:CN2020-01-012020-09-30 0000912061us-gaap:OperatingSegmentsMembernhtc:RussiaAndKazakhstanMember2021-07-012021-09-30 0000912061us-gaap:OperatingSegmentsMembernhtc:RussiaAndKazakhstanMember2020-07-012020-09-30 0000912061us-gaap:OperatingSegmentsMembernhtc:RussiaAndKazakhstanMember2021-01-012021-09-30 0000912061us-gaap:OperatingSegmentsMembernhtc:RussiaAndKazakhstanMember2020-01-012020-09-30 0000912061us-gaap:OperatingSegmentsMember2021-07-012021-09-30 0000912061us-gaap:OperatingSegmentsMember2020-07-012020-09-30 0000912061us-gaap:OperatingSegmentsMember2021-01-012021-09-30 0000912061us-gaap:OperatingSegmentsMember2020-01-012020-09-30 0000912061us-gaap:IntersegmentEliminationMember2021-07-012021-09-30 0000912061us-gaap:IntersegmentEliminationMember2020-07-012020-09-30 0000912061us-gaap:IntersegmentEliminationMember2021-01-012021-09-30 0000912061us-gaap:IntersegmentEliminationMember2020-01-012020-09-30 0000912061country:US2021-07-012021-09-30 0000912061country:US2020-07-012020-09-30 0000912061country:US2021-01-012021-09-30 0000912061country:US2020-01-012020-09-30 0000912061country:CA2021-07-012021-09-30 0000912061country:CA2020-07-012020-09-30 0000912061country:CA2021-01-012021-09-30 0000912061country:CA2020-01-012020-09-30 0000912061country:PE2021-07-012021-09-30 0000912061country:PE2020-07-012020-09-30 0000912061country:PE2021-01-012021-09-30 0000912061country:PE2020-01-012020-09-30 0000912061country:HK2021-07-012021-09-30 0000912061country:HK2020-07-012020-09-30 0000912061country:HK2021-01-012021-09-30 0000912061country:HK2020-01-012020-09-30 0000912061country:TW2021-07-012021-09-30 0000912061country:TW2020-07-012020-09-30 0000912061country:TW2021-01-012021-09-30 0000912061country:TW2020-01-012020-09-30 0000912061country:KR2021-07-012021-09-30 0000912061country:KR2020-07-012020-09-30 0000912061country:KR2021-01-012021-09-30 0000912061country:KR2020-01-012020-09-30 0000912061srt:EuropeMember2021-07-012021-09-30 0000912061srt:EuropeMember2020-07-012020-09-30 0000912061srt:EuropeMember2021-01-012021-09-30 0000912061srt:EuropeMember2020-01-012020-09-30 0000912061nhtc:OtherForeignCountriesMember2021-07-012021-09-30 0000912061nhtc:OtherForeignCountriesMember2020-07-012020-09-30 0000912061nhtc:OtherForeignCountriesMember2021-01-012021-09-30 0000912061nhtc:OtherForeignCountriesMember2020-01-012020-09-30 0000912061us-gaap:SubsequentEventMember2021-11-012021-11-01
 

 

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2021

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______ to _______

 

Commission File Number: 001-36849

 

NATURAL HEALTH TRENDS CORP.

(Exact name of registrant as specified in its charter)

Delaware

59-2705336

(State or other jurisdiction of

(I.R.S. Employer

incorporation or organization)

Identification No.)

 

Units 1205-07, 12F

Mira Place Tower A

132 Nathan Road, Tsimshatsui

Kowloon, Hong Kong

(Address of principal executive offices, including zip code)

 

Registrant’s telephone number, including area code: +852-3107-0800

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

NHTC

The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for shorter period that the registrant was required to submit such files). Yes ☑ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

   

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No ☑

 

At October 29, 2021, the number of shares outstanding of the registrant’s common stock was 11,422,539 shares.

 

 

 

 

 

FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q, in particular “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations,” includes “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). When used in this report, the words or phrases “will likely result,” “expect,” “intend,” “will continue,” “anticipate,” “estimate,” “project,” “believe” and similar expressions are intended to identify “forward-looking statements” within the meaning of the Exchange Act. These statements represent our expectations or beliefs concerning, among other things, future revenue, earnings, growth strategies, new products and initiatives, future operations and operating results, and future business and market opportunities.

 

Forward-looking statements in this report speak only as of the date hereof, and forward-looking statements in documents incorporated by reference speak only as of the date of those documents. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. We caution and advise readers that these statements are based on certain assumptions that may not be realized and involve risks and uncertainties that could cause actual results to differ materially from the expectations and beliefs contained herein.

 

For a summary of certain risks related to our business, see “Part I, Item 1A. Risk Factors” in our most recent Annual Report on Form 10-K, which includes the following:

 

 

Because our Hong Kong operations account for a substantial portion of our overall business, and substantially all of our Hong Kong business is derived from the sale of products to members in China, any material adverse change in our business relating to either Hong Kong or China would likely have a material adverse impact on our overall business;

 

Epidemics, such as the COVID-19 pandemic, or natural disasters, terrorist attacks or acts of war may seriously harm our business;

 

Our Hong Kong operations are being adversely affected by recent political and social developments in Hong Kong, and the negative impact on our operations and financial performance could continue or intensify;

  We experienced negative operating cash flows during the year ended December 31, 2019, and only modest positive operating cash flows during the year ended December 31, 2020. Unless our operating cash flows improve, this negative financial performance could have a material adverse effect on our business and our stock price;
  Adverse publicity associated with our products, ingredients or network marketing program, or those of similar companies, could harm our financial condition and operating results;
 

We are subject to risks relating to product concentration and lack of revenue diversification;
 

The high level of competition in our industry could adversely affect our business;
 

Failure of new products to gain member and market acceptance could harm our business;
 

We rely on a limited number of independent third parties to manufacture and supply our products;

 

Growth may be impeded by the political and economic risks of entering and operating in foreign markets;
  Failure to maintain effective internal controls in accordance with the Sarbanes-Oxley Act of 2002 could negatively impact our business and the market price of our stock;
  We could be adversely affected by management changes or an inability to attract and retain key management, directors and consultants;
  Our recent loss of a significant number of members is adversely affecting our business, and if we cannot stabilize or increase the number of members our business could be further negatively impacted;
  Although virtually all of our members are independent contractors, improper member actions that violate laws or regulations could harm our business;
  An increase in the amount of compensation paid to members would reduce profitability;
 

We may be held responsible for certain taxes or assessments relating to the activities of our members and service providers, which could harm our financial condition and operating results;
  Our business in China is subject to compliance with a myriad of applicable laws and regulations, and any actual or alleged violations of those laws or government actions otherwise directed at us could have a material adverse impact on our business and the value of our company;
  Changes in government trade and economic policies, including the imposition or threatened imposition of tariffs and other restrictive trade policies, and ongoing political and economic disputes between the United States and other jurisdictions, particularly China, may have a negative effect on global economic conditions and our business, financial results and financial condition;
 

Direct-selling laws and regulations may prohibit or severely restrict our direct sales efforts and cause our revenue and profitability to decline, and regulators could adopt new regulations that harm our business;

 

Challenges by third parties to the legality of our business operations could harm our business;

 

We are currently involved in, and may in the future face, lawsuits, claims, and governmental proceedings and inquiries that could harm our business;
 

Currency exchange rate fluctuations could lower our revenue and net income;

 

Changes in tax or duty laws, and unanticipated tax or duty liabilities, could adversely affect our net income;

 

Transfer pricing regulations affect our business and results of operations;

 

Our products and related activities are subject to extensive government regulation, which could delay, limit or prevent the sale of some of our products in some markets;

 

New regulations governing the marketing and sale of nutritional supplements could harm our business;
 

Regulations governing the production and marketing of our personal care products could harm our business;
 

If we are found not to be in compliance with good manufacturing practices our operations could be harmed;
 

Failure to comply with domestic and foreign laws and regulations governing product claims and advertising could harm our business;
 

We are subject to anti-bribery laws, including the U.S. Foreign Corrupt Practices Act;
 

We do not have a comprehensive product liability insurance program and product liability claims could hurt our business;

 

 

 

We may be unable to protect or use our intellectual property rights;
 

We rely on and are subject to risks associated with our reliance upon information technology systems;
 

System disruptions or failures, cybersecurity risks, and compromises of data could harm our business;
 

Our systems, software and data reside on third-party servers, exposing us to risks that disruption or intrusion of those servers could temporarily or permanently interrupt our access and damage our business;
 

Our common stock is particularly subject to volatility because of the industry and markets in which we operate; and
 

Our common stock continues to experience wide fluctuations in trading volumes and prices. This may make it more difficult for holders of our common stock to sell shares when they want and at prices they find attractive.

 

Additional factors that could cause actual results to differ materially from our forward-looking statements are set forth in this report, including under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and in our financial statements and the related notes.

 

 
 

 

PART I - FINANCIAL INFORMATION

 

Item 1. FINANCIAL STATEMENTS

  

NATURAL HEALTH TRENDS CORP.

CONSOLIDATED BALANCE SHEETS

(In Thousands, Except Share Data) 

 

  

September 30, 2021

  

December 31, 2020

 
  

(Unaudited)

     

ASSETS

        

Current assets:

        

Cash and cash equivalents

 $84,640  $92,367 

Inventories

  4,390   3,779 

Other current assets

  4,386   3,595 

Total current assets

  93,416   99,741 

Property and equipment, net

  463   539 

Operating lease right-of-use assets

  3,339   3,745 

Restricted cash

  524   525 

Deferred tax asset

  660   731 

Other assets

  574   661 

Total assets

 $98,976  $105,942 

LIABILITIES AND STOCKHOLDERS’ EQUITY

        

Current liabilities:

        

Accounts payable

 $879  $580 

Income taxes payable

  1,844   1,481 

Accrued commissions

  3,441   3,496 

Other accrued expenses

  1,758   1,922 

Deferred revenue

  6,038   3,091 

Amounts held in eWallets

  6,756   8,503 

Operating lease liabilities

  1,304   1,163 

Other current liabilities

  847   1,270 

Total current liabilities

  22,867   21,506 

Income taxes payable

  12,130   13,748 

Deferred tax liability

  215   216 

Operating lease liabilities

  2,209   2,775 

Total liabilities

  37,421   38,245 

Commitments and contingencies (Note 7)

          

Stockholders’ equity:

        

Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding

      

Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at September 30, 2021 and December 31, 2020

  13   13 

Additional paid-in capital

  86,102   86,102 

Retained earnings

  1,820   7,822 

Accumulated other comprehensive loss

  (476)  (336)

Treasury stock, at cost; 1,556,875 shares at September 30, 2021 and December 31, 2020

  (25,904)  (25,904)

Total stockholders’ equity

  61,555   67,697 

Total liabilities and stockholders’ equity

 $98,976  $105,942 

 

 

See accompanying notes to consolidated financial statements.

 

 

 

NATURAL HEALTH TRENDS CORP. 

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(In Thousands, Except Per Share Data)

 

   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2021

   

2020

   

2021

   

2020

 

Net sales

  $ 14,276     $ 14,124     $ 43,897     $ 45,476  

Cost of sales

    3,668       3,635       10,857       12,966  

Gross profit

    10,608       10,489       33,040       32,510  

Operating expenses:

                               

Commissions expense

    6,027       5,620       18,468       19,336  

Selling, general and administrative expenses

    4,102       4,201       13,488       13,771  

Total operating expenses

    10,129       9,821       31,956       33,107  

Income (loss) from operations

    479       668       1,084       (597 )

Other income (expense), net

    (53 )     385       (92 )     603  

Income before income taxes

    426       1,053       992       6  

Income tax provision (benefit)

    (45 )     418       139       (90 )

Net income

  $ 471     $ 635     $ 853     $ 96  

Net income per common share:

                               

Basic

  $ 0.04     $ 0.06     $ 0.08     $ 0.01  

Diluted

  $ 0.04     $ 0.06     $ 0.07     $ 0.01  

Weighted average common shares outstanding:

                               

Basic

    11,063       10,678       10,969       10,581  

Diluted

    11,424       11,424       11,424       11,424  

 

 

See accompanying notes to consolidated financial statements.

 

 

 

NATURAL HEALTH TRENDS CORP.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)

(In Thousands)

 

   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2021

   

2020

   

2021

   

2020

 

Net income

  $ 471     $ 635     $ 853     $ 96  

Other comprehensive income (loss), net of tax:

                               

Foreign currency translation adjustment

    (72 )     493       (158 )     355  

Unrealized gains (losses) on available-for-sale securities

    9       (2 )     18       16  

Comprehensive income

  $ 408     $ 1,126     $ 713     $ 467  

 

 

See accompanying notes to consolidated financial statements.

 

 

 

NATURAL HEALTH TRENDS CORP.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED)

(In Thousands, Except Share Data)

 

Nine months ended September 30, 2021

 

                          

Accumulated

             
                  

Additional

      

Other

             
  

Preferred Stock

  

Common Stock

  

Paid-In

  

Retained

  

Comprehensive

  

Treasury Stock

     
  

Shares

  

Amount

  

Shares

  

Amount

  

Capital

  

Earnings

  

Loss

  

Shares

  

Amount

  

Total

 
                                         

BALANCE, December 31, 2020

    $   12,979,414  $13  $86,102  $7,822  $(336)  (1,556,875) $(25,904) $67,697 

Net income

                 153            153 

Dividends declared, $0.20/share

                 (2,285)           (2,285)

Foreign currency translation adjustments

                    (182)        (182)

Unrealized losses on available-for-sale securities

                    (7)        (7)

BALANCE, March 31, 2021

        12,979,414   13   86,102   5,690   (525)  (1,556,875)  (25,904)  65,376 

Net income

                 229            229 

Dividends declared, $0.20/share

                 (2,285)           (2,285)

Foreign currency translation adjustments

                    96         96 

Unrealized gains on available-for-sale securities

                    16         16 

BALANCE, June 30, 2021

        12,979,414   13   86,102   3,634   (413)  (1,556,875)  (25,904)  63,432 

Net income

                 471            471 

Dividends declared, $0.20/share

                 (2,285)           (2,285)

Foreign currency translation adjustments

                    (72)        (72)

Unrealized gains on available-for-sale securities

                    9         9 

BALANCE, September 30, 2021

    $   12,979,414  $13  $86,102  $1,820  $(476)  (1,556,875) $(25,904) $61,555 

 

 

Nine months ended September 30, 2020

 

                          

Accumulated

             
                  

Additional

      

Other

             
  

Preferred Stock

  

Common Stock

  

Paid-In

  

Retained

  

Comprehensive

  

Treasury Stock

     
  

Shares

  

Amount

  

Shares

  

Amount

  

Capital

  

Earnings

  

Loss

  

Shares

  

Amount

  

Total

 

BALANCE, December 31, 2019

    $   12,979,414  $13  $86,102  $16,117  $(1,264)  (1,556,875) $(25,904) $75,064 

Net loss

                 (573)           (573)

Dividends declared, $0.20/share

                 (2,285)           (2,285)

Foreign currency translation adjustments

                    (222)        (222)

Unrealized losses on available-for-sale securities

                    (87)        (87)

BALANCE, March 31, 2020

        12,979,414   13   86,102   13,259   (1,573)  (1,556,875)  (25,904)  71,897 

Net income

                 34            34 

Dividends declared, $0.20/share

                 (2,285)            (2,285)

Foreign currency translation adjustments

                    84         84 

Unrealized gains on available-for-sale securities

                    105         105 

BALANCE, June 30, 2020

        12,979,414   13   86,102   11,008   (1,384)  (1,556,875)  (25,904)  69,835 

Net income

                 635            635 

Dividends declared, $0.20/share

                 (2,285)            (2,285)

Foreign currency translation adjustments

                    493         493 

Unrealized losses on available-for-sale securities

                    (2)        (2)

BALANCE, September 30, 2020

    $   12,979,414  $13  $86,102  $9,358  $(893)  (1,556,875) $(25,904) $68,676 

 

See accompanying notes to consolidated financial statements.

 

 

 

NATURAL HEALTH TRENDS CORP.

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(In Thousands)

 

   

Nine Months Ended September 30,

 
   

2021

   

2020

 

CASH FLOWS FROM OPERATING ACTIVITIES:

               

Net income

  $ 853     $ 96  

Adjustments to reconcile net income to net cash used in operating activities:

               

Depreciation and amortization

    237       301  

Noncash lease expense

    895       1,199  

Deferred income taxes

    66       979  

Changes in assets and liabilities:

               

Inventories

    (675 )     2,193  

Other current assets

    (823 )     923  

Other assets

    65       120  

Accounts payable

    300       206  

Income taxes payable

    (1,253 )     (1,790 )

Accrued commissions

    29       136  

Other accrued expenses

    (157 )     (598 )

Deferred revenue

    2,973       (1,045 )

Amounts held in eWallets

    (1,716 )     (3,163 )

Operating lease liabilities

    (935 )     (1,120 )

Other current liabilities

    (416 )     33  

Net cash used in operating activities

    (557 )     (1,530 )

CASH FLOWS FROM INVESTING ACTIVITIES:

               

Purchases of property and equipment

    (165 )     (147 )

Net cash used in investing activities

    (165 )     (147 )

CASH FLOWS FROM FINANCING ACTIVITIES:

               

Dividends paid

    (6,855 )     (6,855 )

Net cash used in financing activities

    (6,855 )     (6,855 )

Effect of exchange rates on cash, cash equivalents and restricted cash

    (151 )     413  

Net decrease in cash, cash equivalents and restricted cash

    (7,728 )     (8,119 )

CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period

    92,892       99,425  

CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period

  $ 85,164     $ 91,306  

SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:

               

Right-of-use assets obtained in exchange for operating lease liabilities

  $ 516     $ 2,724  

 

 

See accompanying notes to consolidated financial statements.

 

 

NATURAL HEALTH TRENDS CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

 

1. NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION

 

Nature of Operations 

 

Natural Health Trends Corp., a Delaware corporation (whether or not including its subsidiaries, the “Company”), is an international direct-selling and e-commerce company. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.

 

The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia, Thailand and Vietnam; South Korea; Japan; India; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.

 

Basis of Presentation 

 

The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s 2020 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on February 26, 2021.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.

 

Reclassification

 

Certain income taxes payable balances have been reclassified in the prior year consolidated statement of cash flows to conform to current year presentation.

 

Net Income Per Common Share

 

Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized, if any, is assumed to be used to repurchase shares.

 

The following table illustrates the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data):

 

  

Three Months Ended September 30,

 
  

2021

  

2020

 
  

Income (Numerator)

  

Shares (Denominator)

  

Per Share Amount

  

Income (Numerator)

  

Shares (Denominator)

  

Per Share Amount

 

Basic net income per common share:

                        

Net income available to common stockholders

 $471   11,063  $0.04  $635   10,678  $0.06 

Effect of dilutive securities:

                        

Non-vested restricted stock

     361          746     

Diluted net income per common share:

                        

Net income available to common stockholders plus assumed conversions

 $471   11,424  $0.04  $635   11,424  $0.06 

 

  

Nine Months Ended September 30,

 
  

2021

  

2020

 
  

Income (Numerator)

  

Shares (Denominator)

  

Per Share Amount

  

Income (Numerator)

  

Shares (Denominator)

  

Per Share Amount

 

Basic net income per common share:

                        

Net income available to common stockholders

 $853   10,969  $0.08  $96   10,581  $0.01 

Effect of dilutive securities:

                        

Non-vested restricted stock

     455          843     

Diluted net income per common share:

                        

Net income available to common stockholders plus assumed conversions

 $853   11,424  $0.07  $96   11,424  $0.01 

 

 

6

 

Recent Accounting Pronouncements

 

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis and added Topic 326 to the FASB ASC. In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. The amendments to ASU 2019-11 clarify, correct and make improvements to Topic 326. ASU 2016-13 as well as the updates in ASU 2019-11 are effective for interim and annual periods beginning after December 15, 2022, and early adoption is permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements.

 

Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

 

 

2. REVENUE

 

Revenue Recognition

 

All revenue is recognized when the performance obligations under a contract, including any product vouchers sold on a stand-alone basis in Hong Kong, are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature.

 

Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from 14 days to one year, and their historical return rates, which range from 1% to 8% of sales.  Sales returns were 1% of sales for each of the nine-month periods ended September 30, 2021 and 2020No material changes in estimates have been recognized during the periods presented. See Note 3 for additional information.

 

The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.

 

Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.

 

Deferred Revenue

 

The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product orders and unredeemed product vouchers are considered a contract liability and are recorded as deferred revenue. The increase in deferred revenue from December 31, 2020 to September 30, 2021 is primarily due to $4.0 million of cash received for unshipped product orders and unredeemed vouchers offset by $1.0 million of revenue recognized during the nine months ended September 30, 2021 that was included in deferred revenue as of December 31, 2020. See Note 3 for additional information.

 

Disaggregation of Revenue

 

The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to consumers through an e-commerce retail platform and the Russia and Kazakhstan market where the Company operates through an engagement of a third-party service provider. See Note 11 for revenue by market information.

 

7

 

The Company’s net sales by product and service are as follows (in thousands):

 

  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 
  

2021

  

2020

  

2021

  

2020

 

Product sales

 $12,809  $12,023  $39,405  $41,234 

Administrative fees, freight and other

  1,524   2,316   4,777   4,854 

Less: sales returns

  (57)  (215)  (285)  (612)

Total net sales

 $14,276  $14,124  $43,897  $45,476 

 

Concentration

 

No single market other than Hong Kong had net sales greater than 10% of total net sales. Sales are made to the Company’s members and no single customer accounted for 10% or more of net sales for the three and nine months ended September 30, 2021 and 2020. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.

 

Arrangements with Multiple Performance Obligations

 

The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged for individual products to similar customers.

 

Practical Expedients

 

The Company generally expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded in commissions expense.

 

The Company does not provide certain disclosures about unsatisfied performance obligations for contracts with an original expected length of one year or less.

 

8

 

 

 

3. BALANCE SHEET COMPONENTS

 

The components of certain balance sheet amounts are as follows (in thousands):

 

   

September 30, 2021

   

December 31, 2020

 

Cash, cash equivalents and restricted cash:

               

Cash

  $ 18,091     $ 23,977  

Cash equivalents

    66,549       68,390  
      84,640       92,367  

Restricted cash

    524       525  
    $ 85,164     $ 92,892  

Inventories:

               

Finished goods

  $ 3,851     $ 3,071  

Raw materials

    602       1,047  

Reserve for obsolescence

    (63 )     (339 )
    $ 4,390     $ 3,779  

Other accrued expenses:

               

Sales returns

  $ 127     $ 189  

Employee-related expense

    917       1,149  

Warehousing, inventory-related and other

    714       584  
    $ 1,758     $ 1,922  

Deferred revenue:

               

Unshipped product and unredeemed product vouchers

  $ 4,023     $ 1,005  

Auto ship advances

    1,909       1,977  

Other

    106       109  
    $ 6,038     $ 3,091  

 

 

4. FAIR VALUE MEASUREMENTS

 

As of September 30, 2021, cash and cash equivalents include the Company’s investments in money market funds, government and municipal debt securities, and corporate debt securities. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.  Debt securities classified as cash equivalents are required to be accounted for in accordance with the FASB Accounting Standards Codification (“ASC”) 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at September 30, 2021 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income (expense). Realized gains and losses, as well as interest income, are also included in other income (expense). The fair values of securities are based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs.

 

The carrying amounts of the Company’s financial instruments, including cash and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents.

 

Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.

 

9

 

Investments by significant category included in cash equivalents at the end of each period were as follows (in thousands):

 

     

September 30, 2021

   

December 31, 2020

 
 

Fair Value Level1

 

Adjusted Cost

   

Gross Unrealized Gains (Losses)

   

Fair Value

   

Adjusted Cost

   

Gross Unrealized Losses

   

Fair Value

 

Money market funds

Level 1

  $ 37,534     $     $ 37,534     $ 21,042     $     $ 21,042  

Time deposits

Level 2

                      5,458             5,458  

Government and municipal debt securities

Level 2

    11,849       (1 )     11,848       30,280       (5 )     30,275  

Corporate debt securities

Level 2

    17,159       8       17,167       11,621       (6 )     11,615  

Total investments

  $ 66,542     $ 7     $ 66,549     $ 68,401     $ (11 )   $ 68,390  

 


 

1 FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

 

 

5. LEASES

 

The Company leases 7,300 square feet of office space in Hong Kong and 4,900 square feet of office space in Rolling Hills Estates, California for its corporate staff.  In June 2020, the Company extended the Rolling Hills Estates office lease for an additional five years with a term now expiring in September 2030.  Effective July 1, 2020, the Company modified the terms of its largest Hong Kong office lease resulting in a lease extension through June 2023.  To help further develop the market for its products in North America, the Company leases 1,600 square feet of retail space in each of Rowland Heights, California and Richmond, British Columbia and 2,000 square feet of retail space in Metuchen, New Jersey. The Rowland Heights, Richmond and Metuchen locations have terms expiring in November 2025, February 2024, and November 2022, respectively.

 

The Company leases eight branch offices throughout China, and additional office space in Peru, Japan, Taiwan, South Korea, Singapore, Malaysia, Vietnam, Indonesia, Thailand, India, and the Cayman Islands. The Company also leases a factory in Zhongshan, China. The Company contracts with third parties for fulfillment and distribution operations in all of its international markets. None of the Company’s third party logistics contracts contain a lease as the Company does not have the right to access the warehouses or move its inventories at will.

 

The components of lease cost for the three and nine months ended September 30, 2021 and 2020 were as follows (in thousands):

 

   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2021

   

2020

   

2021

   

2020

 

Operating leases

  $ 338     $ 377     $ 996     $ 1,292  

Short-term leases

    44       72       133       237  

Total lease cost

  $ 382     $ 449     $ 1,129     $ 1,529  

 

Cash paid for amounts included in the measurement of operating leases liabilities was $327,000 and $342,000 for the three months ended  September 30, 2021 and 2020, respectively, and $1.0 million and $1.2 million for the nine months ended September 30, 2021 and 2020, respectively.

 

The weighted-average remaining lease term and discount rate related to operating leases as of September 30, 2021 were as follows:

 

Weighted-average remaining lease term (in years)

    5.1  

Weighted-average discount rate

    3.3 %

 

10

 

As most of our leases do not provide an implicit rate, the Company used its incremental borrowing rate, or the rate of each of its subsidiaries if available, based on the information available at the lease commencement date to determine the present value of lease payments.

 

The annual scheduled lease payments of our operating lease liabilities as of September 30, 2021 were as follows (in thousands):

 

Remainder of 2021

  $ 327  

2022

    1,303  

2023

    675  

2024

    272  

2025

    261  

Thereafter

    990  

Total lease payments

  $ 3,828  

Less: imputed interest

    (315 )

Present value of lease liabilities

  $ 3,513  

 

For all asset classes, the Company elected not to recognize assets or liabilities at the acquisition date for leases that, at the acquisition date, have a remaining lease term of 12 months or less. Additionally, for all asset classes, the Company choose not to separate nonlease components from lease components and instead account for the combined lease and nonlease components associated with that lease component as a single lease component.

 

 

6. INCOME TAXES

 

The effective income tax rate for the three and nine months ended September 30, 2021 includes an estimate for the Global Intangible Low-Taxed Income (“GILTI”) inclusion. As of September 30, 2021, the Company does not have a valuation allowance against its U.S. deferred tax assets. The Company analyzed all sources of available income and determined that they are more likely than not to realize the tax benefits of their deferred assets. As of September 30, 2021, the Company has a valuation allowance against deferred tax assets in certain foreign jurisdictions with an overall net operating loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.

 

As of September 30, 2021, the Company has U.S. federal net operating losses of $603,000 generated in the tax year ended December 31, 2020 available to offset taxable income. The Company intends to carry back those losses to the year ended December 31, 2016, as there is sufficient income in the 2016 tax year to utilize the losses. The Company has post-apportioned U.S. state net operating loss carryforwards of $427,000 that begin expiring in 2039. At September 30, 2021, the Company has foreign net operating loss carryforwards of approximately $2.8 million in various jurisdictions with various expirations.

 

As a result of capital return activities, the Company determined that a portion of its current undistributed foreign earnings is no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. For state income tax purposes, the Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable state corporate income tax rate(s). As of September 30, 2021, the Company has not recorded a state deferred tax liability for earnings that the Company plans to repatriate out of accumulated earnings in future periods because all earnings as of September 30, 2021 have already been repatriated. Due to the U.S. Tax Cuts and Jobs Act in 2017, repatriation from foreign subsidiaries will be offset with a dividends received deduction, resulting in little to no impact on federal tax expense. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of September 30, 2021.

 

11

 

The Company and its subsidiaries file tax returns in the United States, California, New Jersey, Texas and various foreign jurisdictions. During the fourth quarter of 2018, the Company was notified that it was selected for audit of the 2016 tax year by the U.S. Internal Revenue Service (the “IRS”). The audit was subsequently expanded to also include the 2017, 2018 and 2019 tax years. On October 12, 2021, the Company received notification from the IRS that it had completed the audit process for all tax years with no changes made to the Company's previously reported tax. The Company is no longer subject to state income tax examinations for years prior to 2015. No other jurisdictions are currently examining any income tax returns of the Company.

 

 

7. COMMITMENTS AND CONTINGENCIES

 

The SEC conducted a non-public investigation since August 2016 to determine whether there had been violations of the federal securities laws relating to the trading of the Company’s securities and/or its public disclosures. On September 30, 2021, the Company was notified by the SEC that it had concluded its investigation and does not intend to recommend an enforcement action.

 

 

8. STOCK-BASED INCENTIVE PLANS

 

Restricted Stock

 

At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. At September 30, 2021, 1,219,583 shares remained available for issuance under the 2016 Plan.

 

The following table summarizes the Company’s restricted stock activity under the 2016 Plan:

 

   

Shares

   

Wtd. Avg. Price at Date of Issuance

 

Nonvested at December 31, 2020

    566,272     $ 7.21  

Vested

    (285,024 )   $ 7.27  

Nonvested at September 30, 2021

    281,248     $ 7.14  

 

Phantom Equity

 

On March 15, 2021, the Company’s Board of Directors approved and adopted a Phantom Equity Plan (the “Phantom Plan”). Under the terms of the Phantom Plan, the Compensation Committee may grant to the Company’s employees, officers, directors, contractors, consultants, or advisors awards of phantom shares entitling grantees the right to receive a cash payment equal to the fair market value of an equal number of shares of the Company’s common stock upon the close of a vesting period, subject to any maximum payment value that the Compensation Committee may set. The vesting of phantom shares is subject to such vesting conditions as the Compensation Committee may specify in a grantee’s award agreement. Grantees of phantom shares shall not by virtue of their receipt of phantom shares have any ownership rights in shares of the Company’s common stock. The Phantom Plan shall continue for a period of ten years, after which no further phantom shares may be awarded (although any phantom shares awarded prior to the expiration of such 10-year period shall be unaffected by the termination of the Phantom Plan).

 

Also on March 15, 2021, awards for 223,307 phantom shares were granted to the Company’s employees and its non-employee directors.  The phantom shares vest in eight equal three-month vesting increments, subject to the satisfaction of both a time-based vesting condition and a performance vesting condition. These vesting conditions were deemed satisfied on the grant date for the initial vesting increment. In order for the time-based vesting condition to be satisfied for each vesting period, the grantee must remain continuously employed by, or be otherwise continuously providing services to, the Company through the end of the vesting period, and in order for the performance vesting condition to be satisfied for each vesting period, the performance criteria designated by the Compensation Committee must be satisfied. The initial performance vesting condition to be applied to measure performance for the period between March 15, 2021 and June 15, 2021 was designated by the Compensation Committee on or before April 14, 2021, and will apply to all future performance periods unless the Compensation Committee elects to change the performance vesting condition on a prospective basis. Future changes to the performance vesting condition shall be made on or before the fifteenth day of any future performance period. If either vesting condition is not satisfied for a vesting date, then the phantom shares scheduled to vest on such date will be forfeited. These phantom shares are subject to a maximum payment value of $12.00 per phantom share. An additional award with similar vesting conditions for 9,074 phantom shares was granted on May 14, 2021 to the Company's new non-employee director, while unvested 9,074 phantom shares granted to the Company's departing non-employee director were forfeited on or about the same date.

 

The phantom share awards are accounted for as liabilities in accordance with FASB Accounting Standards Codification (“ASC”) Topic 718, Compensation Stock Compensation since they require cash settlement. The grant date of each vesting increment will be established when the Company and the grantees reach a mutual understanding of the key terms and conditions of an award, which is the date upon which each performance vesting condition is communicated to the grantees. Compensation expense is recognized over the requisite service period if it is probable that the performance vesting condition will be achieved. The fair value of the liability incurred is remeasured at the end of each reporting period with any changes in fair value recognized as compensation expense over the requisite service period.

 

Awards totaling 27,913 and 83,739 phantom shares vested during the three and nine months ended September 30, 2021, respectively, resulting in compensation expense of $195,000 and $588,000 during the three and nine months ended September 30, 2021, respectively, related to their cash settlement.

 

 

 

12

 

9. STOCKHOLDERS’ EQUITY

 

Dividends

 

The Company declared and paid cash dividends of $0.20 per common share during each of the first three quarters of 2021, totaling an aggregate of $6.9 million. Declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.

 

Stock Repurchases

 

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. As of September 30, 2021, $21.9 million of the $70.0 million stock repurchase program remained available for future purchases, inclusive of related estimated income tax.

 

Accumulated Other Comprehensive Loss

 

The changes in accumulated other comprehensive loss by component for the first nine months of 2021 were as follows (in thousands):

 

  Foreign Currency Translation Adjustments  Unrealized Gains (Losses) on Available-For-Sale Investments  

Total

 

Balance, December 31, 2020

 $(325) $(11) $(336)

Other comprehensive income (loss)

  (158)  18   (140)

Balance, September 30, 2021

 $(483) $7  $(476)

 

 

10. RELATED PARTY TRANSACTIONS

 

The Company is a party to a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called ReStor™. George K. Broady, a former director of the Company and beneficial owner of more than 5% of its outstanding common stock, is an indirect owner of BHS. Brunde E. Broady, a director of the Company and daughter of Mr. Broady, is the President and Chief Executive Officer of BHS. Under this agreement (as amended), the Company agreed to pay BHS a royalty based on a price per unit in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide by or through multi-level marketing or network marketing. The Company recognized royalties of $25,000 and $14,000 during the three months ended September 30, 2021 and 2020, respectively, and $44,000 and $64,000 during the nine months ended September 30, 2021 and 2020, respectively, under this agreement. The Company is not required to purchase any product under the agreement, and the agreement may be terminated under certain circumstances with no notice. The agreement terminates March 31, 2025, after which it shall be automatically renewed for successive one-year terms unless notice is given by either party at least 90 days in advance of the expiration of the then-current term.

 

13

 
 

11.    SEGMENT INFORMATION

 

The Company sells products to a member network that operates in a seamless manner from market to market, except for the China market where it sells to some consumers through an e-commerce platform, and the Russia and Kazakhstan market where the Company’s engagement of a third-party service provider results in a different economic structure than its other markets. Otherwise, the Company believes that all of its other operating segments have similar economic characteristics and are similar in the nature of the products sold, the product acquisition process, the types of customers products are sold to, the methods used to distribute the products, and the nature of the regulatory environment. Therefore, the Company aggregates its other operating segments (including its Hong Kong operating segment) into a single reporting segment (the “Primary Reporting Segment”).

 

The Company reviews its net sales and operating income (loss) by operating segment, and reviews its assets and capital expenditures on a consolidated basis and not by operating segment. As such, net sales and operating income (loss) are presented by reportable segment and assets and capital expenditures by operating segment are not presented. Segment operating income is adjusted for certain direct costs and commission allocation.

 

The Company’s operating information by geographic area are as follows (in thousands):

 

   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2021

   

2020

   

2021

   

2020

 

Net sales:

                               

Primary Reporting Segment

  $ 13,576     $ 13,294     $ 41,679     $ 42,718  

China

    501       640       1,596       2,156  

Russia and Kazakhstan

    199       190       622       602  

Total net sales

  $ 14,276     $ 14,124     $ 43,897     $ 45,476  
                                 

Income (loss) from operations:

                               

Primary Reporting Segment

  $ 2,558     $ 2,715     $ 7,803     $ 6,038  

China

    5       134       51       64  

Russia and Kazakhstan

    5       (59 )     (101 )     (37 )

Income from operations for reportable segments, net

    2,568       2,790       7,753       6,065  

Unallocated corporate expenses

    (2,089 )     (2,122 )     (6,669 )     (6,662 )

Other income (expense), net

    (53 )     385       (92 )     603  

Income before income taxes

  $ 426     $ 1,053     $ 992     $ 6  

 

The Company’s net sales by geographic area are as follows (in thousands):

 

   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2021

   

2020

   

2021

   

2020

 

Net sales from external customers:

                               

United States

  $ 279     $ 338     $ 918     $ 1,202  

Canada

    140       132       481       536  

Peru

    608       357       1,752       954  

Hong Kong1

    11,201       11,132       34,227       36,238  

China

    501       640       1,596       2,156  

Taiwan

    584       771       1,990       2,261  

South Korea

    51       52       202       220  

Russia and Kazakhstan

    199       190       622       602  

Europe

    258       259       869       747  

Other foreign countries

    455       253       1,240       560  

Total net sales

  $ 14,276     $ 14,124     $ 43,897     $ 45,476  

 


1 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors” in this report and in our most recent Annual Report on Form 10-K.

 

14

 
 

12. SUBSEQUENT EVENT

 

On November 1, 2021, the Board of Directors declared a quarterly cash dividend of $0.20 on each share of common stock outstanding. The dividend will be payable on November 26, 2021 to stockholders of record on November 16, 2021. The declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.

 

15

 
 

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Business Overview

 

We are an international direct-selling and e-commerce company. Subsidiaries controlled by us sell personal care, wellness, and “quality of life” products under the “NHT Global” brand. Our wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia, Thailand and Vietnam; South Korea; Japan; India; and Europe. We also operate in Russia and Kazakhstan through our engagement with a local service provider.

 

As of September 30, 2021, we were conducting business through 45,950 active members, compared to 46,860 three months ago and 53,300 a year ago. We consider a member “active” if they have placed at least one product order with us during the preceding year. Our priority is to focus our resources in our most promising markets, which we consider to be Greater China and countries where our existing members have the connections to recruit prospects and sell our products, such as Southeast Asia, India, South America and Europe.

 

We generate approximately 93% of our net sales from subsidiaries located outside the Americas, with sales of our Hong Kong subsidiary representing 78% of net sales in the latest fiscal quarter. Because of the size of our foreign operations, operating results can be impacted negatively or positively by factors such as foreign currency fluctuations, and economic, political and business conditions around the world. In addition, our business is subject to various laws and regulations, in particular, regulations related to direct selling activities that create uncertain risks for our business, including improper claims or activities by our members and our potential inability to obtain necessary product registrations. We continually evaluate our operations for compliance with applicable laws and regulations, and this process can and has resulted in the identification of certain matters of potential noncompliance, which we work to satisfactorily address. For further information regarding some of the risks associated with the conduct of our business in China and Hong Kong, see “Item 1A. Risk Factors” in this report and see generally in “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020, and more specifically under the captions “Because our Hong Kong operations account for a substantial portion of our overall business...”, “Our Hong Kong operations are being adversely affected by recent political and social developments in Hong Kong...”, and “Our business in China is subject to compliance with a myriad of applicable laws and regulations...”.

 

China has been and continues to be our most important business development project. We operate an e-commerce direct selling platform in Hong Kong that generates revenue derived from the sale of products to members in Hong Kong and elsewhere, including China. Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. Through a separate Chinese entity, we operate an e-commerce retail platform in China. We believe that neither of these activities require a direct selling license in China, which we do not currently hold. We previously submitted a preliminary application for a direct selling license in China in August 2015, but in 2019 a Chinese governmental authority recommended that we withdraw our application. We understand that the governmental authorities recommended that other companies with pending direct selling license applications also withdraw their applications. We applied to withdraw our application in November 2019, and the governmental authorities approved the withdrawal of our application shortly thereafter. In connection with the withdrawal of our application, we received a refund in March 2020 of a consumer protection fund deposit of CNY 20 million ($2.9 million) that we made upon the submission of our application. We expect to reapply for a direct selling license in China when we believe that circumstances are again ripe for doing so. If we are ultimately able to obtain a direct selling license in China, we believe that the incentives inherent in the direct selling model in China would incrementally benefit our existing business. We do not expect that any increased sales in China derived from obtaining a direct selling license would initially be material and, in any event may be partially offset by the higher fixed costs associated with the establishment and maintenance of required service centers, branch offices, manufacturing facilities, certification programs and other legal requirements. We are unable to predict whether and when we will be successful in obtaining a direct selling license to operate in China, and if we are successful, when we will be permitted to conduct direct selling operations and whether such operations would be profitable.

 

 

 

 

In January 2019, the Chinese government announced a 100-day campaign focused on companies involved in the sale of food, equipment, daily necessities, small home electrical appliances and services that are claimed to promote health. The Chinese government ministries in charge of this campaign indicated that they are targeting illegal practices in the industry, particularly the manufacture and sale of counterfeit and substandard products, and false advertising and misleading claims as to the health benefits of products and services. It is understood that the campaign is specifically focused on the business practices of direct selling companies. During the campaign, we understand that the government is not issuing any additional direct selling licenses, is not issuing certifications of quality or other approvals of various healthcare products, and is reviewing its regulatory oversight of the industry. Since it was implemented, the campaign and associated negative media coverage have had a significant adverse impact on our business, as consumers have widely curtailed their purchases within the affected industries. We, like some of our peers, voluntarily decided in January 2019 to temporarily suspend our member activities, such as product roadshows, product trainings and larger company-sponsored events, in China. We did this because we learned that the 100-day campaign was announced in broad outlines by the central government, and the interpretation and enforcement of the campaign was delegated to the provincial and local governments. We consider it a top priority for our business to develop an understanding of and cooperate with all levels and jurisdictions of the government agencies, and did not want to run the risk of being inadvertently entangled in government enforcement actions as the provincial and local governments formulate and implement their interpretive guidance and rule-making. Although we have recently been able to relax some restrictions on member activities in certain markets, it may again in the future be necessary or advisable to suspend member activities or take similar actions from time to time, and such periods of reduced activity may have a material adverse effect on our business.

 

Although the 100-day campaign was due to expire on or about April 18, 2019, we are not aware of any information indicating that the campaign has formally concluded. However, on August 27, 2019, the Chinese government announced that it would conduct a “look-back review” to evaluate the 100-day campaign. As part of this review, we understand that various Chinese governmental agencies formed a working group to assess the 100-day campaign, particularly focusing on the health market and its supervision in certain provinces. We understand that during September 2019 the working group evaluated the performance and results of a number of organizations and governmental departments in these provinces and made recommendations for various improvements. It was noted that each province had opened a number of investigative cases, had successfully closed numerous cases, and had imposed various fines and penalties. We understand that the look-back review continued after September 2019, and we are not aware that this review has been completed. As a result, the business environment in China for health product companies continues to be challenging, which has been exacerbated by negative social media sentiment expressed for these types of companies. We believe that the campaign, as well as its extension and aftermath (including the look-back review), will continue to negatively impact our business in China in the near-term, but will ultimately benefit us and Chinese consumers in the long-term as purveyors of substandard products are driven from the market.

 

In late 2019 or early 2020 an outbreak of COVID-19 was first identified in China and subsequently spread around the world. On March 11, 2020 the World Health Organization declared the COVID-19 outbreak a global pandemic. The outbreak caused the Chinese government to implement powerful measures to control the virus, such as requiring businesses to close throughout various areas of China and restricting public gatherings and certain travel within the country. We have significant business in China and in 2020 generated approximately 79% of our revenue in Hong Kong, substantially all of which was derived from the sale of products to members in China. The Chinese government continues to adjust the restrictive measures that it imposes to control COVID-19 based on then-current local circumstances, as have the governments of the other countries in which we operate. The scope and impact of the pandemic and related control measures are uncertain, but we have taken steps to adapt some of our marketing programs, such as relying on certain product promotions and webcast training, to overcome the physical restrictions imposed in response to the pandemic. We have also canceled or rescheduled a number of in-person member events over the course of the pandemic. The severity of the impact on us of the COVID-19 pandemic will depend on future developments, including the duration and spread of the virus, and related control measures, which we are unable to accurately predict. Regardless, these disruptions have materially negatively impacted our financial results throughout 2020 and the first nine months of 2021, and we expect that our financial results for the near-term may be adversely affected. For example, in February 2021 several COVID-19 outbreaks caused the Chinese government to abruptly reintroduce restrictions on personal mobility and strongly discourage gathering and travel ahead of the Chinese New Year. These measures effectively lengthened the traditional holiday and reduced the number of working days in the first quarter of 2021, which had a significant short-term effect on the level of our net sales. Further, due to scattered outbreaks of COVID-19 and the Chinese government's imposition of restrictions, the quarter ended September 30, 2021 marked the first quarter since the beginning of the pandemic that we were unable to sponsor any in-person member events in China, Macau or Hong Kong, which we believe also had a negative effect on net sales. The disruptions associated with the COVID-19 pandemic have also adversely affected the operations of some of our third-party logistics providers, and we expect that the future operations of these logistics providers and other third parties with whom we work may be adversely affected by these disruptions. We will continue to assess the operational and financial impact of the COVID-19 pandemic. See “Item 1A. Risk Factors - Epidemics, such as the COVID-19 pandemic, or natural disasters, terrorist attacks or acts of war…” in our most recent Annual Report on Form 10-K.

 

Recent political and social developments in Hong Kong, along with the impact of the COVID-19 pandemic and related government control measures, are also adversely affecting our Hong Kong operations and recently led us to cease conducting in-person member events in Hong Kong. Inasmuch as in-person member events in Hong Kong have in the past served as an important component of our product marketing and distribution efforts, we believe that this action has negatively affected our operations and financial performance. If current conditions continue or further deteriorate, we anticipate that our business, financial condition and results of operations will be adversely affected. See “Item 1A. Risk Factors - Our Hong Kong operations are being adversely affected by recent political and social developments in Hong Kong...” in our most recent Annual Report on Form 10-K.

 

 

 

 

Although the recently enacted tariffs and the trade disputes between the United States and China have not materially impacted our business to date, they may have negatively impacted the value of the Chinese yuan. For example, the value of the Chinese yuan relative to that of the U.S. dollar decreased during much of 2018 and 2019, which we believe negatively affected our Hong Kong revenues because the prices at which our Chinese members could purchase our products was effectively increased. In the event that political and trade tensions involving the United States, China and Hong Kong continue or intensify, our business could be negatively impacted in the future. For more information, see “Item 1A. Risk Factors,” and more specifically under the caption “Risk Factors - Changes in government trade and economic policies...” in our most recent Annual Report on Form 10-K.

 

Our Hong Kong net sales (substantially all of which were derived from products shipped to members residing in China) for the first nine months of 2021 were lower than the comparable period in 2020. The decline in net sales during the first nine months of 2021 resulted in modest income from operations for the period, as well as negative cash flows from operations. We anticipate that our financial performance for the near-term may continue to be adversely impacted.

 

 

Statement of Operations Presentation

 

We mainly derive revenue from sales of products. Substantially all of our product sales are to independent members at published wholesale prices. Product sales are recognized when the products are shipped and title passes to independent members, which generally is upon our delivery to the carrier that completes delivery to the members. We estimate and accrue a reserve for product returns based on our return policies and historical experience. We bill members for shipping charges and recognize the freight revenue in net sales. We have elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrue for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Event and training revenue is deferred and recognized as the event or training occurs.

 

Cost of sales consists primarily of products purchased from third-party manufacturers, freight cost for transporting products to our foreign subsidiaries and shipping products to members, import duties, packing materials, product royalties, costs of promotional materials sold to our members at or near cost, and provisions for slow moving or obsolete inventories. Cost of sales also includes purchasing costs, receiving costs, inspection costs and warehousing costs.

 

Member commissions are our most significant expense and are classified as an operating expense. Under our compensation plan, members are paid weekly commissions by our subsidiary in which they are enrolled, generally in their home country currency, for product purchases by their down-line member network across all geographic markets. Our China subsidiary maintains an e-commerce retail platform and does not pay commissions, although our Chinese members may participate in our compensation plan through our other subsidiaries. This “seamless” compensation plan enables a member located in one country to enroll other members located in other countries where we are authorized to conduct our business. Currently, there are basically two ways in which our members can earn income:

 

 

through commissions paid on the accumulated bonus volume from product purchases made by their down-line members and customers; and

 

 

through retail profits on sales of products purchased by members at wholesale prices and resold at retail prices (for purchasers in some of our smaller markets and purchasers from our China subsidiary, sales are for personal consumption only and income may not be earned through retail profits).

 

Each of our products is designated a specified number of bonus volume points. Commissions are based on total personal and group bonus volume points per weekly sales period. Bonus volume points are essentially a percentage of a product’s wholesale price. As the member’s business expands from successfully enrolling other members who in turn expand their own businesses by selling product to other members, the member receives higher commissions from purchases made by an expanding down-line network. In some of our markets, to be eligible to receive commissions, a member may be required to make nominal monthly or other periodic purchases of our products. Certain of our subsidiaries do not require these nominal purchases for a member to be eligible to receive commissions. In determining commissions, the number of levels of down-line members included within the member’s commissionable group increases as the number of memberships directly below the member increases.

 

 

Under our current compensation plan, certain of our commission payouts may be limited to a hard cap dollar amount per week or a specific percentage of total product sales. In some markets, commissions may be further limited. In some markets, we also pay certain bonuses on purchases by up to three generations of personally sponsored members, as well as bonuses on commissions earned by up to seven generations of personally sponsored members. Members can also earn additional income, trips and other prizes in specific time-limited promotions and contests we hold from time to time. Member commissions are dependent on the sales mix and, for the first nine months of 2021 and 2020, represented 42% and 43% of net sales, respectively. Occasionally, we make modifications and enhancements to our compensation plan to help motivate members, which can have an impact on member commissions. We may also enter into performance-based agreements for business or market development, which can result in additional compensation to specific members.

 

Selling, general and administrative expenses consist of administrative compensation and benefits, travel, credit card fees and assessments, professional fees, certain occupancy costs, and other corporate administrative expenses (including stock-based compensation). In addition, this category includes selling, marketing, and promotion expenses (including the costs of member training events and conventions that are designed to increase both product awareness and member recruitment). Because our various member conventions are not always held at the same time each year, interim period comparisons will be impacted accordingly.

 

The functional currency of our international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates. The resulting translation adjustments are recorded directly into stockholders’ equity.

 

Sales by our foreign subsidiaries are generally transacted in the respective local currencies and are translated into U.S. dollars using average rates of exchange for each monthly accounting period to which they relate. Most of our product purchases from third-party manufacturers are transacted in U.S. dollars. Consequently, our sales and net earnings are affected by changes in currency exchange rates, with sales and earnings generally increasing with a weakening U.S. dollar and decreasing with a strengthening U.S. dollar.

 

 

Results of Operations 

 

The following table sets forth our operating results as a percentage of net sales for the periods indicated.

 

   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2021

   

2020

   

2021

   

2020

 

Net sales

    100.0 %     100.0 %     100.0 %     100.0 %

Cost of sales

    25.7       25.7       24.7       28.5  

Gross profit

    74.3       74.3       75.3       71.5  

Operating expenses:

                               

Commissions expense

    42.2       39.8       42.1       42.5  

Selling, general and administrative expenses

    28.7       29.7       30.7       30.3  

Total operating expenses

    70.9       69.5       72.8       72.8  

Income (loss) from operations

    3.4       4.8       2.5       (1.3 )

Other income (expense), net

    (0.4 )     2.7       (0.2 )     1.3  

Income before income taxes

    3.0       7.5       2.3       0.0  

Income tax provision (benefit)

    (0.3 )     3.0       0.3       (0.2 )

Net income

    3.3 %     4.5 %     2.0 %     0.2 %

 

 

Net Sales

 

The following table sets forth revenue by market for the periods indicated (in thousands):

 

   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2021

   

2020

   

2021

   

2020

 

Americas1

  $ 1,027       7.2 %   $ 827       5.9 %   $ 3,151       7.2 %   $ 2,692       5.9 %

Hong Kong2

    11,201       78.4       11,132       78.8       34,227       78.0       36,238       79.7  

China

    501       3.5       640       4.5       1,596       3.6       2,156       4.8  

Taiwan

    584       4.1       771       5.5       1,990       4.5       2,261       5.0  

South Korea

    51       0.4       52       0.4       202       0.5       220       0.5  

Japan

    204       1.4       70       0.5       540       1.2       184       0.4  

Singapore

    8       0.1       19       0.1       31       0.1       55       0.1  

Malaysia

    112       0.8       111       0.8       295       0.7       198       0.4  

Russia and Kazakhstan

    199       1.4       190       1.3       622       1.4       602       1.3  

Europe

    258       1.8       259       1.8       869       2.0       747       1.6  

India

    131       0.9       53       0.4       374       0.8       123       0.3  

Total

  $ 14,276       100.0 %   $ 14,124       100.0 %   $ 43,897       100.0 %   $ 45,476       100.0 %

 

1 United States, Canada, Mexico and Peru

2 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors” in this report and in our most recent Annual Report on Form 10-K.

 

Net sales were $14.3 million for the three months ended September 30, 2021 compared with $14.1 million for the comparable period a year ago, an increase of $152,000, or 1%. Hong Kong net sales, substantially all of which were derived from the sale of products shipped to members residing in China, increased $69,000, or 1%, over the comparable period a year ago. The overall increase in Hong Kong net sales was mitigated due to the recognition of lower administrative fees in the current-year quarter, as compared to the prior year quarter. Notwithstanding the increase in Hong Kong net sales, we believe that our net sales continue to be negatively impacted by scattered outbreaks of COVID-19 in China and the Chinese government's imposition of related measures to control the virus, including the required closure of some businesses and restrictions on public gatherings and travel. For example, the current-year quarter marks the first quarter since the beginning of the COVID-19 pandemic that we were unable to sponsor any in-person member events in China, Macau or Hong Kong. Clearly, the operating environment for our business in China remains restrictive. Outside of our Hong Kong business, net sales increased $83,000, or 3%, over the comparable three-month period a year ago.

 

Net sales were $43.9 million for the nine months ended September 30, 2021 compared with $45.5 million for the comparable period a year ago, a decrease of $1.6 million, or 3%. The overall decrease in our Hong Kong net sales primarily resulted from the increase in deferred revenue, as unshipped product orders and unredeemed product vouchers increased $3.0 million from December 31, 2020, while unshipped product orders and unredeemed product vouchers decreased $993,000 during the comparable period in the prior year. Outside of our Hong Kong business, net sales increased $432,000, or 5%, over the comparable nine-month period a year ago. As of September 30, 2021, deferred revenue was $6.0 million, which primarily consisted of $4.0 million pertaining to unshipped product orders and unredeemed product vouchers, as well as $1.9 million in auto ship advances.

 

Gross Profit

 

Gross profit was 74.3% of net sales for each of the three months ended September 30, 2021 and 2020. Gross profit was 75.3% of net sales for the nine months ended September 30, 2021 compared with 71.5% of net sales for the nine months ended September 30, 2020. Excluding the impact of administrative fee revenue referred to above, gross profit for both the third quarter and for the first nine months of 2021 increased as compared to the comparable periods in the prior year due to lower logistics costs and fewer product promotions.

 

Commissions Expense

 

Commissions were 42.2% of net sales for the three months ended September 30, 2021 compared with 39.8% of net sales for the three months ended September 30, 2020, and 42.1% of net sales for the nine months ended September 30, 2021 compared with 42.5% of net sales for the nine months ended September 30, 2020. Excluding the impact of administrative fee revenue referred to above, commissions as a percentage of net sales for both the third quarter and for the first nine months of 2021 decreased slightly as compared to the comparable periods in the prior year.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses of $4.1 million for the three months ended September 30, 2021 were relatively consistent with $4.2 million in the same period a year ago. For the nine months ended September 30, 2021, selling, general and administrative expenses were $13.5 million compared with $13.8 million for the comparable period a year ago. The decrease in selling, general and administrative expenses during the first nine months of 2021 as compared to the comparable period in the prior year is primarily due to lower professional fees and lease costs offset by higher employee-related costs and event costs, as we held our first major event in June 2021 since the initial COVID-19 outbreak.

 

 

Income Taxes

 

An income tax benefit of $45,000 and an income tax provision of $418,000 was recognized during the three months ended September 30, 2021 and 2020, respectively. The tax benefit during the three months ended September 30, 2021 primarily resulted from income tax benefits recognized for return to provision true-ups related to the year ended December 31, 2020, as well as the permanent benefit recognized for carrying back net operating losses generated from the year ended December 31, 2020 to the year ended December 31, 2016. An income tax provision of $139,000 and an income tax benefit of $90,000 was recognized during the nine months ended September 30, 2021 and 2020, respectively. The tax benefit during the first nine months of 2020 resulted primarily from a $512,000 deferred tax asset adjustment necessary to reflect the net operating losses arising from the 2019 tax year, which is due to the U.S. Coronavirus Aid, Relief, and Economic Security ("CARES") Act enacted in March 2020 and which were carried back in August 2020 to offset taxable income in tax year 2016.

 

 

Liquidity and Capital Resources

 

At September 30, 2021, our cash and cash equivalents totaled $84.6 million. Total cash and cash equivalents decreased by $7.7 million from December 31, 2020 to September 30, 2021, primarily due to the dividends paid during the first nine months of 2021. We consider all highly liquid investments with original maturities of three months or less, when purchased, to be cash equivalents. As of September 30, 2021, we had $66.5 million in available-for-sale investments classified as cash equivalents. In addition, cash and cash equivalents included $3.8 million held in banks located within China subject to foreign currency controls. In April 2021, the Company adjusted the registered capital of its primary Chinese subsidiary and repatriated $9.0 million from China.

 

As of September 30, 2021, the ratio of current assets to current liabilities was 4.1 to 1.00 and we had $70.5 million of working capital. Working capital as of September 30, 2021 decreased $7.7 million compared to our working capital as of December 31, 2020.

 

Cash used in operations was $557,000 for the first nine months of 2021, compared with cash used in operations of $1.5 million in the comparable period of 2020. The improvement in operating cash flows resulted primarily from improved profitability during 2021.

 

Cash flows used in investing activities totaled $165,000 and $147,000 during the first nine months of 2021 and 2020, respectively.

 

Cash flows used in financing activities during the first nine months of 2021 and 2020 consisted solely of quarterly dividend payments of $0.20 per common share, totaling $6.9 million in each period. Subsequent to September 30, 2021, on November 1, 2021, the Board of Directors declared another quarterly cash dividend of $0.20 on each share of common stock outstanding. The dividend will be payable on November 26, 2021 to stockholders of record on November 16, 2021. We expect to continue paying a quarterly cash dividend of $0.20 on each share of common stock outstanding for the foreseeable future. However, any future cash dividends will be at the sole discretion of the Company’s Board of Directors, and will depend on our results of operations, financial condition, capital requirements and other factors considered relevant by the Board of Directors.

 

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and are made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. As of September 30, 2021, $21.9 million of the $70.0 million stock repurchase program remained available for future purchases, inclusive of related estimated income tax.

 

We believe that our existing internal liquidity, supported by cash on hand and cash flows from operations, should be adequate to fund normal business operations and address our financial commitments for the foreseeable future.

 

We do not have any significant unused sources of liquid assets. If necessary, we may attempt to generate more funding from the capital markets, but currently we do not believe that will be necessary.

 

 

Our priority is to focus our resources on investing in our most important markets, which we consider to be Greater China and countries where our existing members may have the connections to recruit prospects and sell our products, such as Southeast Asia, India, South America and Europe. We will continue to invest in our Mainland China entity for such purposes as establishing China-based manufacturing capabilities, increasing public awareness of our brand and our products, sourcing more Chinese-made products, building a chain of service stations, opening additional Healthy Lifestyle Centers or branch offices, adding local staffing and other requirements for a prospective China direct selling license application.

 

Critical Accounting Policies and Estimates 

 

A summary of our significant accounting policies is provided in Note 1 of the Notes to Consolidated Financial Statements in “Item 8. Financial Statements and Supplementary Data” of our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on February 26, 2021. The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.

 

Critical accounting policies and estimates are defined as both those that are material to the portrayal of our financial condition and results of operations and as those that require management’s most subjective judgments.  Management believes our critical accounting policies and estimates are those related to revenue recognition, as well as those used in the determination of liabilities related to member commissions and income taxes.

 

Revenue Recognition. All revenue is recognized when the performance obligations under a contract, including product vouchers sold on a stand-alone basis in Hong Kong, are satisfied. Product sales are recorded when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon our delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” We primarily receive payment by credit card at the time members place orders. Our sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. Amounts received for unshipped product orders and unredeemed product vouchers are recorded as deferred revenue. Such amounts totaled $4.0 million and $1.0 million at September 30, 2021 and December 31, 2020, respectively. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs.

 

Additionally, deferred revenue includes advances for auto ship orders. In certain markets, when a member’s cumulative commission income reaches a certain threshold, a percentage of the member’s weekly commission is held back as an advance and applied to an auto ship order once the accumulated amount of the advances is sufficient to pay for the pre-selected auto ship package of the member.  Such advances were $1.9 million and $2.0 million at September 30, 2021 and December 31, 2020, respectively.

 

Commissions Expense. Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of our products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  We accrue commissions when earned and as the related revenue is recognized and pay commissions on product sales generally two weeks following the end of the weekly sales period.

 

Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  For each individual incentive, we estimate the total number of qualifiers as well as the expected per qualifier cost and accrue all costs associated with incentives throughout the qualification period. We regularly review and update, if necessary, the estimates of both qualifiers and cost as more information is obtained during the qualification period. Any resulting change in total cost is recognized over the remaining qualification period. Long-term promotions and incentives (lasting up to one year) can, in particular, result in uncertain ultimate cost. Accrued commissions, including the estimated cost of our international recognition incentive program and other supplemental programs, totaled $3.4 million and $3.5 million at September 30, 2021 and December 31, 2020, respectively.

 

 

Income Taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory rates for the years in which the temporary differences are expected to be recovered or settled. We evaluate the probability of realizing the future benefits of any of our deferred tax assets and record a valuation allowance when we believe a portion or all of our deferred tax assets may not be realized. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Based on the technical merits of our tax position, tax benefits may be recognized if we determine it is more likely than not that our position will be sustained on examination by tax authorities. The complex nature of these estimates requires us to anticipate the likely application of tax law and make judgments on the largest benefit that has a greater than fifty percent likelihood of being realized prior to the completion and filing of tax returns for such periods. As of September 30, 2021, we do not have a valuation allowance against our U.S. deferred tax assets. We maintain a valuation allowance in certain foreign jurisdictions with an overall tax loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.

 

Provision for income taxes depends on the statutory tax rates in each of the jurisdictions in which we operate. As a result of capital return activities, we determined that a portion of our current undistributed foreign earnings are no longer deemed reinvested indefinitely by our non-U.S. subsidiaries. The Tax Act, enacted on December 22, 2017 by the U.S. government, required a one-time repatriation tax on certain un-repatriated earnings of foreign subsidiaries at a rate of 15.5% tax on post-1986 foreign earnings held in cash and an 8% rate on all other post-1986 earnings. Due to the adoption of a territorial tax regime, any foreign source portion of a qualified dividend received by a 10% U.S. corporate shareholder is exempt from U.S. federal tax, therefore resulting in any future repatriation having a minimal effect on our effective tax rate. For state income tax purposes, we will continue to periodically reassess the needs of our foreign subsidiaries and update our indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, we expect to recognize additional income tax provision at the applicable U.S. state corporate tax rate(s). As of September 30, 2021, we have not recorded a state deferred tax liability for earnings to be repatriated in the future because all earnings as of September 30, 2021 have already been repatriated. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of September 30, 2021.

 

The U.S. Coronavirus Aid, Relief, and Economic Security (“CARES”) Act was enacted on March 27, 2020. The CARES Act was enacted to provide tax relief to companies impacted by the COVID-19 pandemic. In addition to other broad changes, the CARES Act allowed for a 5-year carryback period for net operating losses arising in tax years beginning after 2017 and before 2021, effectively taking advantage of differences in tax rate as a result of enactment of the Tax Act. We booked a tax benefit of $512,000 during 2020 due to the net operating loss generated in the taxable year ended December 31, 2019. We booked a tax benefit of $84,000 during 2021 due to the net operating loss generated in the taxable year ended December 31, 2020 for the rate differential resulting from the carryback.

 

We estimate what our effective tax rate will be for the full fiscal year at each interim reporting period and record a quarterly tax provision based on that estimated effective tax rate. Throughout the year that estimated rate may change based on variations in our business, changes in our corporate structure, changes in the geographic mix and amount of income, applicable tax laws and regulations, communications with tax authorities, as well as our estimated and actual level of annual pre-tax income. We adjust our income tax provision in the reporting period in which the change in our estimated rate occurs so that the year-to-date provision is consistent with the anticipated annual tax rate. The Company’s effective tax rate projected for the year ending December 31, 2021 differs from the year ended December 31, 2020 primarily as a result of the CARES Act.

 

 

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable under smaller reporting company disclosure rules.

 

Item 4. CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

Management, with the participation of the Company’s principal executive officer and principal financial officer, evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of September 30, 2021. The Company’s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to management, including the Company’s principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, the principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of September 30, 2021.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in internal control over financial reporting that occurred during the fiscal quarter ended September 30, 2021 that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

 

 

 

PART II — OTHER INFORMATION

 

 

Item 1. LEGAL PROCEEDINGS

 

None.

 

Item 1A. RISK FACTORS

 

Our operations and financial results are subject to various risks and uncertainties, including those described in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020, which could adversely affect our business, financial condition, results of operations, cash flows, and the trading price of our common stock. There have been no material changes to our risk factors since our Annual Report on Form 10-K for the year ended December 31, 2020, except that we added the following risk factor in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021:

 

Our business is subject to a variety of laws, regulations and other obligations regarding privacy, data protection and information security.  Any actual or perceived failure by us or our third-party vendors to comply with such laws, regulations or other obligations could materially adversely affect our business.

 

We collect certain personal information, including payment data, from members and consumers, as well as our employees.   We also develop and maintain sensitive and proprietary business information.  We are therefore subject to numerous laws, regulations and other obligations that address privacy, data protection and information security in the various markets in which we conduct business.   We are particularly focused on the evolving state of laws and regulations in China applicable to privacy, data protection and information security.   Of particular note is that on June 10, 2021, the Standing Committee of the National People's Congress of China promulgated the Data Security Law, which will take effect in September 2021. The Data Security Law imposes data security and privacy obligations on entities and individuals carrying out data activities, and introduces a data classification and hierarchical protection system based on the importance of data in economic and social development, as well as the degree of harm it will cause to national security, public interests, or legitimate rights and interests of individuals or organizations when such data is tampered with, destroyed, leaked, or illegally acquired or used. The Data Security Law also provides for a national security review procedure for data activities that may affect national security and imposes export restrictions on certain data and information.

 

The interpretation, application and enforcement of privacy, data security and information security laws, regulations and other obligations evolve from time to time and their scope may continually change, through new legislation, amendments to existing legislation and changes in interpretation and enforcement. We have incurred, and will continue to incur, significant expenses in an effort to comply with such laws, regulations and other obligations, as well as related security standards and protocols.  Despite our compliance efforts, we may not meet all of the requirements imposed on us.  Any failure on our part or on the part of our third-party vendors to comply with applicable laws, regulations or other obligations relating to privacy, data protection or information security could damage our reputation, result in investigations, fines or other penalties imposed by governmental authorities and private claims or litigation, any of which could materially adversely affect our business, financial condition and results of operations. Even if our practices or those of our third-party vendors are not subject to legal challenge, the perception of data or privacy concerns, whether or not valid, may harm our reputation and brand and adversely affect our business, financial condition and results of operations.

 

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

Item 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

Item 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

Item 5. OTHER INFORMATION

 

None.

 

Item 6. EXHIBITS

 

Exhibit

Number

 

 

Exhibit Description

 

 

 

31.1

 

Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

 

Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

 

Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

     

101.INS

 

Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

101.SCH

 

Inline XBRL Taxonomy Extension Schema

101.CAL

 

Inline XBRL Taxonomy Extension Calculation

101.DEF

 

Inline XBRL Taxonomy Extension Definition

101.LAB

 

Inline XBRL Taxonomy Extension Labels

101.PRE

 

Inline XBRL Taxonomy Extension Presentation

104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

NATURAL HEALTH TRENDS CORP.

 

 

 

 

Date: November 3, 2021

/s/ Timothy S. Davidson

 

 

Timothy S. Davidson

 

 

Senior Vice President and Chief Financial Officer

 

 

(Principal Financial Officer)

 

 

 

EXHIBIT INDEX

 

Exhibit

Number

 

Exhibit Description

 

 

 

31.1

 

Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

 

Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

 

Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

     

101.INS

 

Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

101.SCH

 

Inline XBRL Taxonomy Extension Schema

101.CAL

 

Inline XBRL Taxonomy Extension Calculation

101.DEF

 

Inline XBRL Taxonomy Extension Definition

101.LAB

 

Inline XBRL Taxonomy Extension Labels

101.PRE

 

Inline XBRL Taxonomy Extension Presentation

104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

26
EX-31.1 2 ex_277499.htm EXHIBIT 31.1 ex_277499.htm

EXHIBIT 31.1

 

CERTIFICATION

 

I, Chris T. Sharng, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Natural Health Trends Corp.;

 

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.  The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.  The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 3, 2021

/s/ Chris T. Sharng

 

 

Chris T. Sharng

 

 

President

 

 

(Principal Executive Officer)

 

 

 
EX-31.2 3 ex_277500.htm EXHIBIT 31.2 ex_277500.htm

EXHIBIT 31.2

 

CERTIFICATION

 

I, Timothy S. Davidson, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Natural Health Trends Corp.;

 

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.  The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.  The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 3, 2021

/s/ Timothy S. Davidson

 

 

Timothy S. Davidson

 

 

Senior Vice President and Chief Financial Officer

 

 

(Principal Financial Officer)

 

 

 
EX-32.1 4 ex_277501.htm EXHIBIT 32.1 ex_277501.htm

EXHIBIT 32.1

 

 

CERTIFICATIONS PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Natural Health Trends Corp. (the “Company”) on Form 10-Q for the period ended September 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Chris T. Sharng, the Principal Executive Officer, and Timothy S. Davidson, the Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 3, 2021

/s/ Chris T. Sharng

 

 

Chris T. Sharng

 

 

President

 

 

(Principal Executive Officer)

 

 

 

 

 

 

 

Date: November 3, 2021

/s/ Timothy S. Davidson

 

 

Timothy S. Davidson

 

 

Senior Vice President and Chief Financial Officer

 

 

(Principal Financial Officer)

 

 

 

The foregoing certifications are not deemed filed with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), and are not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 
EX-101.SCH 5 nhtc-20210930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statements of Comprehensive Income (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 007 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 1 - Nature of Operations, Basis of Presentation and Consolidation link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 2 - Revenue link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 3 - Balance Sheet Components link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 4 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 5 - Leases link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 6 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 7 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 8 - Stock-based Incentive Plans link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 9 - Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 10 - Related Party Transactions link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 11 - Segment Information link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 12 - Subsequent Event link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 1 - Nature of Operations, Basis of Presentation and Consolidation (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 2 - Revenue (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 3 - Balance Sheet Components (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 4 - Fair Value Measurements (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 5 - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 8 - Stock-based Incentive Plans (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 9 - Stockholders' Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 11 - Segment Information (Tables) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 1 - Nature of Operations, Basis of Presentation and Consolidation - Earnings Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 2 - Revenue (Details Textual) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 2 - Revenue - Net Sales by Product and Service (Details) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 3 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 4 - Fair Value Measurements - Investments (Details) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 5 - Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 5 - Leases - Lease Cost (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 5 - Leases - Maturity of Lease Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 6 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 8 - Stock-based Incentive Plans (Details Textual) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 8 - Stock-based Incentive Plans - Restricted Stock Activity (Details) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 9 - Stockholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 9 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 10 - Related Party Transactions (Details Textual) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 11 - Segment Information - Operating Information by Geographic Area (Details) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 11 - Segment Information - Net Sales by Geographic Area (Details) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 12 - Subsequent Event (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 6 nhtc-20210930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 nhtc-20210930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 nhtc-20210930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Note To Financial Statement Details Textual Significant Accounting Policies 2022 Note 1 - Nature of Operations, Basis of Presentation and Consolidation Debt Securities, Available-for-sale [Table Text Block] 2023 Note 2 - Revenue Note 3 - Balance Sheet Components Note 4 - Fair Value Measurements Note 5 - Leases Note 8 - Stock-based Incentive Plans Note 9 - Stockholders' Equity Note 11 - Segment Information Income Tax Disclosure [Text Block] Note 1 - Nature of Operations, Basis of Presentation and Consolidation - Earnings Per Share (Details) Unrealized gains (losses) on available-for-sale securities Note 2 - Revenue - Net Sales by Product and Service (Details) Note 3 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details) Lessee, Operating Lease, Liability, Maturity [Table Text Block] Note 4 - Fair Value Measurements - Investments (Details) Other assets Remainder of 2021 Note 5 - Leases - Lease Cost (Details) us-gaap_LiabilitiesCurrent Total current liabilities Note 5 - Leases - Maturity of Lease Liabilities (Details) Note 8 - Stock-based Incentive Plans - Restricted Stock Activity (Details) Note 9 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details) Other current liabilities Note 11 - Segment Information - Operating Information by Geographic Area (Details) Earnings Per Share, Policy [Policy Text Block] Note 11 - Segment Information - Net Sales by Geographic Area (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] Operating expenses: Vested, wtd. avg. price (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Balance, weighted avg. price (in dollars per share) Balance, weighted avg. price (in dollars per share) Foreign currency translation adjustment Foreign currency translation adjustments us-gaap_LesseeOperatingLeaseRenewalTerm Lessee, Operating Lease, Renewal Term (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Balance (in shares) Balance (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) Vested (in shares) Depreciation and amortization Corporate Debt Securities [Member] Nonvested Restricted Stock Shares Activity [Table Text Block] us-gaap_AssetsCurrent Total current assets Stockholders' Equity Note Disclosure [Text Block] Treasury stock, shares (in shares) Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at September 30, 2021 and December 31, 2020 Adjustments to reconcile net income to net cash used in operating activities: Common stock, authorized (in shares) Common stock, issued (in shares) Deferred revenue Common stock, par value (in dollars per share) us-gaap_AccruedLiabilitiesCurrent Accrued Liabilities, Current, Total us-gaap_DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance, Total Income taxes payable Statistical Measurement [Domain] us-gaap_OperatingLeasePayments Operating Lease, Payments Maximum [Member] Minimum [Member] Lessee, Operating Leases [Text Block] Accounts payable Product and Service [Axis] Other current assets Product and Service [Domain] Statistical Measurement [Axis] Employee-related expense Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding Other accrued expenses Preferred stock, issued (in shares) us-gaap_PolicyTextBlockAbstract Accounting Policies Geographical [Axis] Geographical [Domain] Preferred stock, authorized (in shares) Europe [Member] Inventories Inventory, Net, Total Accrued commissions us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) Preferred stock, par value (in dollars per share) Raw materials us-gaap_InventoryValuationReserves Reserve for obsolescence Revenue from External Customers by Products and Services [Table Text Block] us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchases of property and equipment Non-vested restricted stock (in shares) Finished goods SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION: Fair Value Hierarchy and NAV [Domain] us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month) Product and Service, Other [Member] Fair Value Hierarchy and NAV [Axis] The Phantom Plan [Member] Information pertaining to the phantom plan. Current liabilities: Supplemental Balance Sheet Disclosures [Text Block] Phantom Shares [Member] Information pertaining to phantom shares. Product [Member] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] us-gaap_Assets Total assets Inventories: Plan Name [Axis] Plan Name [Domain] Employees and Non-Employee Directors [Member] Information pertaining to employees and non-employee directors. CASH FLOWS FROM OPERATING ACTIVITIES: Net income available to common stockholders Net income available to common stockholders plus assumed conversions Statement [Line Items] Non-vested restricted stock AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Additional paid-in capital Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Deferred tax asset Share-based Payment Arrangement [Text Block] AOCI Attributable to Parent [Member] Stockholders’ equity: Other income (expense), net Segment Reporting Disclosure [Text Block] nhtc_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPaymentPerShare Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Maximum Payment Per Share (in dollars per share) Represents the maximum payment value per share of equity instruments other than options under share based compensation arrangement. Business Description and Basis of Presentation [Text Block] Award Type [Domain] Amounts held in eWallets Amount liability recognized from cost incurred to obtain or fulfill contract with customer; classified as current. Current assets: Fair Value Disclosures [Text Block] Award Type [Axis] Net income Net income us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period Effect of exchange rates on cash, cash equivalents and restricted cash us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net decrease in cash, cash equivalents and restricted cash Restricted Stock [Member] us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash used in financing activities us-gaap_Liabilities Total liabilities Commitments and contingencies (Note 7) Director [Member] Noncash lease expense Represents the amount of lessee's noncash lease expense during the period. Deferred income taxes Represents the amount of deferred income tax expense (benefit), excluding effects of foreign exchange. us-gaap_OperatingIncomeLoss Income (loss) from operations Income (loss) from operations us-gaap_ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities nhtc_RevenueFromContractWithCustomersHistoricalSalesReturnsPercent Revenue from Contract with Customers, Historical Sales Returns, Percent Represents the percentage of historical sales returns. nhtc_RevenueFromContractWithCustomersSalesReturnsPercent Revenue from Contract with Customers, Sales Returns, Percent Represents the percentage of sales returns. us-gaap_GrossProfit Gross profit nhtc_IncreaseDecreaseInAccruedSalesCommissions Accrued commissions Amount of increase (decrease) in accrued sales commissions. Cost of sales nhtc_IncreaseDecreaseInOperatingLeaseLiabilities Operating lease liabilities Amount of increase (decrease) in operating lease liabilities. nhtc_IncreaseDecreaseInCapitalizedContractCostLiability Amounts held in eWallets Amount of increase (decrease) in capitalized contract cost liability. nhtc_RevenueFromContractWithCustomerSalesReturnsPolicyTerm Revenue from Contract with Customer, Sales Returns Policy Term (Day) Represents the sales returns policy term. Deferred tax liability Consolidation Items [Domain] nhtc_NumberOfMajorCustomers Number of Major Customers Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc. nhtc_NumberOfMajorMarkets Number of Major Markets Represents the number of major markets accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc. Commitments and Contingencies Disclosure [Text Block] Property and equipment, net Bank Time Deposits [Member] Consolidation Items [Axis] us-gaap_Dividends Dividends declared nhtc_RevenueFromContractWithCustomerSalesReturns Less: sales returns Represents the amount of sales returns during the period. us-gaap_PaymentsOfDividends Dividends paid Unshipped Product [Member] Information pertaining to unshipped product. Auto ship advances [Member] Information pertaining to auto ship advances. Sales returns Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales returns. Schedule of Additional Balance Sheet Components [Table Text Block] Tabular disclosure of additional balance sheet components. CASH FLOWS FROM INVESTING ACTIVITIES: Warehousing, inventory-related and other Carrying value as of the balance sheet date of obligations incurred through that date and payable for warehousing and inventory related expense. Fair value Fair value Retained Earnings [Member] Net sales Title of Individual [Domain] Title of Individual [Axis] Treasury Stock [Member] Income taxes payable us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 Stock Repurchase Program, Remaining Authorized Repurchase Amount Intersegment Eliminations [Member] Additional Paid-in Capital [Member] CANADA Common Stock [Member] us-gaap_StockRepurchaseProgramAuthorizedAmount1 Stock Repurchase Program, Authorized Amount Related Party Transactions Disclosure [Text Block] Preferred Stock [Member] us-gaap_IncreaseDecreaseInAccruedLiabilities Other accrued expenses Income tax provision (benefit) Equity Components [Axis] Equity Component [Domain] CHINA nhtc_LesseeNumberOfBranches Lessee, Number of Branches Represents the lessees' number of branches. us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable Rolling Hills Estates [Member] Information pertaining to Rolling Hills Estates. Richmond, British Columbia [Member] Information pertaining to Richmond, British Columbia. Metuchen, New Jersey [Member] Information pertaining to Metuchen, New Jersey. Income before income taxes Income before income taxes us-gaap_OperatingExpenses Total operating expenses nhtc_OperatingLossCarryforwardsSubjectToExpiration Operating Loss Carryforwards, Subject to Expiration Amount of operating loss carryforward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws. Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] nhtc_CommonStockPercentageOfBeneficialStockOutstanding Common Stock, Percentage of Beneficial Stock Outstanding Represents the percentage of beneficial stock outstanding. Cash Cash equivalents BHS [Member] Information pertaining to BHS. Cash and cash equivalents Cash and cash equivalents State and Local Jurisdiction [Member] Equity Incentive Plan 2016 [Member] Information pertaining to the 2016 Equity Incentive Plan. us-gaap_IncreaseDecreaseInOtherCurrentLiabilities Other current liabilities Income Tax Authority [Axis] Income Tax Authority [Domain] Domestic Tax Authority [Member] us-gaap_AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense Foreign Tax Authority [Member] Royalty Agreement and License [Member] Information pertaining to the Royalty Agreement and License. nhtc_RelatedPartyTransactionAutomaticRenewalPeriodOfAgreement Related Party Transaction, Automatic Renewal Period of Agreement (Year) Represents the automatic renewal period of the agreement in related party transaction. Revenue from Contract with Customer [Text Block] nhtc_NumberOfDaysTerminationNotice Number of Days Termination Notice (Day) Represents the number of days for termination notice. Primary Reporting Segment [Member] Information pertaining to the primary reporting segment. Russia and Kazakhstan [Member] Information pertaining to Russia and Kazakhstan. Document Quarterly Report us-gaap_RoyaltyExpense Royalty Expense Amendment Flag Entity Incorporation, State or Country Code HONG KONG Accounting Policies [Abstract] Other comprehensive income (loss), net of tax: us-gaap_ComprehensiveIncomeNetOfTax Comprehensive income Document Transition Report City Area Code Basis of Accounting, Policy [Policy Text Block] Other Foreign Countries [Member] Information pertaining to other foreign countries. New Accounting Pronouncements, Policy [Policy Text Block] Entity Interactive Data Current Dividends declared, per share (in dollars per share) Common Stock, Dividends, Per Share, Declared (in dollars per share) us-gaap_CommonStockDividendsPerShareCashPaid Common Stock, Dividends, Per Share, Cash Paid (in dollars per share) Reclassification, Comparability Adjustment [Policy Text Block] Deferred revenue us-gaap_IncreaseDecreaseInContractWithCustomerLiability Increase (Decrease) in Contract with Customer, Liability us-gaap_SharesOutstanding BALANCE (in shares) BALANCE (in shares) Security Exchange Name Preferred stock, outstanding (in shares) Title of 12(b) Security Current Fiscal Year End Date us-gaap_LeaseCost Total lease cost Weighted-average discount rate Document Fiscal Period Focus Operating leases Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Short-term leases Lease, Cost [Table Text Block] Document Period End Date Right-of-use assets obtained in exchange for operating lease liabilities Weighted-average remaining lease term (in years) (Year) Entity File Number KOREA, REPUBLIC OF Entity Emerging Growth Company Document Type Entity Small Business Entity Shell Company NewNonEmployeeDirectorsMember Document Information [Line Items] Other accrued expenses: Document Information [Table] Entity Filer Category Entity Current Reporting Status us-gaap_DividendsCommonStock Dividends, Common Stock, Total Segments [Axis] Segments [Domain] Weighted average common shares outstanding: Diluted (in shares) Statement of Comprehensive Income [Abstract] Entity Tax Identification Number Entity Central Index Key us-gaap_OperatingLossCarryforwards Operating Loss Carryforwards, Total Administrative Fees, Freight and Other [Member] Information related to administrative fees, freight and other. Entity Registrant Name Net income per common share: Entity [Domain] Customer Concentration Risk [Member] Legal Entity [Axis] Statement [Table] Entity Address, Address Line One Statement of Financial Position [Abstract] Diluted (in dollars per share) Basic (in shares) Entity Address, City or Town Geographic Concentration Risk [Member] Entity Address, Country Basic (in dollars per share) Concentration Risk Type [Axis] Concentration Risk Type [Domain] Deferred revenue: us-gaap_TreasuryStockValue Treasury stock, at cost; 1,556,875 shares at September 30, 2021 and December 31, 2020 Statement of Cash Flows [Abstract] PERU Entity Common Stock, Shares Outstanding Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] Statement of Stockholders' Equity [Abstract] Other comprehensive income (loss) Income Statement [Abstract] Municipal Bonds [Member] Revenue Benchmark [Member] us-gaap_IncreaseDecreaseInOtherCurrentAssets Other current assets us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Other assets Investments [Domain] us-gaap_IncreaseDecreaseInInventories Inventories Trading Symbol Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Investment Type [Axis] Local Phone Number us-gaap_TableTextBlock Notes Tables Related Party [Axis] Related Party [Domain] us-gaap_AreaOfLand Area of Land (Square Foot) Selling, general and administrative expenses Commissions expense CASH FLOWS FROM FINANCING ACTIVITIES: Thereafter Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). TAIWAN, PROVINCE OF CHINA us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholders’ equity UNITED STATES Related Party Transaction [Axis] Related Party Transaction [Domain] Retained earnings Accumulated other comprehensive loss Money Market Funds [Member] Changes in assets and liabilities: us-gaap_StockholdersEquity Total stockholders’ equity Balance Balance us-gaap_AccruedIncomeTaxesNoncurrent Income taxes payable us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Subsequent Event [Member] us-gaap_OperatingLeaseLiabilityNoncurrent Operating lease liabilities Class of Stock [Axis] Restricted cash Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Present value of lease liabilities Subsequent Event Type [Axis] Operating lease liabilities Subsequent Event Type [Domain] us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Gross unrealized losses Subsequent Events [Text Block] Operating Segments [Member] Operating lease right-of-use assets us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Total lease payments us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less: imputed interest Adjusted cost 2024 2025 EX-101.PRE 9 nhtc-20210930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 nhtc20210930_10q_htm.xml IDEA: XBRL DOCUMENT 0000912061 2021-01-01 2021-09-30 0000912061 2021-10-29 0000912061 2021-09-30 0000912061 2020-12-31 0000912061 2021-07-01 2021-09-30 0000912061 2020-07-01 2020-09-30 0000912061 2020-01-01 2020-09-30 0000912061 us-gaap:PreferredStockMember 2020-12-31 0000912061 us-gaap:CommonStockMember 2020-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000912061 us-gaap:RetainedEarningsMember 2020-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000912061 us-gaap:TreasuryStockMember 2020-12-31 0000912061 us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0000912061 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000912061 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000912061 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0000912061 2021-01-01 2021-03-31 0000912061 us-gaap:PreferredStockMember 2021-03-31 0000912061 us-gaap:CommonStockMember 2021-03-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000912061 us-gaap:RetainedEarningsMember 2021-03-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000912061 us-gaap:TreasuryStockMember 2021-03-31 0000912061 2021-03-31 0000912061 us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0000912061 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000912061 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0000912061 us-gaap:TreasuryStockMember 2021-04-01 2021-06-30 0000912061 2021-04-01 2021-06-30 0000912061 us-gaap:PreferredStockMember 2021-06-30 0000912061 us-gaap:CommonStockMember 2021-06-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000912061 us-gaap:RetainedEarningsMember 2021-06-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000912061 us-gaap:TreasuryStockMember 2021-06-30 0000912061 2021-06-30 0000912061 us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0000912061 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000912061 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000912061 us-gaap:TreasuryStockMember 2021-07-01 2021-09-30 0000912061 us-gaap:PreferredStockMember 2021-09-30 0000912061 us-gaap:CommonStockMember 2021-09-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000912061 us-gaap:RetainedEarningsMember 2021-09-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0000912061 us-gaap:TreasuryStockMember 2021-09-30 0000912061 us-gaap:PreferredStockMember 2019-12-31 0000912061 us-gaap:CommonStockMember 2019-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000912061 us-gaap:RetainedEarningsMember 2019-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000912061 us-gaap:TreasuryStockMember 2019-12-31 0000912061 2019-12-31 0000912061 us-gaap:PreferredStockMember 2020-01-01 2020-03-31 0000912061 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000912061 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000912061 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0000912061 2020-01-01 2020-03-31 0000912061 us-gaap:PreferredStockMember 2020-03-31 0000912061 us-gaap:CommonStockMember 2020-03-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000912061 us-gaap:RetainedEarningsMember 2020-03-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000912061 us-gaap:TreasuryStockMember 2020-03-31 0000912061 2020-03-31 0000912061 us-gaap:PreferredStockMember 2020-04-01 2020-06-30 0000912061 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000912061 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0000912061 us-gaap:TreasuryStockMember 2020-04-01 2020-06-30 0000912061 2020-04-01 2020-06-30 0000912061 us-gaap:PreferredStockMember 2020-06-30 0000912061 us-gaap:CommonStockMember 2020-06-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000912061 us-gaap:RetainedEarningsMember 2020-06-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000912061 us-gaap:TreasuryStockMember 2020-06-30 0000912061 2020-06-30 0000912061 us-gaap:PreferredStockMember 2020-07-01 2020-09-30 0000912061 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000912061 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000912061 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0000912061 us-gaap:PreferredStockMember 2020-09-30 0000912061 us-gaap:CommonStockMember 2020-09-30 0000912061 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000912061 us-gaap:RetainedEarningsMember 2020-09-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000912061 us-gaap:TreasuryStockMember 2020-09-30 0000912061 2020-09-30 0000912061 srt:MinimumMember 2021-01-01 2021-09-30 0000912061 srt:MaximumMember 2021-01-01 2021-09-30 0000912061 us-gaap:ProductMember 2021-07-01 2021-09-30 0000912061 us-gaap:ProductMember 2020-07-01 2020-09-30 0000912061 us-gaap:ProductMember 2021-01-01 2021-09-30 0000912061 us-gaap:ProductMember 2020-01-01 2020-09-30 0000912061 nhtc:AdministrativeFeesFreightAndOtherMember 2021-07-01 2021-09-30 0000912061 nhtc:AdministrativeFeesFreightAndOtherMember 2020-07-01 2020-09-30 0000912061 nhtc:AdministrativeFeesFreightAndOtherMember 2021-01-01 2021-09-30 0000912061 nhtc:AdministrativeFeesFreightAndOtherMember 2020-01-01 2020-09-30 0000912061 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-07-01 2021-09-30 0000912061 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-09-30 0000912061 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-09-30 0000912061 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-07-01 2020-09-30 0000912061 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000912061 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000912061 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0000912061 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0000912061 nhtc:UnshippedProductMember 2021-09-30 0000912061 nhtc:UnshippedProductMember 2020-12-31 0000912061 nhtc:AutoShipAdvancesMember 2021-09-30 0000912061 nhtc:AutoShipAdvancesMember 2020-12-31 0000912061 us-gaap:ProductAndServiceOtherMember 2021-09-30 0000912061 us-gaap:ProductAndServiceOtherMember 2020-12-31 0000912061 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2021-09-30 0000912061 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2020-12-31 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember 2021-09-30 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember 2020-12-31 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2021-09-30 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2020-12-31 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2021-09-30 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0000912061 country:HK 2021-09-30 0000912061 nhtc:RollingHillsEstatesMember 2021-09-30 0000912061 nhtc:RichmondBritishColumbiaMember 2021-09-30 0000912061 nhtc:MetuchenNewJerseyMember 2021-09-30 0000912061 country:CN 2021-09-30 0000912061 us-gaap:DomesticCountryMember 2021-09-30 0000912061 us-gaap:StateAndLocalJurisdictionMember 2021-09-30 0000912061 us-gaap:ForeignCountryMember 2021-09-30 0000912061 nhtc:EquityIncentivePlan2016Member 2021-09-30 0000912061 us-gaap:RestrictedStockMember 2020-12-31 0000912061 us-gaap:RestrictedStockMember 2021-01-01 2021-09-30 0000912061 us-gaap:RestrictedStockMember 2021-09-30 0000912061 nhtc:ThePhantomPlanMember 2021-03-15 2021-03-15 0000912061 nhtc:EmployeesAndNonEmployeeDirectorsMember nhtc:PhantomSharesMember nhtc:ThePhantomPlanMember 2021-03-15 2021-03-15 0000912061 srt:MaximumMember nhtc:EmployeesAndNonEmployeeDirectorsMember nhtc:PhantomSharesMember nhtc:ThePhantomPlanMember 2021-03-15 0000912061 nhtc:NewnonemployeedirectorsMember nhtc:PhantomSharesMember nhtc:ThePhantomPlanMember 2021-05-14 2021-05-14 0000912061 nhtc:EmployeesAndNonEmployeeDirectorsMember nhtc:PhantomSharesMember nhtc:ThePhantomPlanMember 2021-07-01 2021-09-30 0000912061 nhtc:EmployeesAndNonEmployeeDirectorsMember nhtc:PhantomSharesMember nhtc:ThePhantomPlanMember 2021-01-01 2021-09-30 0000912061 2015-07-28 0000912061 2016-01-12 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-12-31 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-09-30 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-01-01 2021-09-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2021-09-30 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-09-30 0000912061 srt:DirectorMember 2021-06-30 0000912061 nhtc:RoyaltyAgreementAndLicenseMember nhtc:BHSMember 2021-07-01 2021-09-30 0000912061 nhtc:RoyaltyAgreementAndLicenseMember nhtc:BHSMember 2020-07-01 2020-09-30 0000912061 nhtc:RoyaltyAgreementAndLicenseMember nhtc:BHSMember 2021-01-01 2021-09-30 0000912061 nhtc:RoyaltyAgreementAndLicenseMember nhtc:BHSMember 2020-01-01 2020-09-30 0000912061 nhtc:PrimaryReportingSegmentMember 2021-07-01 2021-09-30 0000912061 nhtc:PrimaryReportingSegmentMember 2020-07-01 2020-09-30 0000912061 nhtc:PrimaryReportingSegmentMember 2021-01-01 2021-09-30 0000912061 nhtc:PrimaryReportingSegmentMember 2020-01-01 2020-09-30 0000912061 country:CN 2021-07-01 2021-09-30 0000912061 country:CN 2020-07-01 2020-09-30 0000912061 country:CN 2021-01-01 2021-09-30 0000912061 country:CN 2020-01-01 2020-09-30 0000912061 nhtc:RussiaAndKazakhstanMember 2021-07-01 2021-09-30 0000912061 nhtc:RussiaAndKazakhstanMember 2020-07-01 2020-09-30 0000912061 nhtc:RussiaAndKazakhstanMember 2021-01-01 2021-09-30 0000912061 nhtc:RussiaAndKazakhstanMember 2020-01-01 2020-09-30 0000912061 us-gaap:OperatingSegmentsMember nhtc:PrimaryReportingSegmentMember 2021-07-01 2021-09-30 0000912061 us-gaap:OperatingSegmentsMember nhtc:PrimaryReportingSegmentMember 2020-07-01 2020-09-30 0000912061 us-gaap:OperatingSegmentsMember nhtc:PrimaryReportingSegmentMember 2021-01-01 2021-09-30 0000912061 us-gaap:OperatingSegmentsMember nhtc:PrimaryReportingSegmentMember 2020-01-01 2020-09-30 0000912061 us-gaap:OperatingSegmentsMember country:CN 2021-07-01 2021-09-30 0000912061 us-gaap:OperatingSegmentsMember country:CN 2020-07-01 2020-09-30 0000912061 us-gaap:OperatingSegmentsMember country:CN 2021-01-01 2021-09-30 0000912061 us-gaap:OperatingSegmentsMember country:CN 2020-01-01 2020-09-30 0000912061 us-gaap:OperatingSegmentsMember nhtc:RussiaAndKazakhstanMember 2021-07-01 2021-09-30 0000912061 us-gaap:OperatingSegmentsMember nhtc:RussiaAndKazakhstanMember 2020-07-01 2020-09-30 0000912061 us-gaap:OperatingSegmentsMember nhtc:RussiaAndKazakhstanMember 2021-01-01 2021-09-30 0000912061 us-gaap:OperatingSegmentsMember nhtc:RussiaAndKazakhstanMember 2020-01-01 2020-09-30 0000912061 us-gaap:OperatingSegmentsMember 2021-07-01 2021-09-30 0000912061 us-gaap:OperatingSegmentsMember 2020-07-01 2020-09-30 0000912061 us-gaap:OperatingSegmentsMember 2021-01-01 2021-09-30 0000912061 us-gaap:OperatingSegmentsMember 2020-01-01 2020-09-30 0000912061 us-gaap:IntersegmentEliminationMember 2021-07-01 2021-09-30 0000912061 us-gaap:IntersegmentEliminationMember 2020-07-01 2020-09-30 0000912061 us-gaap:IntersegmentEliminationMember 2021-01-01 2021-09-30 0000912061 us-gaap:IntersegmentEliminationMember 2020-01-01 2020-09-30 0000912061 country:US 2021-07-01 2021-09-30 0000912061 country:US 2020-07-01 2020-09-30 0000912061 country:US 2021-01-01 2021-09-30 0000912061 country:US 2020-01-01 2020-09-30 0000912061 country:CA 2021-07-01 2021-09-30 0000912061 country:CA 2020-07-01 2020-09-30 0000912061 country:CA 2021-01-01 2021-09-30 0000912061 country:CA 2020-01-01 2020-09-30 0000912061 country:PE 2021-07-01 2021-09-30 0000912061 country:PE 2020-07-01 2020-09-30 0000912061 country:PE 2021-01-01 2021-09-30 0000912061 country:PE 2020-01-01 2020-09-30 0000912061 country:HK 2021-07-01 2021-09-30 0000912061 country:HK 2020-07-01 2020-09-30 0000912061 country:HK 2021-01-01 2021-09-30 0000912061 country:HK 2020-01-01 2020-09-30 0000912061 country:TW 2021-07-01 2021-09-30 0000912061 country:TW 2020-07-01 2020-09-30 0000912061 country:TW 2021-01-01 2021-09-30 0000912061 country:TW 2020-01-01 2020-09-30 0000912061 country:KR 2021-07-01 2021-09-30 0000912061 country:KR 2020-07-01 2020-09-30 0000912061 country:KR 2021-01-01 2021-09-30 0000912061 country:KR 2020-01-01 2020-09-30 0000912061 srt:EuropeMember 2021-07-01 2021-09-30 0000912061 srt:EuropeMember 2020-07-01 2020-09-30 0000912061 srt:EuropeMember 2021-01-01 2021-09-30 0000912061 srt:EuropeMember 2020-01-01 2020-09-30 0000912061 nhtc:OtherForeignCountriesMember 2021-07-01 2021-09-30 0000912061 nhtc:OtherForeignCountriesMember 2020-07-01 2020-09-30 0000912061 nhtc:OtherForeignCountriesMember 2021-01-01 2021-09-30 0000912061 nhtc:OtherForeignCountriesMember 2020-01-01 2020-09-30 0000912061 us-gaap:SubsequentEventMember 2021-11-01 2021-11-01 shares thunderdome:item iso4217:USD iso4217:USD shares utr:D utr:Y pure utr:sqft utr:M 0000912061 Natural Health Trends Corp. false --12-31 Q3 2021 0.001 0.001 5000000 5000000 0 0 0 0 0.001 0.001 50000000 50000000 12979414 12979414 1556875 1556875 0.20 0.20 0.20 0.20 0.20 0.20 P14D P1Y 0 0 0 0 0 0 0 0 P5Y 8 0 P10Y P3M 0.20 0.20 P1Y P90D 10-Q true 2021-09-30 false 001-36849 DE 59-2705336 132 Nathan Road Tsimshatsui HK 852 3107-0800 Common Stock, par value $0.001 per share NHTC NASDAQ Yes Yes Non-accelerated Filer true false false 11422539 84640000 92367000 4390000 3779000 4386000 3595000 93416000 99741000 463000 539000 3339000 3745000 524000 525000 660000 731000 574000 661000 98976000 105942000 879000 580000 1844000 1481000 3441000 3496000 1758000 1922000 6038000 3091000 6756000 8503000 1304000 1163000 847000 1270000 22867000 21506000 12130000 13748000 215000 216000 2209000 2775000 37421000 38245000 0 0 13000 13000 86102000 86102000 1820000 7822000 -476000 -336000 25904000 25904000 61555000 67697000 98976000 105942000 14276000 14124000 43897000 45476000 3668000 3635000 10857000 12966000 10608000 10489000 33040000 32510000 6027000 5620000 18468000 19336000 4102000 4201000 13488000 13771000 10129000 9821000 31956000 33107000 479000 668000 1084000 -597000 -53000 385000 -92000 603000 426000 1053000 992000 6000 -45000 418000 139000 -90000 471000 635000 853000 96000 0.04 0.06 0.08 0.01 0.04 0.06 0.07 0.01 11063000 10678000 10969000 10581000 11424000 11424000 11424000 11424000 471000 635000 853000 96000 -72000 493000 -158000 355000 9000 -2000 18000 16000 408000 1126000 713000 467000 0 0 12979414 13000 86102000 7822000 -336000 -1556875 -25904000 67697000 0 0 0 153000 0 0 153000 -0 -0 -0 2285000 -0 -0 2285000 0 0 0 0 -182000 0 -182000 0 0 0 0 -7000 0 -7000 0 0 12979414 13000 86102000 5690000 -525000 -1556875 -25904000 65376000 0 0 0 229000 0 0 229000 -0 -0 -0 2285000 -0 -0 2285000 0 0 0 0 96000 0 96000 0 0 0 0 16000 0 16000 0 0 12979414 13000 86102000 3634000 -413000 -1556875 -25904000 63432000 0 0 0 471000 0 0 471000 -0 -0 -0 2285000 -0 -0 2285000 0 0 0 0 -72000 0 -72000 0 0 0 0 9000 0 9000 0 0 12979414 13000 86102000 1820000 -476000 -1556875 -25904000 61555000 0 0 12979414 13000 86102000 16117000 -1264000 -1556875 -25904000 75064000 0 0 0 -573000 0 0 -573000 -0 -0 -0 2285000 -0 -0 2285000 0 0 0 0 -222000 0 -222000 0 0 0 0 -87000 0 -87000 0 0 12979414 13000 86102000 13259000 -1573000 -1556875 -25904000 71897000 0 0 0 34000 0 0 34000 -0 -0 -0 2285000 -0 2285000 0 0 0 0 84000 0 84000 0 0 0 0 105000 0 105000 0 0 12979414 13000 86102000 11008000 -1384000 -1556875 -25904000 69835000 0 0 0 635000 0 0 635000 -0 -0 -0 2285000 -0 2285000 0 0 0 0 493000 0 493000 0 0 0 0 -2000 0 -2000 0 0 12979414 13000 86102000 9358000 -893000 -1556875 -25904000 68676000 853000 96000 237000 301000 895000 1199000 66000 979000 675000 -2193000 823000 -923000 -65000 -120000 300000 206000 -1253000 -1790000 29000 136000 -157000 -598000 2973000 -1045000 -1716000 -3163000 -935000 -1120000 -416000 33000 -557000 -1530000 165000 147000 -165000 -147000 6855000 6855000 -6855000 -6855000 -151000 413000 -7728000 -8119000 92892000 99425000 85164000 91306000 516000 2724000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">1.</em> NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:9pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Nature of Operations</i> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:9pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">Natural Health Trends Corp., a Delaware corporation (whether or <em style="font: inherit;">not</em> including its subsidiaries, the “Company”), is an international direct-selling and e-commerce company. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia, Thailand and Vietnam; South Korea; Japan; India; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Basis of Presentation</i> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:9pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form <em style="font: inherit;">10</em>-Q and Rule <em style="font: inherit;">10</em>-<em style="font: inherit;">01</em> of Regulation S-<em style="font: inherit;">X.</em> As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information for the interim periods presented. The results of operations of any interim period are <em style="font: inherit;">not</em> necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s <em style="font: inherit;">2020</em> Annual Report on Form <em style="font: inherit;">10</em>-K filed with the United States Securities and Exchange Commission (SEC) on <em style="font: inherit;"> February 26, 2021.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>Principles of Consolidation</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:9pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:27pt;">The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:27pt;"> </p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:27pt;"/> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><i/></p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><i>Reclassification</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Certain income taxes payable balances have been reclassified in the prior year consolidated statement of cash flows to conform to current year presentation.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Net Income Per Common Share</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 10pt;margin: 0pt;text-align: left;text-indent: 27pt;/* background-color: rgba(0, 0, 0, 0); *//* color: rgb(0, 0, 0); */">Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has <em style="font: inherit;">not</em> yet recognized, if any, is assumed to be used to repurchase shares.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 10pt;margin: 0pt;text-align: left;text-indent: 27pt;/* background-color: rgba(0, 0, 0, 0); *//* color: rgb(0, 0, 0); */"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 10pt;margin: 0pt;text-align: left;text-indent: 27pt;/* background-color: rgba(0, 0, 0, 0); *//* color: rgb(0, 0, 0); */">The following table illustrates the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data):</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 10pt;margin: 0pt;text-align: left;text-indent: 27pt;/* background-color: rgba(0, 0, 0, 0); *//* color: rgb(0, 0, 0); */"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="22" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended September 30,</em></em></em></em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2021</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2020</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Income (Numerator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Shares (Denominator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Per Share Amount</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Income (Numerator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Shares (Denominator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Per Share Amount</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Basic net income per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income available to common stockholders</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">471</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11,063</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.04</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">10,678</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.06</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Effect of dilutive securities:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Non-vested restricted stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">361</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">746</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Diluted net income per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income available to common stockholders plus assumed conversions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">471</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.04</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.06</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="22" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended September 30,</em></em></em></em></em></em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2021</em></em></em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2020</em></em></em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Income (Numerator)</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Shares (Denominator)</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Per Share Amount</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Income (Numerator)</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Shares (Denominator)</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Per Share Amount</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Basic net income per common share:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income available to common stockholders</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">853</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">10,969</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.08</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">96</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,581</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.01</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Effect of dilutive securities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Non-vested restricted stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">455</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">843</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Diluted net income per common share:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Net income available to common stockholders plus assumed conversions</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">853</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">11,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.07</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">96</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,424</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.01</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Recent Accounting Pronouncements</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i> </i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">In <em style="font: inherit;"> June 2016, </em>the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments - Credit Losses (Topic <em style="font: inherit;">326</em>): Measurement of Credit Losses on Financial Instruments</i>, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis and added Topic <em style="font: inherit;">326</em> to the FASB ASC. In <em style="font: inherit;"> November 2019, </em>the FASB issued ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">11,</em> <i>Codification Improvements to Topic <em style="font: inherit;">326,</em> Financial Instruments - Credit Losses</i>. The amendments to ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">11</em> clarify, correct and make improvements to Topic <em style="font: inherit;">326.</em> ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> as well as the updates in ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">11</em> are effective for interim and annual periods beginning after <em style="font: inherit;"> December 15, 2022, </em>and early adoption is permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">Other recently issued accounting pronouncements did <em style="font: inherit;">not</em> or are <em style="font: inherit;">not</em> believed by management to have a material impact on the Company’s present or future financial statements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Basis of Presentation</i> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:9pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form <em style="font: inherit;">10</em>-Q and Rule <em style="font: inherit;">10</em>-<em style="font: inherit;">01</em> of Regulation S-<em style="font: inherit;">X.</em> As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information for the interim periods presented. The results of operations of any interim period are <em style="font: inherit;">not</em> necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s <em style="font: inherit;">2020</em> Annual Report on Form <em style="font: inherit;">10</em>-K filed with the United States Securities and Exchange Commission (SEC) on <em style="font: inherit;"> February 26, 2021.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>Principles of Consolidation</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:9pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:27pt;">The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:27pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><i>Reclassification</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Certain income taxes payable balances have been reclassified in the prior year consolidated statement of cash flows to conform to current year presentation.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Net Income Per Common Share</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 10pt;margin: 0pt;text-align: left;text-indent: 27pt;/* background-color: rgba(0, 0, 0, 0); *//* color: rgb(0, 0, 0); */">Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has <em style="font: inherit;">not</em> yet recognized, if any, is assumed to be used to repurchase shares.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 10pt;margin: 0pt;text-align: left;text-indent: 27pt;/* background-color: rgba(0, 0, 0, 0); *//* color: rgb(0, 0, 0); */"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 10pt;margin: 0pt;text-align: left;text-indent: 27pt;/* background-color: rgba(0, 0, 0, 0); *//* color: rgb(0, 0, 0); */">The following table illustrates the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data):</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif;font-size: 10pt;margin: 0pt;text-align: left;text-indent: 27pt;/* background-color: rgba(0, 0, 0, 0); *//* color: rgb(0, 0, 0); */"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="22" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended September 30,</em></em></em></em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2021</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2020</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Income (Numerator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Shares (Denominator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Per Share Amount</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Income (Numerator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Shares (Denominator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Per Share Amount</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Basic net income per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income available to common stockholders</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">471</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11,063</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.04</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">10,678</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.06</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Effect of dilutive securities:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Non-vested restricted stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">361</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">746</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Diluted net income per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income available to common stockholders plus assumed conversions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">471</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.04</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.06</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="22" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended September 30,</em></em></em></em></em></em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2021</em></em></em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2020</em></em></em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Income (Numerator)</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Shares (Denominator)</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Per Share Amount</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Income (Numerator)</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Shares (Denominator)</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Per Share Amount</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Basic net income per common share:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income available to common stockholders</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">853</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">10,969</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.08</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">96</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,581</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.01</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Effect of dilutive securities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Non-vested restricted stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">455</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">843</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Diluted net income per common share:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Net income available to common stockholders plus assumed conversions</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">853</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">11,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.07</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">96</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,424</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.01</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="22" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended September 30,</em></em></em></em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2021</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2020</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Income (Numerator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Shares (Denominator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Per Share Amount</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Income (Numerator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Shares (Denominator)</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Per Share Amount</em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Basic net income per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income available to common stockholders</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">471</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11,063</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.04</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">10,678</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.06</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Effect of dilutive securities:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Non-vested restricted stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">361</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">746</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Diluted net income per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income available to common stockholders plus assumed conversions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">471</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.04</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.06</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="22" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended September 30,</em></em></em></em></em></em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2021</em></em></em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2020</em></em></em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Income (Numerator)</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Shares (Denominator)</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Per Share Amount</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Income (Numerator)</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Shares (Denominator)</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Per Share Amount</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Basic net income per common share:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income available to common stockholders</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">853</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">10,969</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.08</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">96</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,581</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.01</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Effect of dilutive securities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Non-vested restricted stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">455</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">843</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Diluted net income per common share:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Net income available to common stockholders plus assumed conversions</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">853</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">11,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.07</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">96</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,424</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.01</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> 471000 11063000 0.04 635000 10678000 0.06 0 361000 0 746000 471000 11424000 0.04 635000 11424000 0.06 853000 10969000 0.08 96000 10581000 0.01 0 455000 0 843000 853000 11424000 0.07 96000 11424000 0.01 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Recent Accounting Pronouncements</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i> </i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">In <em style="font: inherit;"> June 2016, </em>the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments - Credit Losses (Topic <em style="font: inherit;">326</em>): Measurement of Credit Losses on Financial Instruments</i>, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis and added Topic <em style="font: inherit;">326</em> to the FASB ASC. In <em style="font: inherit;"> November 2019, </em>the FASB issued ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">11,</em> <i>Codification Improvements to Topic <em style="font: inherit;">326,</em> Financial Instruments - Credit Losses</i>. The amendments to ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">11</em> clarify, correct and make improvements to Topic <em style="font: inherit;">326.</em> ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> as well as the updates in ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">11</em> are effective for interim and annual periods beginning after <em style="font: inherit;"> December 15, 2022, </em>and early adoption is permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">Other recently issued accounting pronouncements did <em style="font: inherit;">not</em> or are <em style="font: inherit;">not</em> believed by management to have a material impact on the Company’s present or future financial statements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">2.</em> REVENUE</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b> </b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Revenue Recognition</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i> </i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">All revenue is recognized when the performance obligations under a contract, including any product vouchers sold on a stand-alone basis in Hong Kong, are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do <em style="font: inherit;">not</em> contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from <span style="-sec-ix-hidden:c77967292">14</span> days to <span style="-sec-ix-hidden:c77967293">one</span> year, and their historical return rates, which range from 1% to 8% of sales.  Sales returns were 1% of sales for each of the <em style="font: inherit;">nine</em>-month periods ended <em style="font: inherit;"> September 30, 2021 </em>and <em style="font: inherit;">2020</em>.  <em style="font: inherit;">No</em> material changes in estimates have been recognized during the periods presented. See Note <em style="font: inherit;">3</em> for additional information.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i> </i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Deferred Revenue</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product orders and unredeemed product vouchers are considered a contract liability and are recorded as deferred revenue. The increase in deferred revenue from <em style="font: inherit;"> December 31, 2020 </em>to <em style="font: inherit;"> September 30, 2021</em> is primarily due to $4.0 million of cash received for unshipped product orders and unredeemed vouchers offset by $1.0 million of revenue recognized during the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021 </em>that was included in deferred revenue as of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020.</em> See Note <em style="font: inherit;">3</em> for additional information.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i> </i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Disaggregation of Revenue</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to consumers through an e-commerce retail platform and the Russia and Kazakhstan market where the Company operates through an engagement of a <em style="font: inherit;">third</em>-party service provider. See Note <em style="font: inherit;">11</em> for revenue by market information.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company’s net sales by product and service are as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended September 30,</em></em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended September 30,</em></em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Product sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,809</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,023</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39,405</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">41,234</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Administrative fees, freight and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,524</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,316</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">4,777</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,854</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less: sales returns</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(57</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(215</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(285</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(612</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total net sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,276</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,124</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">43,897</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">45,476</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><i>Concentration</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="-sec-ix-hidden:c77967308"><span style="-sec-ix-hidden:c77967309"><span style="-sec-ix-hidden:c77967310"><span style="-sec-ix-hidden:c77967311">No</span></span></span></span> single market other than Hong Kong had net sales greater than <em style="font: inherit;">10%</em> of total net sales. Sales are made to the Company’s members and <span style="-sec-ix-hidden:c77967313"><span style="-sec-ix-hidden:c77967314"><span style="-sec-ix-hidden:c77967315"><span style="-sec-ix-hidden:c77967316">no</span></span></span></span> single customer accounted for <em style="font: inherit;">10%</em> or more of net sales for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021</em> and <em style="font: inherit;">2020</em>. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although <em style="font: inherit;">no</em> single member accounted for <em style="font: inherit;">10%</em> or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Arrangements with Multiple Performance Obligations</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i> </i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company’s contracts with customers <em style="font: inherit;"> may </em>include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged for individual products to similar customers.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i> </i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Practical Expedients</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i> </i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company generally expenses sales commissions when incurred because the amortization period would have been <em style="font: inherit;">one</em> year or less. These costs are recorded in commissions expense.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company does <em style="font: inherit;">not</em> provide certain disclosures about unsatisfied performance obligations for contracts with an original expected length of <em style="font: inherit;">one</em> year or less.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> 0.01 0.08 0.01 4000000.0 1000000.0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended September 30,</em></em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended September 30,</em></em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2021</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Product sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,809</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,023</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39,405</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">41,234</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Administrative fees, freight and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,524</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,316</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">4,777</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,854</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less: sales returns</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(57</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(215</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(285</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(612</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total net sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,276</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,124</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">43,897</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">45,476</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 12809000 12023000 39405000 41234000 1524000 2316000 4777000 4854000 -57000 -215000 -285000 -612000 14276000 14124000 43897000 45476000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">3.</em> BALANCE SHEET COMPONENTS</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b> </b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The components of certain balance sheet amounts are as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">September 30, 2021</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">December 31, 2020</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash, cash equivalents and restricted cash:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Cash</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">18,091</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">23,977</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Cash equivalents</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">66,549</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">68,390</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">84,640</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">92,367</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Restricted cash</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">524</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">525</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">85,164</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">92,892</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Inventories:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Finished goods</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">3,851</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">3,071</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Raw materials</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">602</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,047</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Reserve for obsolescence</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(63</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(339</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">4,390</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">3,779</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other accrued expenses:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Sales returns</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">127</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">189</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Employee-related expense</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">917</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,149</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Warehousing, inventory-related and other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">714</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">584</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">1,758</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">1,922</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred revenue:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Unshipped product and unredeemed product vouchers</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,023</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,005</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Auto ship advances</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,909</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,977</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">106</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">109</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,038</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,091</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">September 30, 2021</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">December 31, 2020</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash, cash equivalents and restricted cash:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Cash</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">18,091</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">23,977</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Cash equivalents</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">66,549</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">68,390</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">84,640</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">92,367</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Restricted cash</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">524</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">525</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">85,164</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">92,892</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Inventories:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Finished goods</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">3,851</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">3,071</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Raw materials</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">602</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,047</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Reserve for obsolescence</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(63</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(339</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">4,390</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">3,779</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other accrued expenses:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Sales returns</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">127</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">189</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Employee-related expense</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">917</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,149</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"> <p style="margin-top: 0pt; margin-bottom: 0pt">Warehousing, inventory-related and other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">714</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">584</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">1,758</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">1,922</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred revenue:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Unshipped product and unredeemed product vouchers</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,023</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,005</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Auto ship advances</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,909</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,977</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">106</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">109</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,038</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,091</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 18091000 23977000 66549000 68390000 84640000 92367000 524000 525000 85164000 92892000 3851000 3071000 602000 1047000 63000 339000 4390000 3779000 127000 189000 917000 1149000 714000 584000 1758000 1922000 4023000 1005000 1909000 1977000 106000 109000 6038000 3091000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">4.</em> FAIR VALUE MEASUREMENTS</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">As of <em style="font: inherit;"> September 30, 2021</em>, cash and cash equivalents include the Company’s investments in money market funds, government and municipal debt securities, and corporate debt securities. The Company considers all highly liquid investments with original maturities of <em style="font: inherit;">three</em> months or less when purchased and have insignificant interest rate risk to be cash equivalents.  Debt securities classified as cash equivalents are required to be accounted for in accordance with the FASB Accounting Standards Codification (“ASC”) <em style="font: inherit;">320,</em> <i>Investments - Debt and Equity Securities</i>. As such, the Company determined its investments in debt securities held at <em style="font: inherit;"> September 30, 2021</em> should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income (expense). Realized gains and losses, as well as interest income, are also included in other income (expense). The fair values of securities are based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The carrying amounts of the Company’s financial instruments, including cash and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:9pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to <em style="font: inherit;">not</em> fair value existing eligible items.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">Investments by significant category included in cash equivalents at the end of each period were as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">September 30, 2021</em></em></em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2020</em></em></em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 8.4%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Fair Value Level<sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted Cost</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Gross Unrealized Gains (Losses)</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Fair Value</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted Cost</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Gross Unrealized Losses</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Fair Value</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 19.6%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money market funds</p> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Level 1</em></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37,534</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37,534</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21,042</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21,042</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Time deposits</p> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Level 2</em></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,458</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,458</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Government and municipal debt securities</p> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Level 2</em></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,849</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,848</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30,280</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(5</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30,275</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Corporate debt securities</p> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Level 2</em></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,159</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,167</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,621</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,615</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><em style="font: inherit;">Total investments</em></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">66,542</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">66,549</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">68,401</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(11</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">68,390</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <hr class="hr-custom" style="text-align: left;height: 1px; color: #000000; background-color: #000000; width: 20%; border: none; margin: 0pt auto 0pt 0pt;"/> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><sup style="vertical-align:top;line-height:120%;font-size:pt"><em style="font: inherit;">1</em></sup><sup style="vertical-align:top;line-height:120%;font-size:pt"><i> </i></sup><i>FASB Topic <em style="font: inherit;">820,</em> Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><i>Level <em style="font: inherit;">1:</em> Quoted market prices in active markets for identical assets or liabilities.</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><i>Level <em style="font: inherit;">2:</em> Observable market-based inputs or unobservable inputs that are corroborated by market data.</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><i>Level <em style="font: inherit;">3:</em> Unobservable inputs that are <em style="font: inherit;">not</em> corroborated by market data.</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">September 30, 2021</em></em></em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2020</em></em></em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 8.4%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Fair Value Level<sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted Cost</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Gross Unrealized Gains (Losses)</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Fair Value</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Adjusted Cost</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Gross Unrealized Losses</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Fair Value</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 19.6%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money market funds</p> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Level 1</em></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37,534</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37,534</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21,042</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21,042</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Time deposits</p> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Level 2</em></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,458</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,458</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Government and municipal debt securities</p> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Level 2</em></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,849</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,848</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30,280</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(5</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30,275</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Corporate debt securities</p> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Level 2</em></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,159</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,167</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,621</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,615</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><em style="font: inherit;">Total investments</em></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">66,542</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">66,549</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">68,401</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(11</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">68,390</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 37534000 -0 37534000 21042000 -0 21042000 0 -0 0 5458000 -0 5458000 11849000 1000 11848000 30280000 5000 30275000 17159000 8000 17167000 11621000 6000 11615000 66542000 7000 66549000 68401000 11000 68390000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">5</em></b><b>. LEASES</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">The Company leases 7,300 square feet of office space in Hong Kong and 4,900 square feet of office space in Rolling Hills Estates, California for its corporate staff.  In <em style="font: inherit;"> June 2020, </em>the Company extended the Rolling Hills Estates office lease for an additional <span style="-sec-ix-hidden:c77967462">five</span> years with a term now expiring in <em style="font: inherit;"> September 2030.  </em>Effective <em style="font: inherit;"> July 1, 2020, </em>the Company modified the terms of its largest Hong Kong office lease resulting in a lease extension through <em style="font: inherit;"> June 2023.  </em>To help further develop the market for its products in North America, the Company leases 1,600 square feet of retail space in each of Rowland Heights, California and Richmond, British Columbia and 2,000 square feet of retail space in Metuchen, New Jersey. The Rowland Heights, Richmond and Metuchen locations have terms expiring in <em style="font: inherit;"> November 2025, </em><em style="font: inherit;"> February 2024, </em>and <em style="font: inherit;"> November 2022, </em>respectively.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company leases <span style="-sec-ix-hidden:c77967465">eight</span> branch offices throughout China, and additional office space in Peru, Japan, Taiwan, South Korea, Singapore, Malaysia, Vietnam, Indonesia, Thailand, India, and the Cayman Islands. <span style="background-color:#ffffff;">The Company also leases a factory in Zhongshan, China</span>. The Company contracts with <em style="font: inherit;">third</em> parties for fulfillment and distribution operations in all of its international markets. <em style="font: inherit;">None</em> of the Company’s <em style="font: inherit;">third</em> party logistics contracts contain a lease as the Company does <em style="font: inherit;">not</em> have the right to access the warehouses or move its inventories at will.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The components of lease cost for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021</em> and <em style="font: inherit;">2020</em> were as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended September 30,</em></em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended September 30,</em></em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2021</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2020</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2021</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2020</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating leases</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">338</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">377</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">996</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,292</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Short-term leases</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">44</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">72</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">133</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">237</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total lease cost</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">382</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">449</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,129</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,529</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">Cash paid for amounts included in the measurement of operating leases liabilities was $327,000 and $342,000 for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September 30, 2021</em> and <em style="font: inherit;">2020</em>, respectively, and $1.0 million and $1.2 million for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021</em> and <em style="font: inherit;">2020</em>, respectively.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The weighted-average remaining lease term and discount rate related to operating leases as of <em style="font: inherit;"> September 30, 2021</em> were as follows:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted-average remaining lease term (in years)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.1</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted-average discount rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.3</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> </tbody> </table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">As most of our leases do <em style="font: inherit;">not</em> provide an implicit rate, the Company used its incremental borrowing rate, or the rate of each of its subsidiaries if available, based on the information available at the lease commencement date to determine the present value of lease payments.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The annual scheduled lease payments of our operating lease liabilities as of <em style="font: inherit;"> September 30, 2021</em> were as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Remainder of 2021</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">327</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,303</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">675</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">272</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">261</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">990</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total lease payments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,828</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: imputed interest</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(315</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Present value of lease liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,513</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">For all asset classes, the Company elected <em style="font: inherit;">not</em> to recognize assets or liabilities at the acquisition date for leases that, at the acquisition date, have a remaining lease term of <em style="font: inherit;">12</em> months or less. Additionally, for all asset classes, the Company choose <em style="font: inherit;">not</em> to separate nonlease components from lease components and instead account for the combined lease and nonlease components associated with that lease component as a single lease component.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> 7300 4900 1600 2000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended September 30,</em></em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended September 30,</em></em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2021</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2020</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2021</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2020</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating leases</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">338</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">377</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">996</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,292</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Short-term leases</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">44</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">72</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">133</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">237</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total lease cost</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">382</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">449</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,129</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,529</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted-average remaining lease term (in years)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.1</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted-average discount rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.3</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> </tbody> </table> 338000 377000 996000 1292000 44000 72000 133000 237000 382000 449000 1129000 1529000 327000 342000 1000000.0 1200000 P5Y1M6D 0.033 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Remainder of 2021</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">327</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,303</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">675</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">272</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">261</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">990</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total lease payments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,828</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: imputed interest</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(315</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Present value of lease liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,513</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 327000 1303000 675000 272000 261000 990000 3828000 315000 3513000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">6</em></b><b>. <span style="background-color:#ffffff;">INCOME TAXES</span></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26pt;">The effective income tax rate for the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021</em> includes an estimate for the Global Intangible Low-Taxed Income (“GILTI”) inclusion. As of <em style="font: inherit;"> September 30, 2021</em>, the Company does <em style="font: inherit;">not</em> have a valuation allowance against its U.S. deferred tax assets. The Company analyzed all sources of available income and determined that they are more likely than <span style="-sec-ix-hidden:c77967523">not</span> to realize the tax benefits of their deferred assets. As of <em style="font: inherit;"> September 30, 2021</em>, the Company has a valuation allowance against deferred tax assets in certain foreign jurisdictions with an overall net operating loss. The valuation allowance will be reduced at such time as management believes it is more likely than <em style="font: inherit;">not</em> that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26pt;">As of <em style="font: inherit;"> September 30, 2021</em>, the Company has U.S. federal net operating losses of $603,000 generated in the tax year ended <em style="font: inherit;"> December 31, 2020 </em>available to offset taxable income. The Company intends to carry back those losses to the year ended <em style="font: inherit;"> December 31, 2016, </em>as there is sufficient income in the <em style="font: inherit;">2016</em> tax year to utilize the losses. The Company has post-apportioned U.S. state net operating loss carryforwards of $427,000 that begin expiring in <em style="font: inherit;">2039.</em> At <em style="font: inherit;"> September 30, 2021</em>, the Company has foreign net operating loss carryforwards of approximately $2.8 million in various jurisdictions with various expirations.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26pt;">As a result of capital return activities, the Company determined that a portion of its current undistributed foreign earnings is <em style="font: inherit;">no</em> longer deemed reinvested indefinitely by its non-U.S. subsidiaries. For state income tax purposes, the Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are <em style="font: inherit;">not</em> deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable state corporate income tax rate(s). As of <em style="font: inherit;"> September 30, 2021</em>, the Company has <em style="font: inherit;">not</em> recorded a state deferred tax liability for earnings that the Company plans to repatriate out of accumulated earnings in future periods because all earnings as of <em style="font: inherit;"> September 30, 2021</em> have already been repatriated. Due to the U.S. Tax Cuts and Jobs Act in <em style="font: inherit;">2017,</em> repatriation from foreign subsidiaries will be offset with a dividends received deduction, resulting in little to <em style="font: inherit;">no</em> impact on federal tax expense. All undistributed earnings in excess of <em style="font: inherit;">50%</em> of current earnings on an annual basis are intended to be reinvested indefinitely as of <em style="font: inherit;"> September 30, 2021</em>.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26pt;">The Company and its subsidiaries file tax returns in the United States, California, New Jersey, Texas and various foreign jurisdictions. During the <em style="font: inherit;">fourth</em> quarter of <em style="font: inherit;">2018,</em> the Company was notified that it was selected for audit of the <em style="font: inherit;">2016</em> tax year by the U.S. Internal Revenue Service (the “IRS”). The audit was subsequently expanded to also include the <em style="font: inherit;">2017,</em> <em style="font: inherit;">2018</em> and <em style="font: inherit;">2019</em> tax years. On <em style="font: inherit;"> October 12, 2021, </em>the Company received notification from the IRS that it had completed the audit process for all tax years with <em style="font: inherit;">no</em> changes made to the Company's previously reported tax. The Company is <em style="font: inherit;">no</em> longer subject to state income tax examinations for years prior to <em style="font: inherit;">2015.</em> <em style="font: inherit;">No</em> other jurisdictions are currently examining any income tax returns of the Company.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26pt;"> </p> 603000 427000 2800000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">7</em></b><b>. COMMITMENTS AND CONTINGENCIES</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i> </i></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 27pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">The SEC conducted a non-public investigation since <em style="font: inherit;"> August 2016 </em>to determine whether there had been violations of the federal securities laws relating to the trading of the Company’s securities and/or its public disclosures. On <em style="font: inherit;"> September 30, 2021, </em>the Company was notified by the SEC that it had concluded its investigation and does <em style="font: inherit;">not</em> intend to recommend an enforcement action.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b><em style="font: inherit;">8.</em> STOCK-BASED INCENTIVE PLANS</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Restricted Stock</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">At the Company’s annual meeting of stockholders held on <em style="font: inherit;"> April 7, 2016, </em>the Company’s stockholders approved the Natural Health Trends Corp. <em style="font: inherit;">2016</em> Equity Incentive Plan (the <em style="font: inherit;">“2016</em> Plan”) to replace its <em style="font: inherit;">2007</em> Equity Incentive Plan. The <em style="font: inherit;">2016</em> Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) <em style="font: inherit;"> may </em>be issued pursuant to awards granted. At <em style="font: inherit;"> September 30, 2021</em>, 1,219,583 shares remained available for issuance under the <em style="font: inherit;">2016</em> Plan.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">The following table summarizes the Company’s restricted stock activity under the <em style="font: inherit;">2016</em> Plan:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Shares</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Wtd. Avg. Price at Date of Issuance</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Nonvested at December 31, 2020</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">566,272</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7.21</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Vested</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(285,024</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7.27</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Nonvested at September 30, 2021</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">281,248</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7.14</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><i>Phantom Equity</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">On <em style="font: inherit;"> March 15, 2021, </em>the Company’s Board of Directors approved and adopted a Phantom Equity Plan (the “Phantom Plan”). Under the terms of the Phantom Plan, the Compensation Committee <em style="font: inherit;"> may </em>grant to the Company’s employees, officers, directors, contractors, consultants, or advisors awards of phantom shares entitling grantees the right to receive a cash payment equal to the fair market value of an equal number of shares of the Company’s common stock upon the close of a vesting period, subject to any maximum payment value that the Compensation Committee <em style="font: inherit;"> may </em>set. The vesting of phantom shares is subject to such vesting conditions as the Compensation Committee <em style="font: inherit;"> may </em>specify in a grantee’s award agreement. Grantees of phantom shares shall <em style="font: inherit;">not</em> by virtue of their receipt of phantom shares have any ownership rights in shares of the Company’s common stock. The Phantom Plan shall continue for a period of <span style="-sec-ix-hidden:c77967559">ten</span> years, after which <em style="font: inherit;">no</em> further phantom shares <em style="font: inherit;"> may </em>be awarded (although any phantom shares awarded prior to the expiration of such <em style="font: inherit;">10</em>-year period shall be unaffected by the termination of the Phantom Plan).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Also on <em style="font: inherit;"> March 15, 2021, </em>awards for 223,307 phantom shares were granted to the Company’s employees and its non-employee directors.  The phantom shares vest in <em style="font: inherit;">eight</em> equal <span style="-sec-ix-hidden:c77967564">three</span>-month vesting increments, subject to the satisfaction of both a time-based vesting condition and a performance vesting condition. These vesting conditions were deemed satisfied on the grant date for the initial vesting increment. In order for the time-based vesting condition to be satisfied for each vesting period, the grantee must remain continuously employed by, or be otherwise continuously providing services to, the Company through the end of the vesting period, and in order for the performance vesting condition to be satisfied for each vesting period, the performance criteria designated by the Compensation Committee must be satisfied. The initial performance vesting condition to be applied to measure performance for the period between <em style="font: inherit;"> March 15, 2021 </em>and <em style="font: inherit;"> June 15, 2021 </em>was designated by the Compensation Committee on or before <em style="font: inherit;"> April 14, 2021, </em>and will apply to all future performance periods unless the Compensation Committee elects to change the performance vesting condition on a prospective basis. Future changes to the performance vesting condition shall be made on or before the <em style="font: inherit;">fifteenth</em> day of any future performance period. If either vesting condition is <em style="font: inherit;">not</em> satisfied for a vesting date, then the phantom shares scheduled to vest on such date will be forfeited. These phantom shares are subject to a maximum payment value of $12.00 per phantom share. An additional award with similar vesting conditions for 9,074 phantom shares was granted on <em style="font: inherit;"> May 14, 2021 </em>to the Company's new non-employee director, while unvested 9,074 phantom shares granted to the Company's departing non-employee director were forfeited on or about the same date.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">The phantom share awards are accounted for as liabilities in accordance with FASB Accounting Standards Codification (“ASC”) Topic <em style="font: inherit;">718,</em> <i>Compensation </i>–<i> Stock Compensation</i> since they require cash settlement. The grant date of each vesting increment will be established when the Company and the grantees reach a mutual understanding of the key terms and conditions of an award, which is the date upon which each performance vesting condition is communicated to the grantees. Compensation expense is recognized over the requisite service period if it is probable that the performance vesting condition will be achieved. The fair value of the liability incurred is remeasured at the end of each reporting period with any changes in fair value recognized as compensation expense over the requisite service period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 27pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Awards totaling 27,913 and 83,739 phantom shares vested during the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021</em>, respectively, resulting in compensation expense of $195,000 and $588,000 during the <em style="font: inherit;">three</em> and <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021</em>, respectively, related to their cash settlement.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> 2500000 1219583 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Shares</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Wtd. Avg. Price at Date of Issuance</em></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Nonvested at December 31, 2020</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">566,272</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7.21</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Vested</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(285,024</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7.27</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Nonvested at September 30, 2021</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">281,248</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7.14</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table> 566272 7.21 285024 7.27 281248 7.14 223307 12.00 9074 9074 27913 83739 195000 588000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">9.</em> STOCKHOLDERS’ EQUITY</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:9pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Dividends</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">The Company declared and paid cash dividends of $0.20 per common share during each of the <em style="font: inherit;">first</em> <em style="font: inherit;">three</em> quarters of <em style="font: inherit;">2021,</em> totaling an aggregate of $6.9 million. Declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 27pt; text-align: left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Stock Repurchases</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i> </i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">On <em style="font: inherit;"> January 12, 2016, </em>the Board of Directors authorized an increase to the Company’s stock repurchase program <em style="font: inherit;">first</em> approved on <em style="font: inherit;"> July 28, 2015 </em>from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule <em style="font: inherit;">10b</em>-<em style="font: inherit;">18</em> of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company <em style="font: inherit;"> may </em>enter into <em style="font: inherit;">one</em> or more plans that are compliant with Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does <em style="font: inherit;">not</em> require the Company to acquire a specific number of shares, and <em style="font: inherit;"> may </em>be suspended from time to time or discontinued. As of <em style="font: inherit;"> September 30, 2021</em>, $21.9 million of the <em style="font: inherit;">$70.0</em> million stock repurchase program remained available for future purchases, inclusive of related estimated income tax.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Accumulated Other Comprehensive Loss</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The changes in accumulated other comprehensive loss by component for the <em style="font: inherit;">first</em> <em style="font: inherit;">nine</em> months of <em style="font: inherit;">2021</em> were as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><em style="font: inherit;">Foreign Currency Translation Adjustments</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><em style="font: inherit;">Unrealized Gains (Losses) on Available-For-Sale Investments</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Total</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance, December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(325</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(336</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%"> <p style="margin-top: 0pt; margin-bottom: 0pt">Other comprehensive income (loss)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(158</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(140</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%"> <p style="margin-top: 0pt; margin-bottom: 0pt">Balance, September 30, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">(483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">(476</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">)</td></tr> </tbody></table> 0.20 6900000 15000000.0 70000000.0 21900000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><em style="font: inherit;">Foreign Currency Translation Adjustments</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><em style="font: inherit;">Unrealized Gains (Losses) on Available-For-Sale Investments</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Total</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance, December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(325</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(336</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%"> <p style="margin-top: 0pt; margin-bottom: 0pt">Other comprehensive income (loss)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(158</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(140</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%"> <p style="margin-top: 0pt; margin-bottom: 0pt">Balance, September 30, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">(483</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">(476</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">)</td></tr> </tbody></table> -325000 -11000 -336000 -158000 18000 -140000 -483000 7000 -476000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">10.</em> RELATED PARTY TRANSACTIONS</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">The Company is a party to a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called ReStor™. George K. Broady, a former director of the Company and beneficial owner of more than 5% of its outstanding common stock, is an indirect owner of BHS. Brunde E. Broady, a director of the Company and daughter of Mr. Broady, is the President and Chief Executive Officer of BHS. Under this agreement (as amended), the Company agreed to pay BHS a royalty based on a price per unit in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide by or through multi-level marketing or network marketing. The Company recognized royalties of $25,000 and $14,000 during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September 30, 2021</em> and <em style="font: inherit;">2020</em>, respectively, and $44,000 and $64,000 during the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021</em> and <em style="font: inherit;">2020</em>, respectively, under this agreement. The Company is <em style="font: inherit;">not</em> required to purchase any product under the agreement, and the agreement <em style="font: inherit;"> may </em>be terminated under certain circumstances with <em style="font: inherit;">no</em> notice. The agreement terminates <em style="font: inherit;"> March 31, 2025, </em>after which it shall be automatically renewed for successive <span style="-sec-ix-hidden:c77967638">one</span>-year terms unless notice is given by either party at least <span style="-sec-ix-hidden:c77967639">90</span> days in advance of the expiration of the then-current term.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:27pt;"> </p> 0.05 25000 14000 44000 64000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">11.</em>    SEGMENT INFORMATION</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:9pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company sells products to a member network that operates in a seamless manner from market to market, except for the China market where it sells to some consumers through an e-commerce platform, and the Russia and Kazakhstan market where the Company’s engagement of a <em style="font: inherit;">third</em>-party service provider results in a different economic structure than its other markets. Otherwise, the Company believes that all of its other operating segments have similar economic characteristics and are similar in the nature of the products sold, the product acquisition process, the types of customers products are sold to, the methods used to distribute the products, and the nature of the regulatory environment. Therefore, the Company aggregates its other operating segments (including its Hong Kong operating segment) into a single reporting segment (the “Primary Reporting Segment”).</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company reviews its net sales and operating income (loss) by operating segment, and reviews its assets and capital expenditures on a consolidated basis and <em style="font: inherit;">not</em> by operating segment. As such, net sales and operating income (loss) are presented by reportable segment and assets and capital expenditures by operating segment are <em style="font: inherit;">not</em> presented. Segment operating income is adjusted for certain direct costs and commission allocation.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company’s operating information by geographic area are as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended September 30,</em></em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended September 30,</em></em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2021</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2020</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2021</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2020</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net sales:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Primary Reporting Segment</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,576</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,294</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">41,679</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">42,718</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">China</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">501</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">640</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,596</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,156</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Russia and Kazakhstan</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">199</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">190</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">622</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">602</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total net sales</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,276</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,124</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">43,897</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">45,476</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income (loss) from operations:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Primary Reporting Segment</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,558</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,715</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,803</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,038</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">China</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">134</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">51</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">64</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Russia and Kazakhstan</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(59</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(101</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(37</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income from operations for reportable segments, net</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,568</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,790</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">7,753</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,065</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unallocated corporate expenses</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2,089</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2,122</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(6,669</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(6,662</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other income (expense), net</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(53</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">385</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(92</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">603</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income before income taxes</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">426</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,053</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">992</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company’s net sales by geographic area are as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended September 30,</em></em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended September 30,</em></em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2021</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2020</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2021</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2020</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net sales from external customers:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">United States</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">279</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">338</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">918</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,202</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Canada</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">140</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">132</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">481</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">536</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Peru</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">608</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">357</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,752</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">954</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Hong Kong<sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,201</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,132</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">34,227</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36,238</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">China</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">501</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">640</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,596</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,156</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Taiwan</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">584</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">771</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,990</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,261</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">South Korea</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">51</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">52</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">202</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">220</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Russia and Kazakhstan</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">199</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">190</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">622</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">602</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Europe</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">258</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">259</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">869</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">747</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other foreign countries</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">455</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">253</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">1,240</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">560</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total net sales</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,276</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,124</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">43,897</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">45,476</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <hr class="hr-custom" style="text-align: left;height: 1px; color: #000000; background-color: #000000; width: 15%; border: none; margin: 0pt auto 0pt 0pt;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><sup style="vertical-align:top;line-height:120%;font-size:pt"><em style="font: inherit;">1</em></sup> <i>Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item <em style="font: inherit;">1A.</em> Risk Factors” in this report and in our most recent Annual Report on Form <em style="font: inherit;">10</em>-K.</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i> </i></p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended September 30,</em></em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended September 30,</em></em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2021</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2020</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2021</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2020</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net sales:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Primary Reporting Segment</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,576</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,294</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">41,679</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">42,718</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">China</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">501</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">640</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,596</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,156</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Russia and Kazakhstan</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">199</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">190</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">622</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">602</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total net sales</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,276</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,124</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">43,897</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">45,476</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income (loss) from operations:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Primary Reporting Segment</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,558</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,715</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,803</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,038</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">China</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">134</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">51</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">64</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Russia and Kazakhstan</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(59</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(101</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(37</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income from operations for reportable segments, net</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,568</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,790</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">7,753</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,065</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unallocated corporate expenses</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2,089</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2,122</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(6,669</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(6,662</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other income (expense), net</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(53</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">385</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(92</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">603</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income before income taxes</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">426</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,053</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">992</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody> </table> 13576000 13294000 41679000 42718000 501000 640000 1596000 2156000 199000 190000 622000 602000 14276000 14124000 43897000 45476000 2558000 2715000 7803000 6038000 5000 134000 51000 64000 5000 -59000 -101000 -37000 2568000 2790000 7753000 6065000 -2089000 -2122000 -6669000 -6662000 -53000 385000 -92000 603000 426000 1053000 992000 6000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended September 30,</em></em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended September 30,</em></em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2021</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2020</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2021</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2020</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net sales from external customers:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">United States</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">279</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">338</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">918</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,202</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Canada</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">140</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">132</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">481</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">536</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Peru</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">608</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">357</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,752</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">954</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Hong Kong<sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,201</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,132</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">34,227</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36,238</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">China</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">501</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">640</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,596</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,156</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Taiwan</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">584</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">771</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,990</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,261</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">South Korea</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">51</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">52</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">202</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">220</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Russia and Kazakhstan</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">199</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">190</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">622</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">602</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Europe</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">258</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">259</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">869</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">747</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other foreign countries</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">455</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">253</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">1,240</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">560</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total net sales</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,276</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,124</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">43,897</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">45,476</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 279000 338000 918000 1202000 140000 132000 481000 536000 608000 357000 1752000 954000 11201000 11132000 34227000 36238000 501000 640000 1596000 2156000 584000 771000 1990000 2261000 51000 52000 202000 220000 199000 190000 622000 602000 258000 259000 869000 747000 455000 253000 1240000 560000 14276000 14124000 43897000 45476000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">12.</em> SUBSEQUENT EVENT</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">On <em style="font: inherit;"> November 1, 2021, </em>the Board of Directors declared a quarterly cash dividend of $0.20 on each share of common stock outstanding. The dividend will be payable on <em style="font: inherit;"> November 26, 2021 </em>to stockholders of record on <em style="font: inherit;"> November 16, 2021. </em>The declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> 0.20 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors” in this report and in our most recent Annual Report on Form 10-K. FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. XML 11 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document And Entity Information - shares
9 Months Ended
Sep. 30, 2021
Oct. 29, 2021
Document Information [Line Items]    
Entity Central Index Key 0000912061  
Entity Registrant Name Natural Health Trends Corp.  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2021  
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2021  
Document Transition Report false  
Entity File Number 001-36849  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 59-2705336  
Entity Address, Address Line One 132 Nathan Road  
Entity Address, City or Town Tsimshatsui  
Entity Address, Country HK  
City Area Code 852  
Local Phone Number 3107-0800  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol NHTC  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   11,422,539
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 84,640 $ 92,367
Inventories 4,390 3,779
Other current assets 4,386 3,595
Total current assets 93,416 99,741
Property and equipment, net 463 539
Operating lease right-of-use assets 3,339 3,745
Restricted cash 524 525
Deferred tax asset 660 731
Other assets 574 661
Total assets 98,976 105,942
Current liabilities:    
Accounts payable 879 580
Income taxes payable 1,844 1,481
Accrued commissions 3,441 3,496
Other accrued expenses 1,758 1,922
Deferred revenue 6,038 3,091
Amounts held in eWallets 6,756 8,503
Operating lease liabilities 1,304 1,163
Other current liabilities 847 1,270
Total current liabilities 22,867 21,506
Income taxes payable 12,130 13,748
Deferred tax liability 215 216
Operating lease liabilities 2,209 2,775
Total liabilities 37,421 38,245
Commitments and contingencies (Note 7)
Stockholders’ equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding 0 0
Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at September 30, 2021 and December 31, 2020 13 13
Additional paid-in capital 86,102 86,102
Retained earnings 1,820 7,822
Accumulated other comprehensive loss (476) (336)
Treasury stock, at cost; 1,556,875 shares at September 30, 2021 and December 31, 2020 (25,904) (25,904)
Total stockholders’ equity 61,555 67,697
Total liabilities and stockholders’ equity $ 98,976 $ 105,942
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares
Sep. 30, 2021
Dec. 31, 2020
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, authorized (in shares) 5,000,000 5,000,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, authorized (in shares) 50,000,000 50,000,000
Common stock, issued (in shares) 12,979,414 12,979,414
Treasury stock, shares (in shares) 1,556,875 1,556,875
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Net sales $ 14,276 $ 14,124 $ 43,897 $ 45,476
Cost of sales 3,668 3,635 10,857 12,966
Gross profit 10,608 10,489 33,040 32,510
Operating expenses:        
Commissions expense 6,027 5,620 18,468 19,336
Selling, general and administrative expenses 4,102 4,201 13,488 13,771
Total operating expenses 10,129 9,821 31,956 33,107
Income (loss) from operations 479 668 1,084 (597)
Other income (expense), net (53) 385 (92) 603
Income before income taxes 426 1,053 992 6
Income tax provision (benefit) (45) 418 139 (90)
Net income $ 471 $ 635 $ 853 $ 96
Net income per common share:        
Basic (in dollars per share) $ 0.04 $ 0.06 $ 0.08 $ 0.01
Diluted (in dollars per share) $ 0.04 $ 0.06 $ 0.07 $ 0.01
Weighted average common shares outstanding:        
Basic (in shares) 11,063 10,678 10,969 10,581
Diluted (in shares) 11,424 11,424 11,424 11,424
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Net income $ 471 $ 635 $ 853 $ 96
Other comprehensive income (loss), net of tax:        
Foreign currency translation adjustment (72) 493 (158) 355
Unrealized gains (losses) on available-for-sale securities 9 (2) 18 16
Comprehensive income $ 408 $ 1,126 $ 713 $ 467
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Treasury Stock [Member]
Total
BALANCE (in shares) at Dec. 31, 2019 0 12,979,414       (1,556,875)  
Balance at Dec. 31, 2019 $ 0 $ 13 $ 86,102 $ 16,117 $ (1,264) $ (25,904) $ 75,064
Net income 0 0 0 (573) 0 0 (573)
Dividends declared 0 0 0 (2,285) 0 0 (2,285)
Foreign currency translation adjustments 0 0 0 0 (222) 0 (222)
Unrealized gains (losses) on available-for-sale securities $ 0 $ 0 0 0 (87) $ 0 (87)
BALANCE (in shares) at Mar. 31, 2020 0 12,979,414       (1,556,875)  
Balance at Mar. 31, 2020 $ 0 $ 13 86,102 13,259 (1,573) $ (25,904) 71,897
BALANCE (in shares) at Dec. 31, 2019 0 12,979,414       (1,556,875)  
Balance at Dec. 31, 2019 $ 0 $ 13 86,102 16,117 (1,264) $ (25,904) 75,064
Net income             96
Foreign currency translation adjustments             355
Unrealized gains (losses) on available-for-sale securities             16
BALANCE (in shares) at Sep. 30, 2020 0 12,979,414       (1,556,875)  
Balance at Sep. 30, 2020 $ 0 $ 13 86,102 9,358 (893) $ (25,904) 68,676
BALANCE (in shares) at Mar. 31, 2020 0 12,979,414       (1,556,875)  
Balance at Mar. 31, 2020 $ 0 $ 13 86,102 13,259 (1,573) $ (25,904) 71,897
Net income 0 0 0 34 0 0 34
Dividends declared 0 0 0 (2,285) 0 (2,285)
Foreign currency translation adjustments 0 0 0 0 84 0 84
Unrealized gains (losses) on available-for-sale securities $ 0 $ 0 0 0 105 $ 0 105
BALANCE (in shares) at Jun. 30, 2020 0 12,979,414       (1,556,875)  
Balance at Jun. 30, 2020 $ 0 $ 13 86,102 11,008 (1,384) $ (25,904) 69,835
Net income 0 0 0 635 0 0 635
Dividends declared 0 0 0 (2,285) 0 (2,285)
Foreign currency translation adjustments 0 0 0 0 493 0 493
Unrealized gains (losses) on available-for-sale securities $ 0 $ 0 0 0 (2) $ 0 (2)
BALANCE (in shares) at Sep. 30, 2020 0 12,979,414       (1,556,875)  
Balance at Sep. 30, 2020 $ 0 $ 13 86,102 9,358 (893) $ (25,904) 68,676
BALANCE (in shares) at Dec. 31, 2020 0 12,979,414       (1,556,875)  
Balance at Dec. 31, 2020 $ 0 $ 13 86,102 7,822 (336) $ (25,904) 67,697
Net income 0 0 0 153 0 0 153
Dividends declared 0 0 0 (2,285) 0 0 (2,285)
Foreign currency translation adjustments 0 0 0 0 (182) 0 (182)
Unrealized gains (losses) on available-for-sale securities $ 0 $ 0 0 0 (7) $ 0 (7)
BALANCE (in shares) at Mar. 31, 2021 0 12,979,414       (1,556,875)  
Balance at Mar. 31, 2021 $ 0 $ 13 86,102 5,690 (525) $ (25,904) 65,376
BALANCE (in shares) at Dec. 31, 2020 0 12,979,414       (1,556,875)  
Balance at Dec. 31, 2020 $ 0 $ 13 86,102 7,822 (336) $ (25,904) 67,697
Net income             853
Foreign currency translation adjustments             (158)
Unrealized gains (losses) on available-for-sale securities             18
BALANCE (in shares) at Sep. 30, 2021 0 12,979,414       (1,556,875)  
Balance at Sep. 30, 2021 $ 0 $ 13 86,102 1,820 (476) $ (25,904) 61,555
BALANCE (in shares) at Mar. 31, 2021 0 12,979,414       (1,556,875)  
Balance at Mar. 31, 2021 $ 0 $ 13 86,102 5,690 (525) $ (25,904) 65,376
Net income 0 0 0 229 0 0 229
Dividends declared 0 0 0 (2,285) 0 0 (2,285)
Foreign currency translation adjustments 0 0 0 0 96 0 96
Unrealized gains (losses) on available-for-sale securities $ 0 $ 0 0 0 16 $ 0 16
BALANCE (in shares) at Jun. 30, 2021 0 12,979,414       (1,556,875)  
Balance at Jun. 30, 2021 $ 0 $ 13 86,102 3,634 (413) $ (25,904) 63,432
Net income 0 0 0 471 0 0 471
Dividends declared 0 0 0 (2,285) 0 0 (2,285)
Foreign currency translation adjustments 0 0 0 0 (72) 0 (72)
Unrealized gains (losses) on available-for-sale securities $ 0 $ 0 0 0 9 $ 0 9
BALANCE (in shares) at Sep. 30, 2021 0 12,979,414       (1,556,875)  
Balance at Sep. 30, 2021 $ 0 $ 13 $ 86,102 $ 1,820 $ (476) $ (25,904) $ 61,555
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) - $ / shares
3 Months Ended
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dividends declared, per share (in dollars per share) $ 0.20 $ 0.20 $ 0.20 $ 0.20 $ 0.20 $ 0.20
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income $ 853 $ 96
Adjustments to reconcile net income to net cash used in operating activities:    
Depreciation and amortization 237 301
Noncash lease expense 895 1,199
Deferred income taxes 66 979
Changes in assets and liabilities:    
Inventories (675) 2,193
Other current assets (823) 923
Other assets 65 120
Accounts payable 300 206
Income taxes payable (1,253) (1,790)
Accrued commissions 29 136
Other accrued expenses (157) (598)
Deferred revenue 2,973 (1,045)
Amounts held in eWallets (1,716) (3,163)
Operating lease liabilities (935) (1,120)
Other current liabilities (416) 33
Net cash used in operating activities (557) (1,530)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property and equipment (165) (147)
Net cash used in investing activities (165) (147)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Dividends paid (6,855) (6,855)
Net cash used in financing activities (6,855) (6,855)
Effect of exchange rates on cash, cash equivalents and restricted cash (151) 413
Net decrease in cash, cash equivalents and restricted cash (7,728) (8,119)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period 92,892 99,425
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period 85,164 91,306
SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:    
Right-of-use assets obtained in exchange for operating lease liabilities $ 516 $ 2,724
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Note 1 - Nature of Operations, Basis of Presentation and Consolidation
9 Months Ended
Sep. 30, 2021
Notes to Financial Statements  
Business Description and Basis of Presentation [Text Block]

1. NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION

 

Nature of Operations 

 

Natural Health Trends Corp., a Delaware corporation (whether or not including its subsidiaries, the “Company”), is an international direct-selling and e-commerce company. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.

 

The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia, Thailand and Vietnam; South Korea; Japan; India; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.

 

Basis of Presentation 

 

The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s 2020 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on February 26, 2021.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.

 

Reclassification

 

Certain income taxes payable balances have been reclassified in the prior year consolidated statement of cash flows to conform to current year presentation.

 

Net Income Per Common Share

 

Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized, if any, is assumed to be used to repurchase shares.

 

The following table illustrates the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data):

 

  

Three Months Ended September 30,

 
  

2021

  

2020

 
  

Income (Numerator)

  

Shares (Denominator)

  

Per Share Amount

  

Income (Numerator)

  

Shares (Denominator)

  

Per Share Amount

 

Basic net income per common share:

                        

Net income available to common stockholders

 $471   11,063  $0.04  $635   10,678  $0.06 

Effect of dilutive securities:

                        

Non-vested restricted stock

     361          746     

Diluted net income per common share:

                        

Net income available to common stockholders plus assumed conversions

 $471   11,424  $0.04  $635   11,424  $0.06 

 

  

Nine Months Ended September 30,

 
  

2021

  

2020

 
  

Income (Numerator)

  

Shares (Denominator)

  

Per Share Amount

  

Income (Numerator)

  

Shares (Denominator)

  

Per Share Amount

 

Basic net income per common share:

                        

Net income available to common stockholders

 $853   10,969  $0.08  $96   10,581  $0.01 

Effect of dilutive securities:

                        

Non-vested restricted stock

     455          843     

Diluted net income per common share:

                        

Net income available to common stockholders plus assumed conversions

 $853   11,424  $0.07  $96   11,424  $0.01 

 

Recent Accounting Pronouncements

 

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis and added Topic 326 to the FASB ASC. In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. The amendments to ASU 2019-11 clarify, correct and make improvements to Topic 326. ASU 2016-13 as well as the updates in ASU 2019-11 are effective for interim and annual periods beginning after December 15, 2022, and early adoption is permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements.

 

Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

 

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Note 2 - Revenue
9 Months Ended
Sep. 30, 2021
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]

2. REVENUE

 

Revenue Recognition

 

All revenue is recognized when the performance obligations under a contract, including any product vouchers sold on a stand-alone basis in Hong Kong, are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature.

 

Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from 14 days to one year, and their historical return rates, which range from 1% to 8% of sales.  Sales returns were 1% of sales for each of the nine-month periods ended September 30, 2021 and 2020No material changes in estimates have been recognized during the periods presented. See Note 3 for additional information.

 

The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.

 

Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.

 

Deferred Revenue

 

The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product orders and unredeemed product vouchers are considered a contract liability and are recorded as deferred revenue. The increase in deferred revenue from December 31, 2020 to September 30, 2021 is primarily due to $4.0 million of cash received for unshipped product orders and unredeemed vouchers offset by $1.0 million of revenue recognized during the nine months ended September 30, 2021 that was included in deferred revenue as of December 31, 2020. See Note 3 for additional information.

 

Disaggregation of Revenue

 

The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to consumers through an e-commerce retail platform and the Russia and Kazakhstan market where the Company operates through an engagement of a third-party service provider. See Note 11 for revenue by market information.

 

The Company’s net sales by product and service are as follows (in thousands):

 

  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 
  

2021

  

2020

  

2021

  

2020

 

Product sales

 $12,809  $12,023  $39,405  $41,234 

Administrative fees, freight and other

  1,524   2,316   4,777   4,854 

Less: sales returns

  (57)  (215)  (285)  (612)

Total net sales

 $14,276  $14,124  $43,897  $45,476 

 

Concentration

 

No single market other than Hong Kong had net sales greater than 10% of total net sales. Sales are made to the Company’s members and no single customer accounted for 10% or more of net sales for the three and nine months ended September 30, 2021 and 2020. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.

 

Arrangements with Multiple Performance Obligations

 

The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged for individual products to similar customers.

 

Practical Expedients

 

The Company generally expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded in commissions expense.

 

The Company does not provide certain disclosures about unsatisfied performance obligations for contracts with an original expected length of one year or less.

 

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Note 3 - Balance Sheet Components
9 Months Ended
Sep. 30, 2021
Notes to Financial Statements  
Supplemental Balance Sheet Disclosures [Text Block]

3. BALANCE SHEET COMPONENTS

 

The components of certain balance sheet amounts are as follows (in thousands):

 

   

September 30, 2021

   

December 31, 2020

 

Cash, cash equivalents and restricted cash:

               

Cash

  $ 18,091     $ 23,977  

Cash equivalents

    66,549       68,390  
      84,640       92,367  

Restricted cash

    524       525  
    $ 85,164     $ 92,892  

Inventories:

               

Finished goods

  $ 3,851     $ 3,071  

Raw materials

    602       1,047  

Reserve for obsolescence

    (63 )     (339 )
    $ 4,390     $ 3,779  

Other accrued expenses:

               

Sales returns

  $ 127     $ 189  

Employee-related expense

    917       1,149  

Warehousing, inventory-related and other

    714       584  
    $ 1,758     $ 1,922  

Deferred revenue:

               

Unshipped product and unredeemed product vouchers

  $ 4,023     $ 1,005  

Auto ship advances

    1,909       1,977  

Other

    106       109  
    $ 6,038     $ 3,091  

 

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Note 4 - Fair Value Measurements
9 Months Ended
Sep. 30, 2021
Notes to Financial Statements  
Fair Value Disclosures [Text Block]

4. FAIR VALUE MEASUREMENTS

 

As of September 30, 2021, cash and cash equivalents include the Company’s investments in money market funds, government and municipal debt securities, and corporate debt securities. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.  Debt securities classified as cash equivalents are required to be accounted for in accordance with the FASB Accounting Standards Codification (“ASC”) 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at September 30, 2021 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income (expense). Realized gains and losses, as well as interest income, are also included in other income (expense). The fair values of securities are based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs.

 

The carrying amounts of the Company’s financial instruments, including cash and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents.

 

Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.

 

Investments by significant category included in cash equivalents at the end of each period were as follows (in thousands):

 

     

September 30, 2021

   

December 31, 2020

 
 

Fair Value Level1

 

Adjusted Cost

   

Gross Unrealized Gains (Losses)

   

Fair Value

   

Adjusted Cost

   

Gross Unrealized Losses

   

Fair Value

 

Money market funds

Level 1

  $ 37,534     $     $ 37,534     $ 21,042     $     $ 21,042  

Time deposits

Level 2

                      5,458             5,458  

Government and municipal debt securities

Level 2

    11,849       (1 )     11,848       30,280       (5 )     30,275  

Corporate debt securities

Level 2

    17,159       8       17,167       11,621       (6 )     11,615  

Total investments

  $ 66,542     $ 7     $ 66,549     $ 68,401     $ (11 )   $ 68,390  

 


 

1 FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

 

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Note 5 - Leases
9 Months Ended
Sep. 30, 2021
Notes to Financial Statements  
Lessee, Operating Leases [Text Block]

5. LEASES

 

The Company leases 7,300 square feet of office space in Hong Kong and 4,900 square feet of office space in Rolling Hills Estates, California for its corporate staff.  In June 2020, the Company extended the Rolling Hills Estates office lease for an additional five years with a term now expiring in September 2030.  Effective July 1, 2020, the Company modified the terms of its largest Hong Kong office lease resulting in a lease extension through June 2023.  To help further develop the market for its products in North America, the Company leases 1,600 square feet of retail space in each of Rowland Heights, California and Richmond, British Columbia and 2,000 square feet of retail space in Metuchen, New Jersey. The Rowland Heights, Richmond and Metuchen locations have terms expiring in November 2025, February 2024, and November 2022, respectively.

 

The Company leases eight branch offices throughout China, and additional office space in Peru, Japan, Taiwan, South Korea, Singapore, Malaysia, Vietnam, Indonesia, Thailand, India, and the Cayman Islands. The Company also leases a factory in Zhongshan, China. The Company contracts with third parties for fulfillment and distribution operations in all of its international markets. None of the Company’s third party logistics contracts contain a lease as the Company does not have the right to access the warehouses or move its inventories at will.

 

The components of lease cost for the three and nine months ended September 30, 2021 and 2020 were as follows (in thousands):

 

   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2021

   

2020

   

2021

   

2020

 

Operating leases

  $ 338     $ 377     $ 996     $ 1,292  

Short-term leases

    44       72       133       237  

Total lease cost

  $ 382     $ 449     $ 1,129     $ 1,529  

 

Cash paid for amounts included in the measurement of operating leases liabilities was $327,000 and $342,000 for the three months ended  September 30, 2021 and 2020, respectively, and $1.0 million and $1.2 million for the nine months ended September 30, 2021 and 2020, respectively.

 

The weighted-average remaining lease term and discount rate related to operating leases as of September 30, 2021 were as follows:

 

Weighted-average remaining lease term (in years)

    5.1  

Weighted-average discount rate

    3.3 %

 

As most of our leases do not provide an implicit rate, the Company used its incremental borrowing rate, or the rate of each of its subsidiaries if available, based on the information available at the lease commencement date to determine the present value of lease payments.

 

The annual scheduled lease payments of our operating lease liabilities as of September 30, 2021 were as follows (in thousands):

 

Remainder of 2021

  $ 327  

2022

    1,303  

2023

    675  

2024

    272  

2025

    261  

Thereafter

    990  

Total lease payments

  $ 3,828  

Less: imputed interest

    (315 )

Present value of lease liabilities

  $ 3,513  

 

For all asset classes, the Company elected not to recognize assets or liabilities at the acquisition date for leases that, at the acquisition date, have a remaining lease term of 12 months or less. Additionally, for all asset classes, the Company choose not to separate nonlease components from lease components and instead account for the combined lease and nonlease components associated with that lease component as a single lease component.

 

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Note 6 - Income Taxes
9 Months Ended
Sep. 30, 2021
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

6. INCOME TAXES

 

The effective income tax rate for the three and nine months ended September 30, 2021 includes an estimate for the Global Intangible Low-Taxed Income (“GILTI”) inclusion. As of September 30, 2021, the Company does not have a valuation allowance against its U.S. deferred tax assets. The Company analyzed all sources of available income and determined that they are more likely than not to realize the tax benefits of their deferred assets. As of September 30, 2021, the Company has a valuation allowance against deferred tax assets in certain foreign jurisdictions with an overall net operating loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.

 

As of September 30, 2021, the Company has U.S. federal net operating losses of $603,000 generated in the tax year ended December 31, 2020 available to offset taxable income. The Company intends to carry back those losses to the year ended December 31, 2016, as there is sufficient income in the 2016 tax year to utilize the losses. The Company has post-apportioned U.S. state net operating loss carryforwards of $427,000 that begin expiring in 2039. At September 30, 2021, the Company has foreign net operating loss carryforwards of approximately $2.8 million in various jurisdictions with various expirations.

 

As a result of capital return activities, the Company determined that a portion of its current undistributed foreign earnings is no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. For state income tax purposes, the Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable state corporate income tax rate(s). As of September 30, 2021, the Company has not recorded a state deferred tax liability for earnings that the Company plans to repatriate out of accumulated earnings in future periods because all earnings as of September 30, 2021 have already been repatriated. Due to the U.S. Tax Cuts and Jobs Act in 2017, repatriation from foreign subsidiaries will be offset with a dividends received deduction, resulting in little to no impact on federal tax expense. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of September 30, 2021.

 

The Company and its subsidiaries file tax returns in the United States, California, New Jersey, Texas and various foreign jurisdictions. During the fourth quarter of 2018, the Company was notified that it was selected for audit of the 2016 tax year by the U.S. Internal Revenue Service (the “IRS”). The audit was subsequently expanded to also include the 2017, 2018 and 2019 tax years. On October 12, 2021, the Company received notification from the IRS that it had completed the audit process for all tax years with no changes made to the Company's previously reported tax. The Company is no longer subject to state income tax examinations for years prior to 2015. No other jurisdictions are currently examining any income tax returns of the Company.

 

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Note 7 - Commitments and Contingencies
9 Months Ended
Sep. 30, 2021
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]

7. COMMITMENTS AND CONTINGENCIES

 

The SEC conducted a non-public investigation since August 2016 to determine whether there had been violations of the federal securities laws relating to the trading of the Company’s securities and/or its public disclosures. On September 30, 2021, the Company was notified by the SEC that it had concluded its investigation and does not intend to recommend an enforcement action.

 

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Note 8 - Stock-based Incentive Plans
9 Months Ended
Sep. 30, 2021
Notes to Financial Statements  
Share-based Payment Arrangement [Text Block]

8. STOCK-BASED INCENTIVE PLANS

 

Restricted Stock

 

At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. At September 30, 2021, 1,219,583 shares remained available for issuance under the 2016 Plan.

 

The following table summarizes the Company’s restricted stock activity under the 2016 Plan:

 

   

Shares

   

Wtd. Avg. Price at Date of Issuance

 

Nonvested at December 31, 2020

    566,272     $ 7.21  

Vested

    (285,024 )   $ 7.27  

Nonvested at September 30, 2021

    281,248     $ 7.14  

 

Phantom Equity

 

On March 15, 2021, the Company’s Board of Directors approved and adopted a Phantom Equity Plan (the “Phantom Plan”). Under the terms of the Phantom Plan, the Compensation Committee may grant to the Company’s employees, officers, directors, contractors, consultants, or advisors awards of phantom shares entitling grantees the right to receive a cash payment equal to the fair market value of an equal number of shares of the Company’s common stock upon the close of a vesting period, subject to any maximum payment value that the Compensation Committee may set. The vesting of phantom shares is subject to such vesting conditions as the Compensation Committee may specify in a grantee’s award agreement. Grantees of phantom shares shall not by virtue of their receipt of phantom shares have any ownership rights in shares of the Company’s common stock. The Phantom Plan shall continue for a period of ten years, after which no further phantom shares may be awarded (although any phantom shares awarded prior to the expiration of such 10-year period shall be unaffected by the termination of the Phantom Plan).

 

Also on March 15, 2021, awards for 223,307 phantom shares were granted to the Company’s employees and its non-employee directors.  The phantom shares vest in eight equal three-month vesting increments, subject to the satisfaction of both a time-based vesting condition and a performance vesting condition. These vesting conditions were deemed satisfied on the grant date for the initial vesting increment. In order for the time-based vesting condition to be satisfied for each vesting period, the grantee must remain continuously employed by, or be otherwise continuously providing services to, the Company through the end of the vesting period, and in order for the performance vesting condition to be satisfied for each vesting period, the performance criteria designated by the Compensation Committee must be satisfied. The initial performance vesting condition to be applied to measure performance for the period between March 15, 2021 and June 15, 2021 was designated by the Compensation Committee on or before April 14, 2021, and will apply to all future performance periods unless the Compensation Committee elects to change the performance vesting condition on a prospective basis. Future changes to the performance vesting condition shall be made on or before the fifteenth day of any future performance period. If either vesting condition is not satisfied for a vesting date, then the phantom shares scheduled to vest on such date will be forfeited. These phantom shares are subject to a maximum payment value of $12.00 per phantom share. An additional award with similar vesting conditions for 9,074 phantom shares was granted on May 14, 2021 to the Company's new non-employee director, while unvested 9,074 phantom shares granted to the Company's departing non-employee director were forfeited on or about the same date.

 

The phantom share awards are accounted for as liabilities in accordance with FASB Accounting Standards Codification (“ASC”) Topic 718, Compensation Stock Compensation since they require cash settlement. The grant date of each vesting increment will be established when the Company and the grantees reach a mutual understanding of the key terms and conditions of an award, which is the date upon which each performance vesting condition is communicated to the grantees. Compensation expense is recognized over the requisite service period if it is probable that the performance vesting condition will be achieved. The fair value of the liability incurred is remeasured at the end of each reporting period with any changes in fair value recognized as compensation expense over the requisite service period.

 

Awards totaling 27,913 and 83,739 phantom shares vested during the three and nine months ended September 30, 2021, respectively, resulting in compensation expense of $195,000 and $588,000 during the three and nine months ended September 30, 2021, respectively, related to their cash settlement.

 

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Note 9 - Stockholders' Equity
9 Months Ended
Sep. 30, 2021
Notes to Financial Statements  
Stockholders' Equity Note Disclosure [Text Block]

 

9. STOCKHOLDERS’ EQUITY

 

Dividends

 

The Company declared and paid cash dividends of $0.20 per common share during each of the first three quarters of 2021, totaling an aggregate of $6.9 million. Declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.

 

Stock Repurchases

 

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. As of September 30, 2021, $21.9 million of the $70.0 million stock repurchase program remained available for future purchases, inclusive of related estimated income tax.

 

Accumulated Other Comprehensive Loss

 

The changes in accumulated other comprehensive loss by component for the first nine months of 2021 were as follows (in thousands):

 

  Foreign Currency Translation Adjustments  Unrealized Gains (Losses) on Available-For-Sale Investments  

Total

 

Balance, December 31, 2020

 $(325) $(11) $(336)

Other comprehensive income (loss)

  (158)  18   (140)

Balance, September 30, 2021

 $(483) $7  $(476)
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Note 10 - Related Party Transactions
9 Months Ended
Sep. 30, 2021
Notes to Financial Statements  
Related Party Transactions Disclosure [Text Block]

10. RELATED PARTY TRANSACTIONS

 

The Company is a party to a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called ReStor™. George K. Broady, a former director of the Company and beneficial owner of more than 5% of its outstanding common stock, is an indirect owner of BHS. Brunde E. Broady, a director of the Company and daughter of Mr. Broady, is the President and Chief Executive Officer of BHS. Under this agreement (as amended), the Company agreed to pay BHS a royalty based on a price per unit in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide by or through multi-level marketing or network marketing. The Company recognized royalties of $25,000 and $14,000 during the three months ended September 30, 2021 and 2020, respectively, and $44,000 and $64,000 during the nine months ended September 30, 2021 and 2020, respectively, under this agreement. The Company is not required to purchase any product under the agreement, and the agreement may be terminated under certain circumstances with no notice. The agreement terminates March 31, 2025, after which it shall be automatically renewed for successive one-year terms unless notice is given by either party at least 90 days in advance of the expiration of the then-current term.

 

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Note 11 - Segment Information
9 Months Ended
Sep. 30, 2021
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

11.    SEGMENT INFORMATION

 

The Company sells products to a member network that operates in a seamless manner from market to market, except for the China market where it sells to some consumers through an e-commerce platform, and the Russia and Kazakhstan market where the Company’s engagement of a third-party service provider results in a different economic structure than its other markets. Otherwise, the Company believes that all of its other operating segments have similar economic characteristics and are similar in the nature of the products sold, the product acquisition process, the types of customers products are sold to, the methods used to distribute the products, and the nature of the regulatory environment. Therefore, the Company aggregates its other operating segments (including its Hong Kong operating segment) into a single reporting segment (the “Primary Reporting Segment”).

 

The Company reviews its net sales and operating income (loss) by operating segment, and reviews its assets and capital expenditures on a consolidated basis and not by operating segment. As such, net sales and operating income (loss) are presented by reportable segment and assets and capital expenditures by operating segment are not presented. Segment operating income is adjusted for certain direct costs and commission allocation.

 

The Company’s operating information by geographic area are as follows (in thousands):

 

   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2021

   

2020

   

2021

   

2020

 

Net sales:

                               

Primary Reporting Segment

  $ 13,576     $ 13,294     $ 41,679     $ 42,718  

China

    501       640       1,596       2,156  

Russia and Kazakhstan

    199       190       622       602  

Total net sales

  $ 14,276     $ 14,124     $ 43,897     $ 45,476  
                                 

Income (loss) from operations:

                               

Primary Reporting Segment

  $ 2,558     $ 2,715     $ 7,803     $ 6,038  

China

    5       134       51       64  

Russia and Kazakhstan

    5       (59 )     (101 )     (37 )

Income from operations for reportable segments, net

    2,568       2,790       7,753       6,065  

Unallocated corporate expenses

    (2,089 )     (2,122 )     (6,669 )     (6,662 )

Other income (expense), net

    (53 )     385       (92 )     603  

Income before income taxes

  $ 426     $ 1,053     $ 992     $ 6  

 

The Company’s net sales by geographic area are as follows (in thousands):

 

   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2021

   

2020

   

2021

   

2020

 

Net sales from external customers:

                               

United States

  $ 279     $ 338     $ 918     $ 1,202  

Canada

    140       132       481       536  

Peru

    608       357       1,752       954  

Hong Kong1

    11,201       11,132       34,227       36,238  

China

    501       640       1,596       2,156  

Taiwan

    584       771       1,990       2,261  

South Korea

    51       52       202       220  

Russia and Kazakhstan

    199       190       622       602  

Europe

    258       259       869       747  

Other foreign countries

    455       253       1,240       560  

Total net sales

  $ 14,276     $ 14,124     $ 43,897     $ 45,476  

 


1 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors” in this report and in our most recent Annual Report on Form 10-K.

 

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Note 12 - Subsequent Event
9 Months Ended
Sep. 30, 2021
Notes to Financial Statements  
Subsequent Events [Text Block]

12. SUBSEQUENT EVENT

 

On November 1, 2021, the Board of Directors declared a quarterly cash dividend of $0.20 on each share of common stock outstanding. The dividend will be payable on November 26, 2021 to stockholders of record on November 16, 2021. The declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.

 

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation 

 

The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s 2020 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on February 26, 2021.

 

Consolidation, Policy [Policy Text Block]

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.

 

Reclassification, Comparability Adjustment [Policy Text Block]

Reclassification

 

Certain income taxes payable balances have been reclassified in the prior year consolidated statement of cash flows to conform to current year presentation.

 

Earnings Per Share, Policy [Policy Text Block]

Net Income Per Common Share

 

Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized, if any, is assumed to be used to repurchase shares.

 

The following table illustrates the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data):

 

  

Three Months Ended September 30,

 
  

2021

  

2020

 
  

Income (Numerator)

  

Shares (Denominator)

  

Per Share Amount

  

Income (Numerator)

  

Shares (Denominator)

  

Per Share Amount

 

Basic net income per common share:

                        

Net income available to common stockholders

 $471   11,063  $0.04  $635   10,678  $0.06 

Effect of dilutive securities:

                        

Non-vested restricted stock

     361          746     

Diluted net income per common share:

                        

Net income available to common stockholders plus assumed conversions

 $471   11,424  $0.04  $635   11,424  $0.06 

 

  

Nine Months Ended September 30,

 
  

2021

  

2020

 
  

Income (Numerator)

  

Shares (Denominator)

  

Per Share Amount

  

Income (Numerator)

  

Shares (Denominator)

  

Per Share Amount

 

Basic net income per common share:

                        

Net income available to common stockholders

 $853   10,969  $0.08  $96   10,581  $0.01 

Effect of dilutive securities:

                        

Non-vested restricted stock

     455          843     

Diluted net income per common share:

                        

Net income available to common stockholders plus assumed conversions

 $853   11,424  $0.07  $96   11,424  $0.01 

 

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

 

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis and added Topic 326 to the FASB ASC. In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. The amendments to ASU 2019-11 clarify, correct and make improvements to Topic 326. ASU 2016-13 as well as the updates in ASU 2019-11 are effective for interim and annual periods beginning after December 15, 2022, and early adoption is permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements.

 

Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

 

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Note 1 - Nature of Operations, Basis of Presentation and Consolidation (Tables)
9 Months Ended
Sep. 30, 2021
Notes Tables  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
  

Three Months Ended September 30,

 
  

2021

  

2020

 
  

Income (Numerator)

  

Shares (Denominator)

  

Per Share Amount

  

Income (Numerator)

  

Shares (Denominator)

  

Per Share Amount

 

Basic net income per common share:

                        

Net income available to common stockholders

 $471   11,063  $0.04  $635   10,678  $0.06 

Effect of dilutive securities:

                        

Non-vested restricted stock

     361          746     

Diluted net income per common share:

                        

Net income available to common stockholders plus assumed conversions

 $471   11,424  $0.04  $635   11,424  $0.06 
  

Nine Months Ended September 30,

 
  

2021

  

2020

 
  

Income (Numerator)

  

Shares (Denominator)

  

Per Share Amount

  

Income (Numerator)

  

Shares (Denominator)

  

Per Share Amount

 

Basic net income per common share:

                        

Net income available to common stockholders

 $853   10,969  $0.08  $96   10,581  $0.01 

Effect of dilutive securities:

                        

Non-vested restricted stock

     455          843     

Diluted net income per common share:

                        

Net income available to common stockholders plus assumed conversions

 $853   11,424  $0.07  $96   11,424  $0.01 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Note 2 - Revenue (Tables)
9 Months Ended
Sep. 30, 2021
Notes Tables  
Revenue from External Customers by Products and Services [Table Text Block]
  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 
  

2021

  

2020

  

2021

  

2020

 

Product sales

 $12,809  $12,023  $39,405  $41,234 

Administrative fees, freight and other

  1,524   2,316   4,777   4,854 

Less: sales returns

  (57)  (215)  (285)  (612)

Total net sales

 $14,276  $14,124  $43,897  $45,476 
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Note 3 - Balance Sheet Components (Tables)
9 Months Ended
Sep. 30, 2021
Notes Tables  
Schedule of Additional Balance Sheet Components [Table Text Block]
   

September 30, 2021

   

December 31, 2020

 

Cash, cash equivalents and restricted cash:

               

Cash

  $ 18,091     $ 23,977  

Cash equivalents

    66,549       68,390  
      84,640       92,367  

Restricted cash

    524       525  
    $ 85,164     $ 92,892  

Inventories:

               

Finished goods

  $ 3,851     $ 3,071  

Raw materials

    602       1,047  

Reserve for obsolescence

    (63 )     (339 )
    $ 4,390     $ 3,779  

Other accrued expenses:

               

Sales returns

  $ 127     $ 189  

Employee-related expense

    917       1,149  

Warehousing, inventory-related and other

    714       584  
    $ 1,758     $ 1,922  

Deferred revenue:

               

Unshipped product and unredeemed product vouchers

  $ 4,023     $ 1,005  

Auto ship advances

    1,909       1,977  

Other

    106       109  
    $ 6,038     $ 3,091  
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Note 4 - Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2021
Notes Tables  
Debt Securities, Available-for-sale [Table Text Block]
     

September 30, 2021

   

December 31, 2020

 
 

Fair Value Level1

 

Adjusted Cost

   

Gross Unrealized Gains (Losses)

   

Fair Value

   

Adjusted Cost

   

Gross Unrealized Losses

   

Fair Value

 

Money market funds

Level 1

  $ 37,534     $     $ 37,534     $ 21,042     $     $ 21,042  

Time deposits

Level 2

                      5,458             5,458  

Government and municipal debt securities

Level 2

    11,849       (1 )     11,848       30,280       (5 )     30,275  

Corporate debt securities

Level 2

    17,159       8       17,167       11,621       (6 )     11,615  

Total investments

  $ 66,542     $ 7     $ 66,549     $ 68,401     $ (11 )   $ 68,390  
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Note 5 - Leases (Tables)
9 Months Ended
Sep. 30, 2021
Notes Tables  
Lease, Cost [Table Text Block]
   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2021

   

2020

   

2021

   

2020

 

Operating leases

  $ 338     $ 377     $ 996     $ 1,292  

Short-term leases

    44       72       133       237  

Total lease cost

  $ 382     $ 449     $ 1,129     $ 1,529  

Weighted-average remaining lease term (in years)

    5.1  

Weighted-average discount rate

    3.3 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]

Remainder of 2021

  $ 327  

2022

    1,303  

2023

    675  

2024

    272  

2025

    261  

Thereafter

    990  

Total lease payments

  $ 3,828  

Less: imputed interest

    (315 )

Present value of lease liabilities

  $ 3,513  
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Note 8 - Stock-based Incentive Plans (Tables)
9 Months Ended
Sep. 30, 2021
Notes Tables  
Nonvested Restricted Stock Shares Activity [Table Text Block]
   

Shares

   

Wtd. Avg. Price at Date of Issuance

 

Nonvested at December 31, 2020

    566,272     $ 7.21  

Vested

    (285,024 )   $ 7.27  

Nonvested at September 30, 2021

    281,248     $ 7.14  
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Note 9 - Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2021
Notes Tables  
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]
  Foreign Currency Translation Adjustments  Unrealized Gains (Losses) on Available-For-Sale Investments  

Total

 

Balance, December 31, 2020

 $(325) $(11) $(336)

Other comprehensive income (loss)

  (158)  18   (140)

Balance, September 30, 2021

 $(483) $7  $(476)
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Note 11 - Segment Information (Tables)
9 Months Ended
Sep. 30, 2021
Notes Tables  
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]
   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2021

   

2020

   

2021

   

2020

 

Net sales:

                               

Primary Reporting Segment

  $ 13,576     $ 13,294     $ 41,679     $ 42,718  

China

    501       640       1,596       2,156  

Russia and Kazakhstan

    199       190       622       602  

Total net sales

  $ 14,276     $ 14,124     $ 43,897     $ 45,476  
                                 

Income (loss) from operations:

                               

Primary Reporting Segment

  $ 2,558     $ 2,715     $ 7,803     $ 6,038  

China

    5       134       51       64  

Russia and Kazakhstan

    5       (59 )     (101 )     (37 )

Income from operations for reportable segments, net

    2,568       2,790       7,753       6,065  

Unallocated corporate expenses

    (2,089 )     (2,122 )     (6,669 )     (6,662 )

Other income (expense), net

    (53 )     385       (92 )     603  

Income before income taxes

  $ 426     $ 1,053     $ 992     $ 6  
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]
   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2021

   

2020

   

2021

   

2020

 

Net sales from external customers:

                               

United States

  $ 279     $ 338     $ 918     $ 1,202  

Canada

    140       132       481       536  

Peru

    608       357       1,752       954  

Hong Kong1

    11,201       11,132       34,227       36,238  

China

    501       640       1,596       2,156  

Taiwan

    584       771       1,990       2,261  

South Korea

    51       52       202       220  

Russia and Kazakhstan

    199       190       622       602  

Europe

    258       259       869       747  

Other foreign countries

    455       253       1,240       560  

Total net sales

  $ 14,276     $ 14,124     $ 43,897     $ 45,476  
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Note 1 - Nature of Operations, Basis of Presentation and Consolidation - Earnings Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Net income available to common stockholders $ 471 $ 635 $ 853 $ 96
Basic (in shares) 11,063 10,678 10,969 10,581
Basic (in dollars per share) $ 0.04 $ 0.06 $ 0.08 $ 0.01
Non-vested restricted stock $ 0 $ 0 $ 0 $ 0
Non-vested restricted stock (in shares) 361 746 455 843
Net income available to common stockholders plus assumed conversions $ 471 $ 635 $ 853 $ 96
Diluted (in shares) 11,424 11,424 11,424 11,424
Diluted (in dollars per share) $ 0.04 $ 0.06 $ 0.07 $ 0.01
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Note 2 - Revenue (Details Textual)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
USD ($)
Sep. 30, 2020
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Revenue from Contract with Customers, Sales Returns, Percent     1.00%  
Increase (Decrease) in Contract with Customer, Liability $ 4,000   $ 2,973 $ (1,045)
Contract with Customer, Liability, Revenue Recognized $ 1,000      
Geographic Concentration Risk [Member] | Revenue Benchmark [Member]        
Number of Major Markets 0 0 0 0
Customer Concentration Risk [Member] | Revenue Benchmark [Member]        
Number of Major Customers 0 0 0 0
Minimum [Member]        
Revenue from Contract with Customer, Sales Returns Policy Term (Day)     14 days  
Revenue from Contract with Customers, Historical Sales Returns, Percent     1.00%  
Maximum [Member]        
Revenue from Contract with Customer, Sales Returns Policy Term (Day)     1 year  
Revenue from Contract with Customers, Historical Sales Returns, Percent     8.00%  
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Note 2 - Revenue - Net Sales by Product and Service (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Net sales $ 14,276 $ 14,124 $ 43,897 $ 45,476
Less: sales returns 57 215 285 612
Product [Member]        
Net sales 12,809 12,023 39,405 41,234
Administrative Fees, Freight and Other [Member]        
Net sales $ 1,524 $ 2,316 $ 4,777 $ 4,854
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Note 3 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Cash $ 18,091 $ 23,977
Cash equivalents 66,549 68,390
Cash and cash equivalents 84,640 92,367
Restricted cash 524 525
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance 85,164 92,892
Inventories:    
Finished goods 3,851 3,071
Raw materials 602 1,047
Reserve for obsolescence (63) (339)
Inventory, Net, Total 4,390 3,779
Other accrued expenses:    
Sales returns 127 189
Employee-related expense 917 1,149
Warehousing, inventory-related and other 714 584
Accrued Liabilities, Current, Total 1,758 1,922
Deferred revenue:    
Deferred revenue 6,038 3,091
Unshipped Product [Member]    
Deferred revenue:    
Deferred revenue 4,023 1,005
Auto ship advances [Member]    
Deferred revenue:    
Deferred revenue 1,909 1,977
Product and Service, Other [Member]    
Deferred revenue:    
Deferred revenue $ 106 $ 109
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Note 4 - Fair Value Measurements - Investments (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Adjusted cost [1] $ 66,542 $ 68,401
Gross unrealized losses [1] (7) (11)
Fair value [1] 66,549 68,390
Fair value [1] (66,549) (68,390)
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]    
Adjusted cost [1] 37,534 21,042
Gross unrealized losses [1] 0 0
Fair value [1] 37,534 21,042
Fair value [1] (37,534) (21,042)
Bank Time Deposits [Member] | Fair Value, Inputs, Level 2 [Member]    
Adjusted cost [1] 0 5,458
Gross unrealized losses [1] 0 0
Fair value [1] 0 5,458
Fair value [1] 0 (5,458)
Municipal Bonds [Member] | Fair Value, Inputs, Level 2 [Member]    
Adjusted cost [1] 11,849 30,280
Gross unrealized losses [1] (1) (5)
Fair value [1] 11,848 30,275
Fair value [1] (11,848) (30,275)
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]    
Adjusted cost [1] 17,159 11,621
Gross unrealized losses [1] (8) (6)
Fair value [1] 17,167 11,615
Fair value [1] $ (17,167) $ (11,615)
[1] FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data.
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Note 5 - Leases (Details Textual)
3 Months Ended 9 Months Ended
Sep. 30, 2021
USD ($)
ft²
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
ft²
Sep. 30, 2020
USD ($)
Operating Lease, Payments | $ $ 327,000 $ 342,000 $ 1,000,000.0 $ 1,200,000
HONG KONG        
Area of Land (Square Foot) 7,300   7,300  
Rolling Hills Estates [Member]        
Area of Land (Square Foot) 4,900   4,900  
Lessee, Operating Lease, Renewal Term (Year) 5 years   5 years  
Richmond, British Columbia [Member]        
Area of Land (Square Foot) 1,600   1,600  
Metuchen, New Jersey [Member]        
Area of Land (Square Foot) 2,000   2,000  
CHINA        
Lessee, Number of Branches 8   8  
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Note 5 - Leases - Lease Cost (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Operating leases $ 338 $ 377 $ 996 $ 1,292
Short-term leases 44 72 133 237
Total lease cost $ 382 $ 449 $ 1,129 $ 1,529
Weighted-average remaining lease term (in years) (Year) 5 years 1 month 6 days   5 years 1 month 6 days  
Weighted-average discount rate 3.30%   3.30%  
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Note 5 - Leases - Maturity of Lease Liabilities (Details)
$ in Thousands
Sep. 30, 2021
USD ($)
Remainder of 2021 $ 327
2022 1,303
2023 675
2024 272
2025 261
Thereafter 990
Total lease payments 3,828
Less: imputed interest (315)
Present value of lease liabilities $ 3,513
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Note 6 - Income Taxes (Details Textual)
Sep. 30, 2021
USD ($)
Deferred Tax Assets, Valuation Allowance, Total $ 0
Domestic Tax Authority [Member]  
Operating Loss Carryforwards, Total 603,000
State and Local Jurisdiction [Member]  
Operating Loss Carryforwards, Subject to Expiration 427,000
Foreign Tax Authority [Member]  
Operating Loss Carryforwards, Subject to Expiration $ 2,800,000
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Note 8 - Stock-based Incentive Plans (Details Textual) - USD ($)
3 Months Ended 9 Months Ended
May 14, 2021
Mar. 15, 2021
Sep. 30, 2021
Sep. 30, 2021
Equity Incentive Plan 2016 [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)     2,500,000 2,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)     1,219,583 1,219,583
The Phantom Plan [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)   10 years    
The Phantom Plan [Member] | Phantom Shares [Member] | Employees and Non-Employee Directors [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)   223,307    
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)   3 months    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)     27,913 83,739
Share-based Payment Arrangement, Expense     $ 195,000 $ 588,000
The Phantom Plan [Member] | Phantom Shares [Member] | Employees and Non-Employee Directors [Member] | Maximum [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Maximum Payment Per Share (in dollars per share)   $ 12.00    
The Phantom Plan [Member] | Phantom Shares [Member] | NewNonEmployeeDirectorsMember        
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) 9,074      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) 9,074      
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Note 8 - Stock-based Incentive Plans - Restricted Stock Activity (Details) - Restricted Stock [Member]
9 Months Ended
Sep. 30, 2021
$ / shares
shares
Balance (in shares) | shares 566,272
Balance, weighted avg. price (in dollars per share) | $ / shares $ 7.21
Vested (in shares) | shares (285,024)
Vested, wtd. avg. price (in dollars per share) | $ / shares $ 7.27
Balance (in shares) | shares 281,248
Balance, weighted avg. price (in dollars per share) | $ / shares $ 7.14
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Note 9 - Stockholders' Equity (Details Textual) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2021
Jan. 12, 2016
Jul. 28, 2015
Common Stock, Dividends, Per Share, Declared (in dollars per share) $ 0.20 $ 0.20 $ 0.20 $ 0.20 $ 0.20 $ 0.20      
Dividends, Common Stock, Total             $ 6.9    
Stock Repurchase Program, Authorized Amount               $ 70.0 $ 15.0
Stock Repurchase Program, Remaining Authorized Repurchase Amount $ 21.9           $ 21.9    
Common Stock, Dividends, Per Share, Cash Paid (in dollars per share) $ 0.20 $ 0.20              
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Note 9 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details)
$ in Thousands
9 Months Ended
Sep. 30, 2021
USD ($)
Balance $ 67,697
Balance 61,555
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]  
Balance (325)
Other comprehensive income (loss) (158)
Balance (483)
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]  
Balance (11)
Other comprehensive income (loss) 18
Balance 7
AOCI Attributable to Parent [Member]  
Balance (336)
Other comprehensive income (loss) (140)
Balance $ (476)
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Note 10 - Related Party Transactions (Details Textual) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Jun. 30, 2021
Director [Member]          
Common Stock, Percentage of Beneficial Stock Outstanding         5.00%
BHS [Member] | Royalty Agreement and License [Member]          
Royalty Expense $ 25,000 $ 14,000 $ 44,000 $ 64,000  
Related Party Transaction, Automatic Renewal Period of Agreement (Year)     1 year    
Number of Days Termination Notice (Day)     90 days    
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Note 11 - Segment Information - Operating Information by Geographic Area (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Net sales $ 14,276 $ 14,124 $ 43,897 $ 45,476
Income (loss) from operations 479 668 1,084 (597)
Other income (expense), net (53) 385 (92) 603
Income before income taxes 426 1,053 992 6
Operating Segments [Member]        
Income (loss) from operations 2,568 2,790 7,753 6,065
Intersegment Eliminations [Member]        
Income (loss) from operations (2,089) (2,122) (6,669) (6,662)
CHINA        
Net sales 501 640 1,596 2,156
CHINA | Operating Segments [Member]        
Income (loss) from operations 5 134 51 64
Russia and Kazakhstan [Member]        
Net sales 199 190 622 602
Russia and Kazakhstan [Member] | Operating Segments [Member]        
Income (loss) from operations 5 (59) (101) (37)
Primary Reporting Segment [Member]        
Net sales 13,576 13,294 41,679 42,718
Primary Reporting Segment [Member] | Operating Segments [Member]        
Income (loss) from operations $ 2,558 $ 2,715 $ 7,803 $ 6,038
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.21.2
Note 11 - Segment Information - Net Sales by Geographic Area (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Net sales $ 14,276 $ 14,124 $ 43,897 $ 45,476
UNITED STATES        
Net sales 279 338 918 1,202
CANADA        
Net sales 140 132 481 536
PERU        
Net sales 608 357 1,752 954
HONG KONG        
Net sales [1] 11,201 11,132 34,227 36,238
CHINA        
Net sales 501 640 1,596 2,156
TAIWAN, PROVINCE OF CHINA        
Net sales 584 771 1,990 2,261
KOREA, REPUBLIC OF        
Net sales 51 52 202 220
Russia and Kazakhstan [Member]        
Net sales 199 190 622 602
Europe [Member]        
Net sales 258 259 869 747
Other Foreign Countries [Member]        
Net sales $ 455 $ 253 $ 1,240 $ 560
[1] Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors” in this report and in our most recent Annual Report on Form 10-K.
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.21.2
Note 12 - Subsequent Event (Details Textual) - $ / shares
3 Months Ended
Nov. 01, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Common Stock, Dividends, Per Share, Declared (in dollars per share)   $ 0.20 $ 0.20 $ 0.20 $ 0.20 $ 0.20 $ 0.20
Subsequent Event [Member]              
Common Stock, Dividends, Per Share, Declared (in dollars per share) $ 0.20            
EXCEL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 58 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 59 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 60 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 230 272 1 true 53 0 false 9 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Comprehensive Income (Unaudited) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-comprehensive-income-unaudited Consolidated Statements of Comprehensive Income (Unaudited) Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-unaudited Consolidated Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 006 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-parentheticals Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) Statements 7 false false R8.htm 007 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited Consolidated Statements of Cash Flows (Unaudited) Statements 8 false false R9.htm 008 - Disclosure - Note 1 - Nature of Operations, Basis of Presentation and Consolidation Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation Note 1 - Nature of Operations, Basis of Presentation and Consolidation Notes 9 false false R10.htm 009 - Disclosure - Note 2 - Revenue Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue Note 2 - Revenue Notes 10 false false R11.htm 010 - Disclosure - Note 3 - Balance Sheet Components Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components Note 3 - Balance Sheet Components Notes 11 false false R12.htm 011 - Disclosure - Note 4 - Fair Value Measurements Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements Note 4 - Fair Value Measurements Notes 12 false false R13.htm 012 - Disclosure - Note 5 - Leases Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases Note 5 - Leases Notes 13 false false R14.htm 013 - Disclosure - Note 6 - Income Taxes Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes Note 6 - Income Taxes Notes 14 false false R15.htm 014 - Disclosure - Note 7 - Commitments and Contingencies Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-7-commitments-and-contingencies Note 7 - Commitments and Contingencies Notes 15 false false R16.htm 015 - Disclosure - Note 8 - Stock-based Incentive Plans Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans Note 8 - Stock-based Incentive Plans Notes 16 false false R17.htm 016 - Disclosure - Note 9 - Stockholders' Equity Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity Note 9 - Stockholders' Equity Notes 17 false false R18.htm 017 - Disclosure - Note 10 - Related Party Transactions Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions Note 10 - Related Party Transactions Notes 18 false false R19.htm 018 - Disclosure - Note 11 - Segment Information Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information Note 11 - Segment Information Notes 19 false false R20.htm 019 - Disclosure - Note 12 - Subsequent Event Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-12-subsequent-event Note 12 - Subsequent Event Notes 20 false false R21.htm 020 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies 21 false false R22.htm 021 - Disclosure - Note 1 - Nature of Operations, Basis of Presentation and Consolidation (Tables) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-tables Note 1 - Nature of Operations, Basis of Presentation and Consolidation (Tables) Tables http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation 22 false false R23.htm 022 - Disclosure - Note 2 - Revenue (Tables) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-tables Note 2 - Revenue (Tables) Tables http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue 23 false false R24.htm 023 - Disclosure - Note 3 - Balance Sheet Components (Tables) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-tables Note 3 - Balance Sheet Components (Tables) Tables http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components 24 false false R25.htm 024 - Disclosure - Note 4 - Fair Value Measurements (Tables) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-tables Note 4 - Fair Value Measurements (Tables) Tables http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements 25 false false R26.htm 025 - Disclosure - Note 5 - Leases (Tables) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-tables Note 5 - Leases (Tables) Tables http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases 26 false false R27.htm 026 - Disclosure - Note 8 - Stock-based Incentive Plans (Tables) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-tables Note 8 - Stock-based Incentive Plans (Tables) Tables http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans 27 false false R28.htm 027 - Disclosure - Note 9 - Stockholders' Equity (Tables) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-tables Note 9 - Stockholders' Equity (Tables) Tables http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity 28 false false R29.htm 028 - Disclosure - Note 11 - Segment Information (Tables) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-tables Note 11 - Segment Information (Tables) Tables http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information 29 false false R30.htm 029 - Disclosure - Note 1 - Nature of Operations, Basis of Presentation and Consolidation - Earnings Per Share (Details) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-details Note 1 - Nature of Operations, Basis of Presentation and Consolidation - Earnings Per Share (Details) Details 30 false false R31.htm 030 - Disclosure - Note 2 - Revenue (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-details-textual Note 2 - Revenue (Details Textual) Details http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-tables 31 false false R32.htm 031 - Disclosure - Note 2 - Revenue - Net Sales by Product and Service (Details) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-net-sales-by-product-and-service-details Note 2 - Revenue - Net Sales by Product and Service (Details) Details 32 false false R33.htm 032 - Disclosure - Note 3 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details Note 3 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details) Details 33 false false R34.htm 033 - Disclosure - Note 4 - Fair Value Measurements - Investments (Details) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-investments-details Note 4 - Fair Value Measurements - Investments (Details) Details 34 false false R35.htm 034 - Disclosure - Note 5 - Leases (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-details-textual Note 5 - Leases (Details Textual) Details http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-tables 35 false false R36.htm 035 - Disclosure - Note 5 - Leases - Lease Cost (Details) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-lease-cost-details Note 5 - Leases - Lease Cost (Details) Details 36 false false R37.htm 036 - Disclosure - Note 5 - Leases - Maturity of Lease Liabilities (Details) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-maturity-of-lease-liabilities-details Note 5 - Leases - Maturity of Lease Liabilities (Details) Details 37 false false R38.htm 037 - Disclosure - Note 6 - Income Taxes (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes-details-textual Note 6 - Income Taxes (Details Textual) Details http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes 38 false false R39.htm 038 - Disclosure - Note 8 - Stock-based Incentive Plans (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual Note 8 - Stock-based Incentive Plans (Details Textual) Details http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-tables 39 false false R40.htm 039 - Disclosure - Note 8 - Stock-based Incentive Plans - Restricted Stock Activity (Details) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-restricted-stock-activity-details Note 8 - Stock-based Incentive Plans - Restricted Stock Activity (Details) Details 40 false false R41.htm 040 - Disclosure - Note 9 - Stockholders' Equity (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-details-textual Note 9 - Stockholders' Equity (Details Textual) Details http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-tables 41 false false R42.htm 041 - Disclosure - Note 9 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details Note 9 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details) Details 42 false false R43.htm 042 - Disclosure - Note 10 - Related Party Transactions (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions-details-textual Note 10 - Related Party Transactions (Details Textual) Details http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions 43 false false R44.htm 043 - Disclosure - Note 11 - Segment Information - Operating Information by Geographic Area (Details) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-operating-information-by-geographic-area-details Note 11 - Segment Information - Operating Information by Geographic Area (Details) Details 44 false false R45.htm 044 - Disclosure - Note 11 - Segment Information - Net Sales by Geographic Area (Details) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-net-sales-by-geographic-area-details Note 11 - Segment Information - Net Sales by Geographic Area (Details) Details 45 false false R46.htm 045 - Disclosure - Note 12 - Subsequent Event (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-12-subsequent-event-details-textual Note 12 - Subsequent Event (Details Textual) Details http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-12-subsequent-event 46 false false All Reports Book All Reports nhtc20210930_10q.htm ex_277499.htm ex_277500.htm ex_277501.htm nhtc-20210930.xsd nhtc-20210930_cal.xml nhtc-20210930_def.xml nhtc-20210930_lab.xml nhtc-20210930_pre.xml http://xbrl.sec.gov/country/2021 http://fasb.org/us-gaap/2021-01-31 http://fasb.org/srt/2021-01-31 http://xbrl.sec.gov/dei/2021 true true JSON 63 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nhtc20210930_10q.htm": { "axisCustom": 0, "axisStandard": 17, "contextCount": 230, "dts": { "calculationLink": { "local": [ "nhtc-20210930_cal.xml" ] }, "definitionLink": { "local": [ "nhtc-20210930_def.xml" ] }, "inline": { "local": [ "nhtc20210930_10q.htm" ] }, "labelLink": { "local": [ "nhtc-20210930_lab.xml" ] }, "presentationLink": { "local": [ "nhtc-20210930_pre.xml" ] }, "schema": { "local": [ "nhtc-20210930.xsd" ], "remote": [ "https://xbrl.sec.gov/country/2021/country-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 343, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 30, "http://www.naturalhealthtrendscorp.com/20210930": 13, "http://xbrl.sec.gov/dei/2021": 6, "total": 49 }, "keyCustom": 22, "keyStandard": 250, "memberCustom": 16, "memberStandard": 37, "nsprefix": "nhtc", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "span", "p", "div", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "span", "p", "div", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 2 - Revenue", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue", "shortName": "Note 2 - Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 3 - Balance Sheet Components", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components", "shortName": "Note 3 - Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 4 - Fair Value Measurements", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements", "shortName": "Note 4 - Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 5 - Leases", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases", "shortName": "Note 5 - Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note 6 - Income Taxes", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes", "shortName": "Note 6 - Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 7 - Commitments and Contingencies", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-7-commitments-and-contingencies", "shortName": "Note 7 - Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 8 - Stock-based Incentive Plans", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans", "shortName": "Note 8 - Stock-based Incentive Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 9 - Stockholders' Equity", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity", "shortName": "Note 9 - Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 10 - Related Party Transactions", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions", "shortName": "Note 10 - Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 11 - Segment Information", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information", "shortName": "Note 11 - Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited", "shortName": "Consolidated Balance Sheets (Current Period Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "-3", "lang": null, "name": "us-gaap:OtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note 12 - Subsequent Event", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-12-subsequent-event", "shortName": "Note 12 - Subsequent Event", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Note 1 - Nature of Operations, Basis of Presentation and Consolidation (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-tables", "shortName": "Note 1 - Nature of Operations, Basis of Presentation and Consolidation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note 2 - Revenue (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-tables", "shortName": "Note 2 - Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "nhtc:ScheduleOfAdditionalBalanceSheetComponentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note 3 - Balance Sheet Components (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-tables", "shortName": "Note 3 - Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "nhtc:ScheduleOfAdditionalBalanceSheetComponentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note 4 - Fair Value Measurements (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-tables", "shortName": "Note 4 - Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note 5 - Leases (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-tables", "shortName": "Note 5 - Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note 8 - Stock-based Incentive Plans (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-tables", "shortName": "Note 8 - Stock-based Incentive Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 9 - Stockholders' Equity (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-tables", "shortName": "Note 9 - Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note 11 - Segment Information (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-tables", "shortName": "Note 11 - Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "shortName": "Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 1 - Nature of Operations, Basis of Presentation and Consolidation - Earnings Per Share (Details)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-details", "shortName": "Note 1 - Nature of Operations, Basis of Presentation and Consolidation - Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": "2", "first": true, "lang": null, "name": "nhtc:RevenueFromContractWithCustomersSalesReturnsPercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note 2 - Revenue (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-details-textual", "shortName": "Note 2 - Revenue (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": "2", "first": true, "lang": null, "name": "nhtc:RevenueFromContractWithCustomersSalesReturnsPercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note 2 - Revenue - Net Sales by Product and Service (Details)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-net-sales-by-product-and-service-details", "shortName": "Note 2 - Revenue - Net Sales by Product and Service (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30", "decimals": "-3", "lang": null, "name": "nhtc:RevenueFromContractWithCustomerSalesReturns", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nhtc:ScheduleOfAdditionalBalanceSheetComponentsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note 3 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details", "shortName": "Note 3 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nhtc:ScheduleOfAdditionalBalanceSheetComponentsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note 4 - Fair Value Measurements - Investments (Details)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-investments-details", "shortName": "Note 4 - Fair Value Measurements - Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note 5 - Leases (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-details-textual", "shortName": "Note 5 - Leases (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note 5 - Leases - Lease Cost (Details)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-lease-cost-details", "shortName": "Note 5 - Leases - Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note 5 - Leases - Maturity of Lease Liabilities (Details)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-maturity-of-lease-liabilities-details", "shortName": "Note 5 - Leases - Maturity of Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "i_2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "i_2021-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note 6 - Income Taxes (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes-details-textual", "shortName": "Note 6 - Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "i_2021-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "i_2021-09-30_PlanNameAxis-EquityIncentivePlan2016Member", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Note 8 - Stock-based Incentive Plans (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual", "shortName": "Note 8 - Stock-based Incentive Plans (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-03-15_2021-03-15_AwardTypeAxis-PhantomSharesMember_PlanNameAxis-ThePhantomPlanMember_TitleOfIndividualAxis-EmployeesAndNonEmployeeDirectorsMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Operations (Unaudited)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited", "shortName": "Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "i_2020-12-31_AwardTypeAxis-RestrictedStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Note 8 - Stock-based Incentive Plans - Restricted Stock Activity (Details)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-restricted-stock-activity-details", "shortName": "Note 8 - Stock-based Incentive Plans - Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "i_2020-12-31_AwardTypeAxis-RestrictedStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DividendsCommonStock", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Note 9 - Stockholders' Equity (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-details-textual", "shortName": "Note 9 - Stockholders' Equity (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DividendsCommonStock", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Note 9 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details", "shortName": "Note 9 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-AccumulatedTranslationAdjustmentMember", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "i_2021-06-30_RelatedPartyTransactionsByRelatedPartyAxis-DirectorMember", "decimals": "2", "first": true, "lang": null, "name": "nhtc:CommonStockPercentageOfBeneficialStockOutstanding", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Note 10 - Related Party Transactions (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions-details-textual", "shortName": "Note 10 - Related Party Transactions (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "i_2021-06-30_RelatedPartyTransactionsByRelatedPartyAxis-DirectorMember", "decimals": "2", "first": true, "lang": null, "name": "nhtc:CommonStockPercentageOfBeneficialStockOutstanding", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Note 11 - Segment Information - Operating Information by Geographic Area (Details)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-operating-information-by-geographic-area-details", "shortName": "Note 11 - Segment Information - Operating Information by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30_ConsolidationItemsAxis-OperatingSegmentsMember", "decimals": "-3", "lang": null, "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Note 11 - Segment Information - Net Sales by Geographic Area (Details)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-net-sales-by-geographic-area-details", "shortName": "Note 11 - Segment Information - Net Sales by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30_StatementGeographicalAxis-US", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-11-01_2021-11-01_SubsequentEventTypeAxis-SubsequentEventMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Note 12 - Subsequent Event (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-12-subsequent-event-details-textual", "shortName": "Note 12 - Subsequent Event (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-11-01_2021-11-01_SubsequentEventTypeAxis-SubsequentEventMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Comprehensive Income (Unaudited)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-comprehensive-income-unaudited", "shortName": "Consolidated Statements of Comprehensive Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-07-01_2021-09-30", "decimals": "-3", "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "shortName": "Consolidated Statements of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-PreferredStockMember", "decimals": "-3", "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "shortName": "Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "007 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 1 - Nature of Operations, Basis of Presentation and Consolidation", "role": "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation", "shortName": "Note 1 - Nature of Operations, Basis of Presentation and Consolidation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20210930_10q.htm", "contextRef": "d_2021-01-01_2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 53, "tag": { "country_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CANADA" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-net-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "country_CN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHINA" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-details-textual" ], "xbrltype": "domainItemType" }, "country_HK": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "HONG KONG" } } }, "localname": "HK", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-details-textual" ], "xbrltype": "domainItemType" }, "country_KR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "KOREA, REPUBLIC OF" } } }, "localname": "KR", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-net-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "country_PE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PERU" } } }, "localname": "PE", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-net-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "country_TW": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TAIWAN, PROVINCE OF CHINA" } } }, "localname": "TW", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-net-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-net-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "countryCodeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-comprehensive-income-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-12-subsequent-event", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-12-subsequent-event-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-net-sales-by-product-and-service-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-investments-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-lease-cost-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-maturity-of-lease-liabilities-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-7-commitments-and-contingencies", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-restricted-stock-activity-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-comprehensive-income-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-12-subsequent-event", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-12-subsequent-event-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-net-sales-by-product-and-service-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-investments-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-lease-cost-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-maturity-of-lease-liabilities-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-7-commitments-and-contingencies", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-restricted-stock-activity-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "nhtc_AccruedSalesReturns": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales returns.", "label": "Sales returns" } } }, "localname": "AccruedSalesReturns", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "nhtc_AccruedWarehousingAndInventoryRelatedExpense": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for warehousing and inventory related expense.", "label": "Warehousing, inventory-related and other" } } }, "localname": "AccruedWarehousingAndInventoryRelatedExpense", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "nhtc_AdministrativeFeesFreightAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to administrative fees, freight and other.", "label": "Administrative Fees, Freight and Other [Member]" } } }, "localname": "AdministrativeFeesFreightAndOtherMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-net-sales-by-product-and-service-details" ], "xbrltype": "domainItemType" }, "nhtc_AutoShipAdvancesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to auto ship advances.", "label": "Auto ship advances [Member]" } } }, "localname": "AutoShipAdvancesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "domainItemType" }, "nhtc_BHSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to BHS.", "label": "BHS [Member]" } } }, "localname": "BHSMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_CapitalizedContractCostsLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount liability recognized from cost incurred to obtain or fulfill contract with customer; classified as current.", "label": "Amounts held in eWallets" } } }, "localname": "CapitalizedContractCostsLiabilityCurrent", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "nhtc_CommonStockPercentageOfBeneficialStockOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of beneficial stock outstanding.", "label": "nhtc_CommonStockPercentageOfBeneficialStockOutstanding", "terseLabel": "Common Stock, Percentage of Beneficial Stock Outstanding" } } }, "localname": "CommonStockPercentageOfBeneficialStockOutstanding", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "percentItemType" }, "nhtc_DeferredIncomeTaxExpenseBenefitExcludingEffectsOfForeignExchange": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of deferred income tax expense (benefit), excluding effects of foreign exchange.", "label": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefitExcludingEffectsOfForeignExchange", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "nhtc_EmployeesAndNonEmployeeDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to employees and non-employee directors.", "label": "Employees and Non-Employee Directors [Member]" } } }, "localname": "EmployeesAndNonEmployeeDirectorsMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_EquityIncentivePlan2016Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the 2016 Equity Incentive Plan.", "label": "Equity Incentive Plan 2016 [Member]" } } }, "localname": "EquityIncentivePlan2016Member", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_IncreaseDecreaseInAccruedSalesCommissions": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued sales commissions.", "label": "nhtc_IncreaseDecreaseInAccruedSalesCommissions", "terseLabel": "Accrued commissions" } } }, "localname": "IncreaseDecreaseInAccruedSalesCommissions", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "nhtc_IncreaseDecreaseInCapitalizedContractCostLiability": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in capitalized contract cost liability.", "label": "nhtc_IncreaseDecreaseInCapitalizedContractCostLiability", "terseLabel": "Amounts held in eWallets" } } }, "localname": "IncreaseDecreaseInCapitalizedContractCostLiability", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "nhtc_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating lease liabilities.", "label": "nhtc_IncreaseDecreaseInOperatingLeaseLiabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "nhtc_LesseeNoncashLeaseExpense": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of lessee's noncash lease expense during the period.", "label": "Noncash lease expense" } } }, "localname": "LesseeNoncashLeaseExpense", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "nhtc_LesseeNumberOfBranches": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the lessees' number of branches.", "label": "nhtc_LesseeNumberOfBranches", "terseLabel": "Lessee, Number of Branches" } } }, "localname": "LesseeNumberOfBranches", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-details-textual" ], "xbrltype": "integerItemType" }, "nhtc_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-maturity-of-lease-liabilities-details": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "nhtc_MetuchenNewJerseyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Metuchen, New Jersey.", "label": "Metuchen, New Jersey [Member]" } } }, "localname": "MetuchenNewJerseyMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_NewnonemployeedirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NewNonEmployeeDirectorsMember" } } }, "localname": "NewnonemployeedirectorsMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "xbrltype": "stringItemType" }, "nhtc_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "xbrltype": "stringItemType" }, "nhtc_NumberOfDaysTerminationNotice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of days for termination notice.", "label": "nhtc_NumberOfDaysTerminationNotice", "terseLabel": "Number of Days Termination Notice (Day)" } } }, "localname": "NumberOfDaysTerminationNotice", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "durationItemType" }, "nhtc_NumberOfMajorCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc.", "label": "nhtc_NumberOfMajorCustomers", "terseLabel": "Number of Major Customers" } } }, "localname": "NumberOfMajorCustomers", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "integerItemType" }, "nhtc_NumberOfMajorMarkets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of major markets accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc.", "label": "nhtc_NumberOfMajorMarkets", "terseLabel": "Number of Major Markets" } } }, "localname": "NumberOfMajorMarkets", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "integerItemType" }, "nhtc_OperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "nhtc_OperatingLossCarryforwardsSubjectToExpiration", "terseLabel": "Operating Loss Carryforwards, Subject to Expiration" } } }, "localname": "OperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "nhtc_OtherForeignCountriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to other foreign countries.", "label": "Other Foreign Countries [Member]" } } }, "localname": "OtherForeignCountriesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-net-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "nhtc_PhantomSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to phantom shares.", "label": "Phantom Shares [Member]" } } }, "localname": "PhantomSharesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_PrimaryReportingSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the primary reporting segment.", "label": "Primary Reporting Segment [Member]" } } }, "localname": "PrimaryReportingSegmentMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "nhtc_RelatedPartyTransactionAutomaticRenewalPeriodOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the automatic renewal period of the agreement in related party transaction.", "label": "nhtc_RelatedPartyTransactionAutomaticRenewalPeriodOfAgreement", "terseLabel": "Related Party Transaction, Automatic Renewal Period of Agreement (Year)" } } }, "localname": "RelatedPartyTransactionAutomaticRenewalPeriodOfAgreement", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "durationItemType" }, "nhtc_RevenueFromContractWithCustomerSalesReturns": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of sales returns during the period.", "label": "nhtc_RevenueFromContractWithCustomerSalesReturns", "negatedLabel": "Less: sales returns" } } }, "localname": "RevenueFromContractWithCustomerSalesReturns", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-net-sales-by-product-and-service-details" ], "xbrltype": "monetaryItemType" }, "nhtc_RevenueFromContractWithCustomerSalesReturnsPolicyTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the sales returns policy term.", "label": "nhtc_RevenueFromContractWithCustomerSalesReturnsPolicyTerm", "terseLabel": "Revenue from Contract with Customer, Sales Returns Policy Term (Day)" } } }, "localname": "RevenueFromContractWithCustomerSalesReturnsPolicyTerm", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "durationItemType" }, "nhtc_RevenueFromContractWithCustomersHistoricalSalesReturnsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of historical sales returns.", "label": "nhtc_RevenueFromContractWithCustomersHistoricalSalesReturnsPercent", "terseLabel": "Revenue from Contract with Customers, Historical Sales Returns, Percent" } } }, "localname": "RevenueFromContractWithCustomersHistoricalSalesReturnsPercent", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "percentItemType" }, "nhtc_RevenueFromContractWithCustomersSalesReturnsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of sales returns.", "label": "nhtc_RevenueFromContractWithCustomersSalesReturnsPercent", "terseLabel": "Revenue from Contract with Customers, Sales Returns, Percent" } } }, "localname": "RevenueFromContractWithCustomersSalesReturnsPercent", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "percentItemType" }, "nhtc_RichmondBritishColumbiaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Richmond, British Columbia.", "label": "Richmond, British Columbia [Member]" } } }, "localname": "RichmondBritishColumbiaMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_RollingHillsEstatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Rolling Hills Estates.", "label": "Rolling Hills Estates [Member]" } } }, "localname": "RollingHillsEstatesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_RoyaltyAgreementAndLicenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the Royalty Agreement and License.", "label": "Royalty Agreement and License [Member]" } } }, "localname": "RoyaltyAgreementAndLicenseMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_RussiaAndKazakhstanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Russia and Kazakhstan.", "label": "Russia and Kazakhstan [Member]" } } }, "localname": "RussiaAndKazakhstanMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "nhtc_ScheduleOfAdditionalBalanceSheetComponentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of additional balance sheet components.", "label": "Schedule of Additional Balance Sheet Components [Table Text Block]" } } }, "localname": "ScheduleOfAdditionalBalanceSheetComponentsTableTextBlock", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-tables" ], "xbrltype": "textBlockItemType" }, "nhtc_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPaymentPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the maximum payment value per share of equity instruments other than options under share based compensation arrangement.", "label": "nhtc_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPaymentPerShare", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Maximum Payment Per Share (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPaymentPerShare", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual" ], "xbrltype": "perShareItemType" }, "nhtc_ThePhantomPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the phantom plan.", "label": "The Phantom Plan [Member]" } } }, "localname": "ThePhantomPlanMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_UnshippedProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to unshipped product.", "label": "Unshipped Product [Member]" } } }, "localname": "UnshippedProductMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "domainItemType" }, "nhtc_statement-statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - Nature of Operations, Basis of Presentation and Consolidation - Earnings Per Share (Details)" } } }, "localname": "statement-statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - Nature of Operations, Basis of Presentation and Consolidation" } } }, "localname": "statement-statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-11-segment-information-net-sales-by-geographic-area-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Segment Information - Net Sales by Geographic Area (Details)" } } }, "localname": "statement-statement-note-11-segment-information-net-sales-by-geographic-area-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-11-segment-information-operating-information-by-geographic-area-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Segment Information - Operating Information by Geographic Area (Details)" } } }, "localname": "statement-statement-note-11-segment-information-operating-information-by-geographic-area-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-11-segment-information-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Segment Information" } } }, "localname": "statement-statement-note-11-segment-information-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-2-revenue-net-sales-by-product-and-service-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Revenue - Net Sales by Product and Service (Details)" } } }, "localname": "statement-statement-note-2-revenue-net-sales-by-product-and-service-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-2-revenue-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Revenue" } } }, "localname": "statement-statement-note-2-revenue-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details)" } } }, "localname": "statement-statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-3-balance-sheet-components-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Balance Sheet Components" } } }, "localname": "statement-statement-note-3-balance-sheet-components-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-4-fair-value-measurements-investments-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Fair Value Measurements - Investments (Details)" } } }, "localname": "statement-statement-note-4-fair-value-measurements-investments-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-4-fair-value-measurements-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Fair Value Measurements" } } }, "localname": "statement-statement-note-4-fair-value-measurements-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-5-leases-lease-cost-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Leases - Lease Cost (Details)" } } }, "localname": "statement-statement-note-5-leases-lease-cost-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-5-leases-maturity-of-lease-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Leases - Maturity of Lease Liabilities (Details)" } } }, "localname": "statement-statement-note-5-leases-maturity-of-lease-liabilities-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-5-leases-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Leases" } } }, "localname": "statement-statement-note-5-leases-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-8-stockbased-incentive-plans-restricted-stock-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Stock-based Incentive Plans - Restricted Stock Activity (Details)" } } }, "localname": "statement-statement-note-8-stockbased-incentive-plans-restricted-stock-activity-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-8-stockbased-incentive-plans-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Stock-based Incentive Plans" } } }, "localname": "statement-statement-note-8-stockbased-incentive-plans-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details)" } } }, "localname": "statement-statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-9-stockholders-equity-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Stockholders' Equity" } } }, "localname": "statement-statement-note-9-stockholders-equity-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "xbrltype": "stringItemType" }, "nhtc_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://www.naturalhealthtrendscorp.com/20210930", "xbrltype": "stringItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r84", "r129", "r141", "r142", "r143", "r144", "r145", "r147", "r151", "r180", "r181", "r182", "r183", "r184", "r185", "r187", "r188", "r190", "r192", "r193" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r84", "r129", "r141", "r142", "r143", "r144", "r145", "r147", "r151", "r180", "r181", "r182", "r183", "r184", "r185", "r187", "r188", "r190", "r192", "r193" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Europe [Member]" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-net-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r195", "r201", "r246", "r247", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r393", "r396", "r435", "r436" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r195", "r201", "r246", "r247", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r393", "r396", "r435", "r436" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r153", "r229", "r233", "r353", "r392", "r394" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-net-sales-by-product-and-service-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r153", "r229", "r233", "r353", "r392", "r394" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-net-sales-by-product-and-service-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r195", "r201", "r236", "r246", "r247", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r393", "r396", "r435", "r436" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r195", "r201", "r236", "r246", "r247", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r393", "r396", "r435", "r436" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r154", "r155", "r229", "r234", "r395", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-details-textual" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r154", "r155", "r229", "r234", "r395", "r422", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r159", "r332" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r29", "r338" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r11", "r12", "r31" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related expense" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r17", "r368", "r381" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "auth_ref": [ "r18", "r368", "r381" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.", "label": "us-gaap_AccruedIncomeTaxesNoncurrent", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other accrued expenses:" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "stringItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_AccruedLiabilitiesCurrent", "totalLabel": "Accrued Liabilities, Current, Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalesCommissionCurrent": { "auth_ref": [ "r11", "r12", "r31" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued commissions" } } }, "localname": "AccruedSalesCommissionCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r44", "r45", "r46", "r50", "r57", "r58", "r59" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r23", "r48", "r49", "r50", "r382", "r401", "r402" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r47", "r50", "r57", "r58", "r59", "r86", "r87", "r88", "r291", "r397", "r398", "r443" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r42", "r50", "r57", "r58", "r59", "r291", "r307", "r308", "r309", "r310", "r312" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r21", "r264", "r338" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r86", "r87", "r88", "r261", "r262", "r263", "r294" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r249", "r259", "r265" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Share-based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits": { "auth_ref": [ "r114" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of stock options or restrictive stock units (RSUs).", "label": "Non-vested restricted stock" } } }, "localname": "AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "us-gaap_AreaOfLand", "terseLabel": "Area of Land (Square Foot)" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-details-textual" ], "xbrltype": "areaItemType" }, "us-gaap_Assets": { "auth_ref": [ "r81", "r137", "r143", "r149", "r166", "r180", "r181", "r182", "r184", "r185", "r186", "r187", "r189", "r191", "r193", "r194", "r287", "r292", "r301", "r336", "r338", "r367", "r380" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r7", "r8", "r40", "r81", "r166", "r180", "r181", "r182", "r184", "r185", "r186", "r187", "r189", "r191", "r193", "r194", "r287", "r292", "r301", "r336", "r338" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r164" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "negatedLabel": "Gross unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-investments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r162", "r168" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Adjusted cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-investments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r161", "r163", "r168", "r370" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Fair value", "negatedLabel": "Fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-investments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r250", "r260" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-restricted-stock-activity-details" ], "xbrltype": "stringItemType" }, "us-gaap_BankTimeDepositsMember": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.", "label": "Bank Time Deposits [Member]" } } }, "localname": "BankTimeDepositsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r4", "r85", "r124" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r27", "r338", "r405", "r406" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r5", "r27", "r77" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "totalLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r72", "r77", "r78" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r72", "r77", "r78" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period", "periodStartLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r72", "r304" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net decrease in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r27" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 0.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r33", "r178", "r371", "r386" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 7)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r175", "r176", "r177", "r179", "r425" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-7-commitments-and-contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "us-gaap_CommonStockDividendsPerShareCashPaid", "terseLabel": "Common Stock, Dividends, Per Share, Cash Paid (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Dividends declared, per share (in dollars per share)", "terseLabel": "Common Stock, Dividends, Per Share, Declared (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-12-subsequent-event-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r86", "r87", "r294" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r20", "r338" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at September 30, 2021 and December 31, 2020" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r53", "r55", "r56", "r62", "r374", "r388" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-comprehensive-income-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-comprehensive-income-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive income (loss), net of tax:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-comprehensive-income-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r122", "r123", "r157", "r299", "r300", "r424" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r122", "r123", "r157", "r299", "r300", "r404", "r424" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r122", "r123", "r157", "r299", "r300", "r404", "r424" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r122", "r123", "r157", "r299", "r300", "r424" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r79", "r289" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred revenue:" } } }, "localname": "ContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r218", "r219", "r230" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r231" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "us-gaap_ContractWithCustomerLiabilityRevenueRecognized", "terseLabel": "Contract with Customer, Liability, Revenue Recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r237", "r245", "r403" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r66", "r353" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited": { "order": 0.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r120", "r157" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r267", "r268" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred tax asset" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r267", "r268" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r273" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "terseLabel": "Deferred Tax Assets, Valuation Allowance, Total" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r75", "r132" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-12-subsequent-event", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-7-commitments-and-contingencies", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity" ], "xbrltype": "stringItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r214", "r379" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "us-gaap_Dividends", "negatedLabel": "Dividends declared" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsCommonStock": { "auth_ref": [ "r214", "r379" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "us-gaap_DividendsCommonStock", "terseLabel": "Dividends, Common Stock, Total" } } }, "localname": "DividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r63", "r91", "r92", "r93", "r94", "r95", "r99", "r102", "r112", "r113", "r114", "r117", "r118", "r295", "r296", "r375", "r389" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-details" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net income per common share:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding:" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r63", "r91", "r92", "r93", "r94", "r95", "r102", "r112", "r113", "r114", "r117", "r118", "r295", "r296", "r375", "r389" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-details" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r115", "r116" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r304" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rates on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r57", "r58", "r59", "r86", "r87", "r88", "r90", "r96", "r98", "r119", "r167", "r213", "r214", "r261", "r262", "r263", "r276", "r277", "r294", "r306", "r307", "r308", "r309", "r310", "r312", "r397", "r398", "r399", "r443" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r196", "r197", "r198", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r245", "r297", "r342", "r343", "r344" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-investments-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r196", "r237", "r238", "r243", "r245", "r297", "r342" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r196", "r197", "r198", "r237", "r238", "r243", "r245", "r297", "r343" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r196", "r197", "r198", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r245", "r342", "r343", "r344" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r121", "r424" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r65", "r81", "r137", "r142", "r145", "r148", "r151", "r166", "r180", "r181", "r182", "r185", "r186", "r187", "r189", "r191", "r193", "r194", "r301" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "us-gaap_GrossProfit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r60", "r137", "r142", "r145", "r148", "r151", "r366", "r372", "r377", "r390" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income before income taxes", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r82", "r270", "r272", "r274", "r278", "r280", "r282", "r283", "r284" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r83", "r97", "r98", "r135", "r269", "r279", "r281", "r391" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax provision (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r74" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r74" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable", "verboseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r74" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities", "terseLabel": "Other accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r74", "r352" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability", "terseLabel": "Increase (Decrease) in Contract with Customer, Liability", "verboseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r74" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r74" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "us-gaap_IncreaseDecreaseInOtherCurrentAssets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r74" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities", "terseLabel": "Other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r74" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r103", "r104", "r105", "r114" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Non-vested restricted stock (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-details" ], "xbrltype": "sharesItemType" }, "us-gaap_IntersegmentEliminationMember": { "auth_ref": [ "r129", "r141", "r142", "r143", "r144", "r145", "r147", "r151" ], "lang": { "en-us": { "role": { "documentation": "Eliminating entries used in operating segment consolidation.", "label": "Intersegment Eliminations [Member]" } } }, "localname": "IntersegmentEliminationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r36" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r6", "r38", "r338" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories", "totalLabel": "Inventory, Net, Total" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventories:" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryRawMaterialsAndSupplies": { "auth_ref": [ "r37" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterialsAndSupplies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r38", "r169" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 0.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "us-gaap_InventoryValuationReserves", "negatedLabel": "Reserve for obsolescence" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-investments-details" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r324", "r326" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-lease-cost-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "us-gaap_LeaseCost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-lease-cost-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r325" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-maturity-of-lease-liabilities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r325" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-maturity-of-lease-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r325" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-maturity-of-lease-liabilities-details": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r325" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-maturity-of-lease-liabilities-details": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r325" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-maturity-of-lease-liabilities-details": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r325" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-maturity-of-lease-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Remainder of 2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r325" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_LesseeOperatingLeaseRenewalTerm", "terseLabel": "Lessee, Operating Lease, Renewal Term (Year)" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r30", "r81", "r144", "r166", "r180", "r181", "r182", "r185", "r186", "r187", "r189", "r191", "r193", "r194", "r288", "r292", "r293", "r301", "r336", "r337" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r26", "r81", "r166", "r301", "r338", "r369", "r384" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r32", "r81", "r166", "r180", "r181", "r182", "r185", "r186", "r187", "r189", "r191", "r193", "r194", "r288", "r292", "r293", "r301", "r336", "r337", "r338" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_MunicipalBondsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Bonds [Member]" } } }, "localname": "MunicipalBondsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r72" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r72" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r72", "r73", "r76" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r3", "r51", "r54", "r59", "r61", "r76", "r81", "r89", "r91", "r92", "r93", "r94", "r97", "r98", "r110", "r137", "r142", "r145", "r148", "r151", "r166", "r180", "r181", "r182", "r185", "r186", "r187", "r189", "r191", "r193", "r194", "r296", "r301", "r373", "r387" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-comprehensive-income-unaudited": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net income", "totalLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-comprehensive-income-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r91", "r92", "r93", "r94", "r99", "r100", "r111", "r114", "r137", "r142", "r145", "r148", "r151" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net income available to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r101", "r106", "r107", "r108", "r109", "r111", "r114" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net income available to common stockholders plus assumed conversions" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r137", "r142", "r145", "r148", "r151" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "terseLabel": "Income (loss) from operations", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r318", "r326" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-lease-cost-details": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating leases" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-lease-cost-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r315" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r315" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r315" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "us-gaap_OperatingLeaseLiabilityNoncurrent", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r316", "r320" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "us-gaap_OperatingLeasePayments", "terseLabel": "Operating Lease, Payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r314" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r323", "r326" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-lease-cost-details" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r322", "r326" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted-average remaining lease term (in years) (Year)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-lease-cost-details" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r275" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "us-gaap_OperatingLossCarryforwards", "terseLabel": "Operating Loss Carryforwards, Total" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r141", "r142", "r143", "r144", "r145", "r151" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r11", "r12", "r13", "r31" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r39", "r338" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r43", "r48", "r302", "r303", "r305" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-comprehensive-income-unaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Foreign currency translation adjustment", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-comprehensive-income-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r52", "r55", "r285", "r286", "r290" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r44", "r48" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-comprehensive-income-unaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Unrealized gains (losses) on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-comprehensive-income-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r10", "r11", "r31", "r338" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r69" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r71" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "us-gaap_PaymentsOfDividends", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r70" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r250", "r260" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r19", "r199" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r19", "r199" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r19", "r338" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProductAndServiceOtherMember": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.", "label": "Product and Service, Other [Member]" } } }, "localname": "ProductAndServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "domainItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-net-sales-by-product-and-service-details" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r14", "r15", "r171", "r338", "r378", "r385" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r142", "r145" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r244", "r330", "r331" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r244", "r330", "r331", "r333" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r244", "r330", "r333", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r328", "r329", "r331", "r334", "r335" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r9", "r16", "r78", "r423" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-restricted-stock-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r22", "r214", "r264", "r338", "r383", "r400", "r402" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r86", "r87", "r88", "r90", "r96", "r98", "r167", "r261", "r262", "r263", "r276", "r277", "r294", "r397", "r399" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r128", "r129", "r141", "r146", "r147", "r153", "r154", "r157", "r228", "r229", "r353" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-net-sales-by-product-and-service-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r232", "r235" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r321", "r326" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-use assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r67" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "us-gaap_RoyaltyExpense", "terseLabel": "Royalty Expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesCommissionsAndFees": { "auth_ref": [ "r68" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).", "label": "Commissions expense" } } }, "localname": "SalesCommissionsAndFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r122", "r157" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r50", "r311", "r312" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "auth_ref": [ "r64", "r154" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]" } } }, "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r125", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r151", "r157", "r173", "r174", "r392" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r125", "r126", "r127", "r137", "r140", "r145", "r149", "r150", "r151", "r152", "r153", "r156", "r157", "r158" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r68" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-restricted-stock-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodEndLabel": "Balance, weighted avg. price (in dollars per share)", "periodStartLabel": "Balance, weighted avg. price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-restricted-stock-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedLabel": "Vested (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-restricted-stock-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Vested, wtd. avg. price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-restricted-stock-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r248", "r254" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-restricted-stock-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "us-gaap_SharesOutstanding", "periodEndLabel": "BALANCE (in shares)", "periodStartLabel": "BALANCE (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r319", "r326" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-lease-cost-details": { "order": 0.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term leases" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-lease-cost-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r2", "r125", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r151", "r157", "r170", "r172", "r173", "r174", "r392" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r35", "r57", "r58", "r59", "r86", "r87", "r88", "r90", "r96", "r98", "r119", "r167", "r213", "r214", "r261", "r262", "r263", "r276", "r277", "r294", "r306", "r307", "r308", "r309", "r310", "r312", "r397", "r398", "r399", "r443" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-comprehensive-income-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-12-subsequent-event", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-12-subsequent-event-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-net-sales-by-product-and-service-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-investments-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-lease-cost-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-maturity-of-lease-liabilities-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-7-commitments-and-contingencies", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-restricted-stock-activity-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r86", "r87", "r88", "r119", "r353" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-comprehensive-income-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-10-related-party-transactions-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-12-subsequent-event", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-12-subsequent-event-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-net-sales-by-product-and-service-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-summary-of-balance-sheet-amounts-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-investments-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-lease-cost-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-maturity-of-lease-liabilities-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-6-income-taxes-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-7-commitments-and-contingencies", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-restricted-stock-activity-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "us-gaap_StockRepurchaseProgramAuthorizedAmount1", "terseLabel": "Stock Repurchase Program, Authorized Amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "terseLabel": "Stock Repurchase Program, Remaining Authorized Repurchase Amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r20", "r24", "r25", "r81", "r160", "r166", "r301", "r338" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r80", "r200", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r214", "r217" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r313", "r340" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-12-subsequent-event", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-12-subsequent-event-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r313", "r340" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-12-subsequent-event", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-12-subsequent-event-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r313", "r340" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-12-subsequent-event", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-12-subsequent-event-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r339", "r341" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-12-subsequent-event" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components" ], "xbrltype": "textBlockItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-11-segment-information-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-2-revenue-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-3-balance-sheet-components-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-4-fair-value-measurements-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-5-leases-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-8-stockbased-incentive-plans-tables", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-9-stockholders-equity-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r34", "r215" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r34", "r215" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury stock, shares (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r34", "r215", "r216" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "us-gaap_TreasuryStockValue", "negatedLabel": "Treasury stock, at cost; 1,556,875 shares at September 30, 2021 and December 31, 2020" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r101", "r114" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-details" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r99", "r114" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20210930/role/statement-consolidated-statements-of-operations-unaudited", "http://www.naturalhealthtrendscorp.com/20210930/role/statement-note-1-nature-of-operations-basis-of-presentation-and-consolidation-earnings-per-share-details" ], "xbrltype": "sharesItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r124": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r158": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r165": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r177": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r179": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r217": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r235": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r266": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r284": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r327": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r335": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r341": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4),(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Subparagraph": "b.", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r4": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r41": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r437": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r438": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r439": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r440": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r441": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r442": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r85": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" } }, "version": "2.1" } ZIP 64 0001437749-21-025042-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-21-025042-xbrl.zip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end